Tokushima University / Educator and Researcher Directory --- Yamada, Shin-ichiro

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Yu Saitou, Mitsuo Shimada, Yuji Morine, Shin-ichiro Yamada and Maki Sugimoto : Essential updates 2020/2021: Current topics of simulation and navigation in hepatectomy., Annals of Gastroenterological Surgery, Vol.6, No.2, 190-196, 2021. (Summary) With the development of three-dimensional (3D) simulation software, preoperative simulation technology is almost completely established. The remaining issue is how to recognize anatomy three-dimensionally. Extended reality is a newly developed technology with several merits for surgical application: no requirement for a sterilized display monitor, better spatial awareness, and the ability to share 3D images among all surgeons. Various technology or devices for intraoperative navigation have also been developed to support the safety and certainty of liver surgery. Consensus recommendations regarding indocyanine green fluorescence were determined in 2021. Extended reality has also been applied to intraoperative navigation, and artificial intelligence (AI) is one of the topics of real-time navigation. AI might overcome the problem of liver deformity with automatic registration. Including the issues described above, this article focuses on recent advances in simulation and navigation in liver surgery from 2020 to 2021. (Tokushima University Institutional Repository) ● Metadata: 117276 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12542 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35261944 ● Search Scopus @ Elsevier (PMID): 35261944 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12542 (Tokushima University Institutional Repository: 117276, DOI: 10.1002/ags3.12542, PubMed: 35261944)
2.	Katsuki Miyazaki, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Tetsuya Ikemoto, Satoru Imura, Haun Hu, Hisayoshi Morioka, Koichi Tsuneyama and Mitsuo Shimada : Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient., International Journal of Clinical Oncology, Vol.26, No.12, 2265-2274, 2021. (Summary) Tumor-infiltrating lymphocytes (TILs) are a prognostic factor or an indicator of chemotherapy response for various malignancies. The aim of this study was to investigate the prognostic impact of TILs in resected intrahepatic cholangiocarcinoma (IHCC). We also investigated the usefulness of the apparent diffusion coefficient (ADC) in diffusion-weighted magnetic resonance imaging (DW-MRI) to predict TILs. We enrolled 23 patients with IHCC who underwent initial hepatic resection in Tokushima University Hospital from 2006 to 2017. We evaluated stromal TILs in the tumor marginal area and central area in surgical specimens. Patients were divided into low vs high stromal TILs groups. We analyzed the patients' clinicopathological factors, including prognosis, according to the degree of stromal TILs. We also analyzed the correlation between stromal TILs and the minimum ADC value. Stromal TILs in the marginal area reflected overall survival more accurately than that in the central area. Additionally, marginal low TILs was significantly associated with lymph node metastasis and portal vein invasion. Both overall- and disease-free survival rates in the marginal low TILs group were significantly worse than those in the marginal high TILs group (P < 0.05). In the multivariate analysis, marginal low TILs were an independent prognostic factor for both overall- and disease-free survival (P < 0.05), and marginal low TILs were significantly associated with lower minimum ADC values (P < 0.02). Stromal TILs, especially in the marginal area, might demonstrate prognostic impact in patients with IHCC. Moreover, the ADC values from MRI may predict TILs in IHCC tumor tissue. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Diffusion Magnetic Resonance Imaging / Humans / Lymphocytes, Tumor-Infiltrating / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-021-02026-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34596803 ● Search Scopus @ Elsevier (PMID): 34596803 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-02026-3 (DOI: 10.1007/s10147-021-02026-3, PubMed: 34596803)
3.	Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Masato Miyake, Yuji Morine, Seiichi Oyadomari and Mitsuo Shimada : Effective three-dimensional culture of hepatocyte-like cells generated from human adipose-derived mesenchymal stem cells., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.28, No.9, 705-715, 2021. (Summary) The aim of this study was to clarify the effectiveness of a new three-dimensional (3D) culture system for hepatocyte-like cells (HLCs) generated from human adipose-derived mesenchymal stem cells (ADSCs). Human ADSCs (2 × 10 ) with or without 0.1 mg/mL human recombinant peptide μ-piece per well were seeded in a 96-well U-bottom plate and then our three-step differentiation protocol was applied for 21 days. At each step, cell morphology and gene expression were investigated. Mature hepatocyte functions were evaluated after HLC differentiation. These parameters were compared between 2D- and 3D-cultured HLCs, and, DNA microarray analysis was also performed. Finally, HLCs were transplanted in to CCl induced acute liver failure model mice. Two-dimensional-cultured HLCs at day 21 did not have a spindle shape and had formed spheroids after day 6, which gradually increased in size for 3D-cultured HLCs. Definitive endoderm, hepatoblast, and hepatocyte genes showed significantly higher expression in the 3D culture group. Three-dimensional-cultured HLCs also had higher albumin expression, CYP3A4 activity, urea synthesis, and ammonium metabolism, and much higher expression of ion transporter, blood coagulation, and cell communication genes. HLC transplantation improved serum liver function, especially in T-Bil levels, and engrafted into immunodeficient mice with HLA class I positive staining. Our new 3D culture protocol is effective to improve hepatocyte functions. Our HLCs might be promising for clinical cell transplantation to treat metabolic disease. (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.1024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34318615 ● Search Scopus @ Elsevier (PMID): 34318615 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.1024 (DOI: 10.1002/jhbp.1024, PubMed: 34318615)
4.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 342-346, 2021. (Summary) Background : Several prognostic factors were reported in pancreatic cancer. The fibrinogen-platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. Cases of non-curative resection were excluded. The FPR was calculated using the preoperative plasma fibrinogen and the platelet counts and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. The patients were divided into high and low FPR groups according to this cut-off value. Results : The cut-off value of FPR was 25.2. Among age, sex, body mass index (BMI), and surgical factors including surgery type, volume of blood loss and surgery time, there was no significant difference between the two groups. Patients in the low FPR group had significantly better overall survival (OS) and relapse-free survival (RFS) compared with the high FPR group (P < 0.05). On multivariate analysis, a high FPR, CA19-9 > 300 U /l, and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 342-346, August, 2021. (Keyword) Biomarkers, Tumor / Fibrinogen / Humans / Neoplasm Recurrence, Local / Pancreatic Neoplasms / Prognosis / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116535 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.342 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759156 ● Search Scopus @ Elsevier (PMID): 34759156 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.342 (Tokushima University Institutional Repository: 116535, DOI: 10.2152/jmi.68.342, PubMed: 34759156)
5.	Shuichi Iwahashi, Feng Rui, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Hepatic Stellate Cells Contribute to the Tumor Malignancy of Hepatocellular Carcinoma Through the IL-6 Pathway., Anticancer Research, Vol.40, No.2, 743-749, 2020. (Summary) The hepatic stellate cells (HSCs) have relationship to cancer progression. The aim of this study is to investigate the effect of HSCs and the role of IL-6/Stat3 pathway on hepatocellular carcinoma (HCC) progression. HCCs were co-cultured with HSCs. The viability and migration ability of cancer cells were detected. Epithelial-mesenchymal transition (EMT) marker (E-cadherin), stem cell marker (CD44) and p-signal transducer and activator of transcription 3 (p-STAT3) of cancer cells were evaluated. Finally, interleukin-6 (IL-6) neutralization was performed. Co-culture of HCCs with HSCs increased cancer cell viability and migration ability. EMT and stemness of cancer cells increased with HSCs. Following IL-6 neutralization, phospho-STAT3 activation, cancer cell viability and migration, as well as EMT, and stemness of cancer cells decreased. HSCs promoted HCC progression through the IL-6/STAT3 pathway. (Keyword) Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Survival / Coculture Techniques / Hep G2 Cells / Hepatic Stellate Cells / Humans / Interleukin-6 / Liver Neoplasms / Neoplastic Stem Cells / STAT3 Transcription Factor / Signal Transduction (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.14005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32014916 ● Search Scopus @ Elsevier (PMID): 32014916 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.14005 (DOI: 10.21873/anticanres.14005, PubMed: 32014916)
6.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Toru Utsunomiya : Effect of epigenetic modulation on cancer sphere., The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 70-74, 2020. (Summary) Background : Cancer stem cell properties are highly relevant to the biology of treatment-resistant cancers. Epigenetic modification regulates gene expressions by chromatin remodeling during malignant transformation. The aim of this study was to elucidate the possible strategy for cancer stem cells focusing on epigenetic modification. Methods : We made cancer sphere from HepG2 cells, and we added Histone deacetylase (HDAC) inhibitor, valproic acid to cancer sphere. And we compared methylation status and the gene expression between normal HepG2 and cancer sphere groups, and between cancer sphere and sphere with HDAC inhibitor treatment groups. Results : Valproic acid (VPA) cancelled this spheroid formation. In comparison between normal HepG2 and cancer sphere, the number of methylation status changes more than 0.1 of beta level was 826 probes, and we could isolate some epithelial-mesenchymal transition (EMT) related genes. And VPA reduced the expressions of EMT related genes in sphere with RT-PCR. On the other hand, in comparison between cancer sphere and sphere with VPA treatment, we detected 29 probe of methylation status change, and VPA reduced the expressions of Bcl-6 in sphere. Conclusions : HDAC inhibitor affected the methylation status of cancer stem cells. Histone-acetylation might overcome treatmet-resistant cancer through the regulation of cancer stem cell. J. Med. Invest. 67 : 70-74, February, 2020. (Keyword) DNA Methylation / Epithelial-Mesenchymal Transition / Hep G2 Cells / Histone Deacetylase Inhibitors / Humans / Neoplasms / Neoplastic Stem Cells / Spheroids, Cellular / Valproic Acid (Tokushima University Institutional Repository) ● Metadata: 114755 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.70 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378621 ● Search Scopus @ Elsevier (PMID): 32378621 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.70 (Tokushima University Institutional Repository: 114755, DOI: 10.2152/jmi.67.70, PubMed: 32378621)
7.	Shogo Ohta, Tetsuya Ikemoto, Yuma Wada, Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : A change in the zinc ion concentration reflects the maturation of insulin-producing cells generated from adipose-derived mesenchymal stem cells., Scientific Reports, Vol.9, No.1, 18731, 2019. (Summary) The generation of insulin-producing cells (IPCs) from pluripotent stem cells could be a breakthrough treatment for type 1 diabetes. However, development of new techniques is needed to exclude immature cells for clinical application. Dithizone staining is used to evaluate IPCs by detecting zinc. We hypothesised that zinc ion (Zn) dynamics reflect the IPC maturation status. Human adipose-derived stem cells were differentiated into IPCs by our two-step protocol using two-dimensional (2D) or 3D culture. The stimulation indexes of 2D -and 3D-cultured IPCs on day 21 were 1.21 and 3.64 (P < 0.05), respectively. The 3D-cultured IPCs were stained with dithizone during culture, and its intensity calculated by ImageJ reached the peak on day 17 (P < 0.05). Blood glucose levels of streptozotocin-induced diabetic nude mice were normalised (4/4,100%) after transplantation of 96 3D-cultured IPCs. Zn concentration changes in the medium of 3D cultures had a negative value in the early period and a large positive value in the latter period. This study suggests that Zn dynamics based on our observations and staining of zinc transporters have critical roles in the differentiation of IPCs, and that their measurement might be useful to evaluate IPC maturation as a non-destructive method. (Tokushima University Institutional Repository) ● Metadata: 114940 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-55172-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31822724 ● Search Scopus @ Elsevier (PMID): 31822724 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-55172-0 (Tokushima University Institutional Repository: 114940, DOI: 10.1038/s41598-019-55172-0, PubMed: 31822724)
8.	Tetsuya Ikemoto, Rui Feng, Shuichi Iwahashi, Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Satoru Imura, Munehide Matsuhisa and Mitsuo Shimada : In vitro and in vivo effects of insulin-producing cells generated by xeno-antigen free 3D culture with RCP piece., Scientific Reports, Vol.9, No.1, 2019. (Summary) To establish widespread cell therapy for type 1 diabetes mellitus, we aimed to develop an effective protocol for generating insulin-producing cells (IPCs) from adipose-derived stem cells (ADSCs). We established a 3D culture using a human recombinant peptide (RCP) petaloid μ-piece with xeno-antigen free reagents. Briefly, we employed our two-step protocol to differentiate ADSCs in 96-well dishes and cultured cells in xeno-antigen free reagents with 0.1 mg/mL RCP μ-piece for 7 days (step 1), followed by addition of histone deacetylase inhibitor for 14 days (step 2). Generated IPCs were strongly stained with dithizone, anti-insulin antibody at day 21, and microstructures resembling insulin secretory granules were detected by electron microscopy. Glucose stimulation index (maximum value, 4.9) and MAFA mRNA expression were significantly higher in 3D cultured cells compared with conventionally cultured cells (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of streptozotocin-induced diabetic nude mice converted to normoglycaemic state around 14 days after transplantation of 96 IPCs under kidney capsule or intra-mesentery. Histological evaluation revealed that insulin and C-peptide positive structures existed at day 120. Our established xeno-antigen free and RCP petaloid μ-piece 3D culture method for generating IPCs may be suitable for clinical application, due to the proven effectiveness in vitro and in vivo. (Tokushima University Institutional Repository) ● Metadata: 114941 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-47257-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31341242 ● Search Scopus @ Elsevier (PMID): 31341242 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-47257-7 (Tokushima University Institutional Repository: 114941, DOI: 10.1038/s41598-019-47257-7, PubMed: 31341242)
9.	Yu Saitou, Shin-ichiro Yamada, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 胆道再建を含む肝切除術 (ビギナーズ特集手術で臓器が「どうなる?」から術後ケアが見える! わかる! イラスト理解消化器外科の術式・術後ケア), Gastroenterological Surgery Nursing, Vol.23, No.8, 709-714, 2018. (Keyword) 和文論文 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521980703420258944 (CiNii: 1521980703420258944)
10.	Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi and Mitsuo Shimada : A learning curve for laparoscopic liver resection: an effective training system and standardization of technique., Translational Gastroenterology and Hepatology, Vol.3, 45, 2018. (Summary) The incidence of laparoscopic liver resection (LHx) has been increased in the past decade. There have been some reports about some advantages of LHx, in both short and long-term outcomes after operation. The use of a minor LHx was regarded as a standard surgical practice, and some peri-operative complications hindered worldwide increase of LHx in the Second International Consensus Conference on LHx at Morioka. However, no suggestions were described in terms with how to provide the best teaching and training necessary to shorten the learning curve for inexperienced surgeons using a new surgical technique while continuing to maintain a low rate of morbidity from the very beginning. This study includes a literature review of published research which looked at a learning curve for LHx. As well, it proposes a new step-wise training method for inexperienced surgeons and standardization of a technique for LHx focusing especially on laparoscopic left hepatectomy (LLHx). (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.21037/tgh.2018.07.03 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30148230 ● Summary page in Scopus @ Elsevier: 2-s2.0-85052017722 (DOI: 10.21037/tgh.2018.07.03, PubMed: 30148230, Elsevier: Scopus)
11.	Satoru Imura, Hiroki Teraoku, Masato Yoshikawa, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria., International Journal of Clinical Oncology, Vol.23, No.1, 98-103, 2018. (Summary) Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study. We investigated the risk factors of recurrence. In addition, we divided them into two groups: mvi-negative group and mvi-positive group, based on pathological findings after surgery. We compared the clinicopathological factors between the two groups and determined the risk factors for mvi. Overall survival rate at 1, 3, and 5 years were 91.6%, 80.5%, and 74.9%, and the recurrence-free survival rate at 1, 3, and 5-years were 72.3%, 51.6%, and 37.2%. Risk factor analysis for tumor recurrence revealed that total bilirubin, albumin, ICGR15, AFP-L3, tumor number, mvi, and tumor stage had a significant predictive value. Multivariate analysis revealed that tumor number and mvi were significant independent risk factors for tumor recurrence. Predictive analysis for risk factors of mvi revealed that multiple tumors and AFP-L3 > 10% were significant independent risk factors for mvi in HCC classified within the Milan criteria. The mvi was one of the independent risk factors for tumor recurrence in HCC classified within the Milan criteria. Multiple tumors and high AFP-L3 value were independent predictive factors for mvi. (Keyword) Aged / Bilirubin / Carcinoma, Hepatocellular / Disease-Free Survival / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Retrospective Studies / Risk Factors / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-017-1189-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28875240 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028981662 (DOI: 10.1007/s10147-017-1189-8, PubMed: 28875240, Elsevier: Scopus)
12.	Shin-ichiro Yamada, Mitsuo Shimada and Yuji Morine : 膵癌・胆道癌 ─基礎・臨床の最新研究動向─, Nihon Rinsho. Japanese Journal of Clinical Medicine, 618-621, 2015. (Keyword) 和文論文
13.	Yu Saitou, Hiroki Mori, Chie Takasu, Masato Komatsu, Jun Hanaoka, Shin-ichiro Yamada, 淺野間理仁, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : Beneficial effects of green tea catechin on massive hepatectomy model in rats., Journal of Gastroenterology, 2013. (Summary) BACKGROUND: Green tea catechin, especially epigallocatechin gallate (EGCG), is a well-known scavenger of reactive oxygen species and it may also function as an antioxidant through modulation of transcriptional factors and enzyme activities. METHODS: Green tea extract (GTE(®)) which contained numerous EGCG was used. Wistar rats were performed 90 % hepatectomy and classified into 2 groups with (GTEHx, n = 25) or without GTE treatment (Hx, n = 25) and sacrificed at 1, 3, 7 and 14 days after operations. All rats had free access to drinking water supplemented with or without GTE from the 7th pre-operative day. Liver regeneration, hepatic inducible nitric oxide synthase (iNOS), anti-oxidative enzymes [superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px)] and inflammatory markers [cyclooxygenase-2 (COX-2), nuclear factor kappa B (NFκB), tumor necrosis factor-α (TNF-α)] were investigated. RESULTS: The liver weight to body weight ratio (p < 0.01), proliferating cell nuclear antigen labeling index (p < 0.05) and phosphorylated extracellular signal-regulated kinase 1/2 (p < 0.05) at day 1 in the GTEHx group significantly increased compared to the Hx group. Hepatic iNOS levels at day 1 significantly decreased (p < 0.01) in the GTEHx group. Hepatic SOD, CAT and GSH-Px levels at day 1 significantly increased (SOD: p < 0.01, CAT and GSH-Px: p < 0.05) in the GTEHx group. In contrast, COX-2, NFκB and TNF-α levels at day 1 significantly decreased (COX-2: p < 0.01, NFκB and TNF-α: p < 0.05) in the GTEHx group. CONCLUSIONS: GTE pretreatment stimulated liver regeneration and improved liver damage after massive hepatectomy through anti-oxidative and anti-inflammatory effects. Green tea catechin might have the potential to attenuate liver dysfunction in early stage after massive hepatectomy. (Keyword) 欧文論文 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-013-0799-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23543313 ● Summary page in Scopus @ Elsevier: 2-s2.0-84899985774 (DOI: 10.1007/s00535-013-0799-9, PubMed: 23543313, Elsevier: Scopus)

Academic Paper (Unrefereed Paper):

1.	Shuhai Chen, Yu Saitou, Yuhei Waki, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : Generation of Highly Functional Hepatocyte-like Organoids from Human Adipose-Derived Mesenchymal Stem Cells Cultured with Endothelial Cells., Cells, Vol.13, No.6, 2024. (Summary) Previously, we successfully established a highly functional, three-dimensional hepatocyte-like cell (3D-HLC) model from adipose-derived mesenchymal stem cells (ADSCs) via a three-step differentiation protocol. The aim of the present study was to investigate whether generating hepatocyte-like organoids (H-organoids) by adding endothelial cells further improved the liver-like functionality of 3D-HLCs and to assess H-organoids' immunogenicity properties. Genes representing liver maturation and function were detected by quantitative reverse transcription-PCR analysis. The expression of hepatic maturation proteins was measured using immunofluorescence staining. Cytochrome P (CYP)450 metabolism activity and ammonia metabolism tests were used to assess liver function. H-organoids were successfully established by adding human umbilical vein endothelial cells at the beginning of the definitive endoderm stage in our 3D differentiation protocol. The gene expression of alpha-1 antitrypsin, carbamoyl-phosphate synthase 1, and apolipoprotein E, which represent liver maturation state and function, was higher in H-organoids than non-organoid 3D-HLCs. H-organoids possessed higher CYP3A4 metabolism activity and comparable ammonia metabolism capacity than 3D-HLCs. Moreover, although H-organoids expressed human leukocyte antigen class I, they expressed little human leukocyte antigen class II, cluster of differentiation (CD)40, CD80, CD86, and programmed cell death ligand 1, suggesting their immunogenicity properties were not significantly upregulated during differentiation from ADSCs. In conclusion, we successfully established an H-organoid model with higher liver-like functionality than previously established 3D-HLCs and comparable immunogenicity to ADSCs. (Keyword) Humans / Ammonia / Hepatocytes / Human Umbilical Vein Endothelial Cells / Mesenchymal Stem Cells / Organoids / HLA Antigens (Link to Publication Site) ● Publication site (DOI): 10.3390/cells13060547 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38534391 ● Search Scopus @ Elsevier (PMID): 38534391 ● Search Scopus @ Elsevier (DOI): 10.3390/cells13060547 (DOI: 10.3390/cells13060547, PubMed: 38534391)
2.	Yuhei Waki, Yu Saitou, Shuhai Chen, Tetsuya Ikemoto, Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : Effects of green light-emitting diode irradiation on hepatic differentiation of hepatocyte-like cells generated from human adipose-derived mesenchymal cells., Scientific reports, Vol.13, No.1, 19954, 2023. (Summary) Light-emitting diode (LED) irradiation has been used in the differentiation of mesenchymal stem cells into a variety of cell types. This study investigated the effect of green LED (GLED) irradiation on the differentiation of adipocyte-derived mesenchymal cells into hepatocyte-like cells (HLCs) and the mechanism of its action. HLCs in the hepatocyte maturation phase were irradiated with GLED (520 nm, 21 W/m, 5 min/day for 10 days). The cells were then assessed for expression of hepatocyte maturity genes and opsin 3 (OPN3), hepatocyte function, viability, apoptosis, and levels of reactive oxygen species (ROS), intracellular adenosine triphosphate (ATP) and calcium ions (Ca). GLED irradiation increased Alpha-1 antitrypsin and Ornithine transcarbamylase gene expression, promoted Cytochrome P450 3A4 activity and urea synthesis, and elevated intracellular ROS, ATP and Ca levels. OPN3 expression was significantly more upregulated in GLED-irradiated HLCs than in the non-irradiated HLCs. No significant difference in cell viability or apoptosis was observed between GLED-irradiated and non-irradiated HLCs. GLED irradiation can promote hepatocyte maturation and functions through OPN3. GLED irradiation also stimulated mitochondrial function via Ca/ATP/ROS activation. GLED irradiation has potential to support cell-based transplantation in patients. (Keyword) Humans / Reactive Oxygen Species / Hepatocytes / Cell Differentiation / Adipocytes / Adenosine Triphosphate / Rod Opsins (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-45967-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37968291 ● Search Scopus @ Elsevier (PMID): 37968291 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-45967-7 (DOI: 10.1038/s41598-023-45967-7, PubMed: 37968291)
3.	仲須千春, Shin-ichiro Yamada, Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 原因が不明であった肝palisading granulomaの1例, Acta Hepatologica Japonica, Vol.64, No.10, 504-509, 2023. (Summary) 患者は50代女性.検診の腹部超音波検査で肝S3に16×14mm大の腫瘤を指摘され精査加療目的に当科紹介となった.既往歴・生肉食歴なし.術前の血液検査で異常なく,末梢好酸球も正常.造影CTの動脈・門脈相では辺縁に造影効果を認めるが,平衡相では造影されず,MRI T1強調像で低信号,T2強調像で低∼等信号,拡散強調像でやや高信号であった.PET-CTで肝臓への集積は認めなった.悪性腫瘍の可能性を完全に否定できず,腹腔鏡下肝部分切除を施行した.病理組織学的には腫瘤全体に凝固壊死像が見られ,辺縁に線維増生を伴い,組織球が柵状に配列したpalisading granulomaであった.原因特定のために複数の染色を行ったが,病原体は同定できなかった.palisading granulomaは術前診断が困難であり,診断的治療として腹腔鏡下肝切除術は有用であると考えられた.(著者抄録) (Keyword) 肝切除肝臓疾患(病理学,画像診断,外科的療法) 超音波診断肉芽腫-好酸球性(病理学,画像診断,外科的療法) 腹腔鏡法幼虫移行症-内臓拡散MRI PET-CT検査ヒト中年(45∼64) 女 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.504 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.504 (DOI: 10.2957/kanzo.64.504)
4.	Kozo Yoshikawa, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Shoichiro Takao : Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy., BMC surgery, Vol.23, No.1, 281, 2023. (Summary) A variety of factors have been reported to affect long-term outcomes after radical resection of hepatocellular carcinoma (HCC). However, the indicators remain controversial. The purpose of this study was to evaluate the relationship between myosteatosis of the multifidus muscle and long-term outcomes after radical surgery for HCC. We retrospectively analyzed clinicopathological data for 187 patients with HCC who underwent radical surgery at Tokushima University between January 2009 and December 2020 and measured the density of fat in the multifidus muscle at L3 on their preoperative magnetic resonance images (MRI). Associations of myosteatosis and clinicopathological factors with long-term outcomes were evaluated. The patients were divided into a myosteatosis-negative group (n = 122) and a myosteatosis-positive group (n = 65). The cancer-specific survival rate after hepatectomy was significantly worse in the myosteatosis-positive group than in the myosteatosis-negative group (p = 0.03). Univariate analysis identified multiple tumors, stage III/IV disease, an alfa-fetoprotein level ≥ 10 ng/ml, PIVKA-II ≥ 400 AU/ml, vp(+) status, and myosteatosis to be prognostic factors for cancer-specific survival. Multivariate analysis revealed multiple tumors, an alfa-fetoprotein level ≥ 10 ng/ml, and myosteatosis to be independent prognostic factors. Myosteatosis measured by MRI is a simple and useful predictor of the long-term outcome after radical surgery for HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Hepatectomy / Retrospective Studies / Liver Neoplasms / Magnetic Resonance Imaging / Fetal Proteins (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-023-02188-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37715229 ● Search Scopus @ Elsevier (PMID): 37715229 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-023-02188-z (DOI: 10.1186/s12893-023-02188-z, PubMed: 37715229)
5.	Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 術前に肝細胞癌との鑑別が困難であった筋腫型肝血管筋脂肪腫の1例, Acta Hepatologica Japonica, Vol.64, No.4, 201-208, 2023. (Summary) 患者は40代女性.検診で肝から突出する15cmの巨大腫瘤を指摘され,精査加療目的に当科紹介となった.既往歴や背景肝に特記事項なく,腫瘍マーカーは正常であったが,造影CTの動脈・門脈相で肝右葉に15cm大の早期濃染と遅延相でwashoutを認めた.EOB-MRI肝細胞相ではdefectとして描出され肝細胞癌が疑われた.破裂の危険性を考慮し,まずTACEを行い,その後拡大肝右葉切除を施行した.病理組織学的には腫瘍の大半が平滑筋様細胞で構成されており,脂肪細胞は認めず,免疫組織化学染色にてVimentin,αSMA,HMB-45,melan Aが陽性であり,Perivascular epithelioid cell tumor(PEComa)として包括される腫瘍群の中の筋腫型の肝血管筋脂肪腫(Angiomyolipoma;AML)と診断した.今回我々は,術前に肝細胞癌との鑑別が困難であった,若年女性に発生した肝原発筋腫型AMLを経験したため報告する.(著者抄録) (Keyword) 肝細胞癌肝切除肝臓腫瘍(画像診断,病理学,外科的療法) 筋腫(画像診断,病理学,外科的療法) 鑑別診断術前評価超音波診断 X線CT 免疫組織化学 *血管筋脂肪腫(画像診断,病理学,外科的療法) 拡散MRI 腹部CT ヒト女 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.201 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.201 (DOI: 10.2957/kanzo.64.201)
6.	Katsuki Miyazaki, Yuji Morine, Caiming Xu, Chiharu Nakasu, Yuuma Wada, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Mitsuo Shimada and Ajay Goel : Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma., Cells, Vol.12, No.4, 2023. (Summary) Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Curcumin / Liver Neoplasms / Proto-Oncogene Proteins c-akt / Phosphatidylinositol 3-Kinases / Cell Line, Tumor / Signal Transduction / Protein Kinase Inhibitors / ErbB Receptors (Tokushima University Institutional Repository) ● Metadata: 118580 (Link to Publication Site) ● Publication site (DOI): 10.3390/cells12040612 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36831279 ● Search Scopus @ Elsevier (PMID): 36831279 ● Search Scopus @ Elsevier (DOI): 10.3390/cells12040612 (Tokushima University Institutional Repository: 118580, DOI: 10.3390/cells12040612, PubMed: 36831279)
7.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki, Takayuki Noma, Tetsuya Ikemoto and Mitsuo Shimada : Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage hepatocellular carcinoma., Hepatology Research, 2023. (Summary) Recent advances in treatment modalities have been made, limiting the indication of hepatic resection in the treatment strategy for hepatocellular carcinoma (HCC) patients. This retrospective study investigated the significance of multiplication of tumor maximum diameter and number (MDN) as a surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC. A total of 49 patients with Barcelona Clinic Liver Cancer intermediate-stage HCC who underwent curative hepatic resection between 2000 and 2020 were enrolled in this study. Prognostic factors of overall survival and disease-free survival, including the product of MDN, were analyzed. Patients with MDN >12 experienced significantly worse prognosis compared with those with MDN ≤12 (p = 0.0395), and 5-year overall survival rates after hepatic resection were 60.0% and 23.4%, respectively. Furthermore, the disease-free survival rate of patients with MDN >12 was significantly worse compared with those with MDN ≤12 (p = 0.0049), and all patients with MDN >12 experienced recurrence within 3 years after hepatic resection. In the multivariate analysis, MDN >12 was identified as the only independent prognostic factor of both overall survival and disease-free survival. In addition, patients with MDN >12 suffered from uncontrollable recurrence by locoregional treatment, such as more than four intrahepatic and extrahepatic recurrences, after hepatic resection. MDN index might be a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage HCC, and influence clinical decision-making for individual treatment strategies. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13887 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36755370 ● Search Scopus @ Elsevier (PMID): 36755370 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13887 (DOI: 10.1111/hepr.13887, PubMed: 36755370)
8.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki, Chiharu Nakasu and Mitsuo Shimada : Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study., BMC surgery, Vol.23, No.1, 6, 2023. (Summary) We investigated the usefulness of apparent diffusion coefficients (ADC) from diffusion-weighted images (DWI) obtained using magnetic resonance imaging (MRI) for prognosis of early hepatocellular carcinoma (HCC): Barcelona Clinic Liver Cancer (BCLC) stage 0 and A. We enrolled 102 patients who had undergone surgical resection for early HCC: BCLC stage 0 and A, and calculated their minimum ADC using DWI-MRI. We divided patients into ADC (n = 72) and ADC (n = 30) groups, and compared clinicopathological factors between the two groups. The ADC group showed higher protein induced by vitamin K absence-II (PIVKA-II) levels (p = 0.02) compared with the ADC group. In overall survival, the ADC group showed significantly worse prognosis than the ADC group (p < 0.01). Univariate analysis identified multiple tumors, infiltrative growth, high PIVKA-II, and low ADC value as prognostic factors. Multivariate analysis identified infiltrative growth and low ADC value as an independent prognostic factor. ADC values can be used to estimate the prognosis of early HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Liver Neoplasms / Case-Control Studies / Retrospective Studies / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01892-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36631851 ● Search Scopus @ Elsevier (PMID): 36631851 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01892-6 (DOI: 10.1186/s12893-022-01892-6, PubMed: 36631851)
9.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki, Chiharu Nakasu and Mitsuo Shimada : Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study., BMC Surgery, Vol.23, No.1, 6, 2023. (Summary) We investigated the usefulness of apparent diffusion coefficients (ADC) from diffusion-weighted images (DWI) obtained using magnetic resonance imaging (MRI) for prognosis of early hepatocellular carcinoma (HCC): Barcelona Clinic Liver Cancer (BCLC) stage 0 and A. We enrolled 102 patients who had undergone surgical resection for early HCC: BCLC stage 0 and A, and calculated their minimum ADC using DWI-MRI. We divided patients into ADC (n = 72) and ADC (n = 30) groups, and compared clinicopathological factors between the two groups. The ADC group showed higher protein induced by vitamin K absence-II (PIVKA-II) levels (p = 0.02) compared with the ADC group. In overall survival, the ADC group showed significantly worse prognosis than the ADC group (p < 0.01). Univariate analysis identified multiple tumors, infiltrative growth, high PIVKA-II, and low ADC value as prognostic factors. Multivariate analysis identified infiltrative growth and low ADC value as an independent prognostic factor. ADC values can be used to estimate the prognosis of early HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Liver Neoplasms / Case-Control Studies / Retrospective Studies / Prognosis (Tokushima University Institutional Repository) ● Metadata: 118558 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12893-022-01892-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36631851 ● Search Scopus @ Elsevier (PMID): 36631851 ● Search Scopus @ Elsevier (DOI): 10.1186/s12893-022-01892-6 (Tokushima University Institutional Repository: 118558, DOI: 10.1186/s12893-022-01892-6, PubMed: 36631851)
10.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Fontan associated liver disease(FALD)関連肝癌に対しての腹腔鏡肝切除の1例 Fontan循環における肝離断対策, Acta Hepatologica Japonica, Vol.64, No.1, 18-25, 2023. (Summary) 30代男性,3歳時に単心房・単心室症を背景にFontan手術を受けた.Fontan associated liver disease(FALD)として肝臓内科にフォローを開始されて以来3年後にFALD関連肝癌を疑われ,腹腔鏡肝切除を施行した.肝離断中は,Central venous pressure(CVP)圧を下げるため,positive end expiratory pressureをオフし,最小限の輸液量,利尿剤併用しながらの麻酔管理を行うも,Fontan循環の影響でCVPコントロールは不良で,静脈性出血が継続したままの肝離断となった.本症例は,術後合併症なく経過したものの,FALD関連肝癌症例は,Fontan循環による高CVP下での肝離断を余儀なくされるため,そのジレンマを解決する必要があり,その対策に関して考察を加え報告する.(著者抄録) (Keyword) 肝細胞癌(画像診断,病理学,外科的療法) 肝切除肝内胆管(画像診断,病理学,外科的療法) 超音波診断胆管癌(画像診断,病理学,外科的療法) 胆管腫瘍(画像診断,病理学,外科的療法) X線CT 中心静脈圧 *腹腔鏡法免疫組織化学複合腫瘍と混合腫瘍(画像診断,病理学,外科的療法) 超音波外科拡散MRI 腹部CT ヒト成人(19∼44) 男 (Link to Publication Site) ● Publication site (DOI): 10.2957/kanzo.64.18 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.2957/kanzo.64.18 (DOI: 10.2957/kanzo.64.18)
11.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 【胆膵疾患と最新テクノロジーの融合】胆膵疾患における最新の術前術中手術支援システム, Journal of Biliary Tract & Pancreas, Vol.43, No.12, 1631-1636, 2022. (Summary) 胆膵手術における術前シミュレーションは,腫瘍進展範囲あるいは主要脈管解剖をいかに正確にイメージできるかが,ポイントとなる．空間認識力という意味で,extended realityは有用である．また,術中ナビゲーションに関しては,ICG蛍光法がゴールドスタンダードとなるが,人工知能を駆使した最新の知見,ならびに自験例も踏まえて,本稿で紹介する．(著者抄録) (Keyword) Indocyanine Green(診断的利用) 術中モニタリング人工知能膵臓疾患(X線診断,外科的療法) 膵頭十二指腸切除ソフトウェア X線CT 胆道疾患(X線診断,外科的療法) DICOM 蛍光血管撮影シミュレーション訓練手術ナビゲーションシステム胆管切除術ヒト
12.	Yuji Morine, Tohru Utsunomiya, Hisami Yamanaka-Okumura, Yu Saitou, Shin-ichiro Yamada, Tetsuya Ikemoto, Satoru Imura, Shohei Kinoshita, Akiyoshi Hirayama, Yasuhito Tanaka and Mitsuo Shimada : Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis., Oncotarget, Vol.13, 1286-1298, 2022. (Summary) Metabolomics, defined as the comprehensive identification of all small metabolites in a biological sample, has the power to shed light on phenotypic changes associated with various diseases, including cancer. To discover potential metabolomic biomarkers of hepatocellular carcinoma (HCC), we investigated the metabolomes of tumor and non-tumor tissue in 20 patients with primary HCC using capillary electrophoresis-time-of-flight mass spectrometry. We also analyzed blood samples taken immediately before and 14 days after hepatectomy to identify associated changes in the serum metabolome. Marked changes were detected in the different quantity of 61 metabolites that could discriminate between HCC tumor and paired non-tumor tissue and additionally between HCC primary tumors and colorectal liver metastases. Among the 30 metabolites significantly upregulated in HCC tumors compared with non-tumor tissues, 10 were amino acids, and 7 were essential amino acids (leucine, valine, tryptophan, isoleucine, methionine, lysine, and phenylalanine). Similarly, the serum metabolomes of HCC patients before hepatectomy revealed a significant increase in 16 metabolites, including leucine, valine, and tryptophan. Our results reveal striking differences in the metabolomes of HCC tumor tissue compared with non-tumor tissue, and identify the essential amino acids leucine, valine, and tryptophan as potential metabolic biomarkers for HCC. (Keyword) Humans / Amino Acids, Essential / Carcinoma, Hepatocellular / Tryptophan / Leucine / Liver Neoplasms / Valine (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.28306 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36441784 ● Search Scopus @ Elsevier (PMID): 36441784 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.28306 (DOI: 10.18632/oncotarget.28306, PubMed: 36441784)
13.	Baasansvren Selenge, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Hiroki Teraoku and Mitsuo Shimada : Impact of L-type amino acid transporter 3 on the prognosis of hepatocellular carcinoma., Oncology Letters, Vol.24, No.5, 418, 2022. (Summary) The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P<0.05). Multivariate analysis revealed that high LAT3 expression and multiple tumors were independent prognostic factors for cancer-specific survival. Furthermore, the rate of p-AKT-positive cases was higher in the LAT3-high group than in the LAT3-low group. Overall, these findings suggested that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression. (Tokushima University Institutional Repository) ● Metadata: 118271 (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13538 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245821 ● Search Scopus @ Elsevier (PMID): 36245821 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13538 (Tokushima University Institutional Repository: 118271, DOI: 10.3892/ol.2022.13538, PubMed: 36245821)
14.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : A Hepatectomy Based on a Hybrid Concept of Portal Perfusion of Anterior Segment and Venous Drainage Area of Superior Right Hepatic Vein., The American Surgeon, 3134820984872, 2022. (Summary) Right hepatic vein sometimes could not be a reliable landmark between the anterior and posterior segment. The aim of this study was to clarify the portal perfusion area of the anterior segment and to propose a less invasive hepatectomy based on both the portal perfusion and the hepatic venous drainage. Three-dimensional computerized tomography images of 66 patients were constructed. A case, in which the perfusion area of the anterior segment crossed over superior right hepatic vein (SRHV), was called as SRHV-inclusion. It was defined as inclusion of more than 1 cm of the proximal site of SRHV surrounded by the portal perfusion area of the anterior segment. SRHV-inclusion was observed in 26%. The cases with large inferior right hepatic vein (IRHV) had more frequent SRHV-inclusion (47%). The elderly patient with hepatic disorder, who had hepatocellular carcinoma near the root of the SRHV, underwent a less invasive hepatectomy (anterior segment + SRHV drainage area) resulting in the preservation of the IRHV. The perfusion area of the anterior segment crossed over SRHV in one fourth of patients in the study. Our proposed less invasive hepatectomy based on a hybrid concept might be an alternative operative procedure other than right hepatectomy. (Link to Publication Site) ● Publication site (DOI): 10.1177/0003134820984872 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33382339 ● Search Scopus @ Elsevier (PMID): 33382339 ● Search Scopus @ Elsevier (DOI): 10.1177/0003134820984872 (DOI: 10.1177/0003134820984872, PubMed: 33382339)
15.	Yu Saitou, Maki Sugimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Intraoperative support with three-dimensional holographic cholangiography in hepatobiliary surgery., Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie, Vol.407, No.3, 1285-1289, 2022. (Summary) This study was performed to investigate the potential of intraoperative three-dimensional (3D) holographic cholangiography, which provides a computer graphics model of the biliary tract, with mixed reality techniques. Two patients with intraductal papillary neoplasm of the bile duct were enrolled in the study. Intraoperative 3D cholangiography was performed in a hybrid operating room. Three-dimensional polygon data using the acquired cholangiography data were installed into a head mount display (HoloLens; Microsoft Corporation, Redmond, WA, USA). Upon completion of intraoperative 3D cholangiography, a hologram was immediately and successfully made in the operating room using the acquired cholangiography data, and several surgeons wearing the HoloLens succeeded in sharing the same hologram. Compared with usual two-dimensional cholangiography, this 3D holographic cholangiography technique contributed to more accurate reappearance of the bile ducts, especially the B1 origination site, and moving the hologram from the respective operators' angles by means of easy gesture-handling without any monitors. Intraoperative 3D holographic cholangiography might be a new next-generation operation-support tool in terms of immediacy, accurate anatomical reappearance, and ease of handling. (Keyword) Bile Duct Neoplasms / Bile Ducts / Biliary Tract / Cholangiography / Humans (Link to Publication Site) ● Publication site (DOI): 10.1007/s00423-021-02336-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34557939 ● Search Scopus @ Elsevier (PMID): 34557939 ● Search Scopus @ Elsevier (DOI): 10.1007/s00423-021-02336-0 (DOI: 10.1007/s00423-021-02336-0, PubMed: 34557939)
16.	Kazunori Tokuda, Tetsuya Ikemoto, Shoko Yamashita, Katsuki Miyazaki, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice., Scientific Reports, Vol.12, No.1, 5852, 2022. (Summary) Insulin-producing cells (IPCs) generated by our established protocol have reached the non-clinical 'proof of concept' stage. Our strategy for their clinical application is the autotransplantation of IPCs into patients with type 1 diabetes mellitus (T1DM). In this context, the autoimmunity that characterized T1DM is important, rather than allorejection. We aimed to determine how these IPCs respond to T1DM autoimmunity. IPCs were generated from the subcutaneous fat tissue of non-obese diabetic (NOD) mice using our protocol. IPCs derived from NOD mice were transplanted under the kidney capsules of NOD mice at the onset of diabetes and the subsequent changes in blood glucose concentration were characterized. Blood glucose decreased within 30 days of transplantation, but increased again after 40-60 days in three of four recipient NOD mice. In tissue samples, the numbers of CD4 and CD8 T cells were significantly higher 60 days after transplantation than 30 days after transplantation. In conclusion, IPCs significantly ameliorate the diabetes of mice in the short term, but are damaged by autoimmunity in the longer term, as evidenced by local T cells accumulation. This study provides new insights into potential stem cell therapies for T1DM. (Keyword) Animals / Autoimmunity / Blood Glucose / CD8-Positive T-Lymphocytes / Diabetes Mellitus, Experimental / Diabetes Mellitus, Type 1 / Humans / Insulin / Insulin-Secreting Cells / Mice / Mice, Inbred NOD / Stem Cells (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-022-09838-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35393479 ● Search Scopus @ Elsevier (PMID): 35393479 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-09838-x (DOI: 10.1038/s41598-022-09838-x, PubMed: 35393479)
17.	Shohei Okikawa, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Hiroki Teraoku, Katsuki Miyazaki, Shoko Yamashita, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer., Oncology Reports, Vol.47, No.4, 2022. (Summary) Tumor-associated macrophage (TAMs) are paramount for tumor progression and immune tolerance in the tumor microenvironment of various types of cancer, including liver cancer. The aim of the present study was to investigate the effect of vascular endothelial growth factor (VEGF) inhibition on TAM polarization and function during their interactions with macrophages and liver cancer cells. TAMs were induced by culturing M0 macrophages with cancer cell-conditioned medium. TAMs cultured with cancer cell-conditioned medium and vascular endothelial growth factor (VEGF) inhibitor were defined as modified TAMs, and the expression levels of TAM-associated markers and VEGF receptor 2 were evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of TAMs and modified TAMs on cancer cell proliferation and migration were investigated using conditioned medium. Programmed death-ligand 1 (PD-L1) mRNA expression in modified TAMs and cancer cells cultured in modified TAM-conditioned medium (TAM-CM) for 48 h was examined using RT-qPCR. In order to investigate signaling pathways in macrophages, western blot analysis was performed. CD163 and CD206 and M2 macrophage marker expression was upregulated in TAMs and modified TAMs. Modified TAM-CM exhibited a decreased ability to promote cancer cell proliferation and migration in comparison with the use of TAM-CM. The VEGF concentration was significantly higher in the TAMs than in M0 macrophages; however, the modified TAMs displayed a significantly lower VEGF secretion than TAMs. PD-L1 expression was decreased in modified TAMs as compared with TAMs. Western blot analysis revealed that the Akt/mTOR signaling pathway was significantly suppressed in the modified TAMs compared with TAMs. It was observed that TAMs cultured in a VEGF-depleted environment displayed lower secretion levels of cytokines involved in tumor progression and a decreased immune tolerance-inducing ability. On the whole, the results of the present study suggested that VEGF inhibition in TAMs may be a potential therapeutic target for liver cancer. (Keyword) Cell Line, Tumor / Humans / Liver Neoplasms / Signal Transduction / Tumor Microenvironment / Tumor-Associated Macrophages / Vascular Endothelial Growth Factor A (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2022.8282 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35169858 ● Search Scopus @ Elsevier (PMID): 35169858 ● Search Scopus @ Elsevier (DOI): 10.3892/or.2022.8282 (DOI: 10.3892/or.2022.8282, PubMed: 35169858)
18.	Shuhai Chen, Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Newly Generated 3D Schwann-Like Cell Spheroids From Human Adipose-Derived Stem Cells Using a Modified Protocol., Cell Transplantation, Vol.31, 9636897221093312, 2022. (Summary) Peripheral nerve injury (PNI) is a relatively frequent type of trauma that results in the suffering of many patients worldwide every year. Schwann cells (SCs) are expected to be applied in cell therapy because of their ability to promote peripheral nerve regeneration. However, the lack of clinically renewable sources of SCs hinders the application of SC-based therapies. Adipose-derived stem cells (ADSCs) have generated great interest in recent years because of their multipotency and ease of harvest, and they have already been verified to differentiate into Schwann-like cells (SLCs) in vitro. However, the efficiency of differentiation and the functions of SLCs remain unsatisfactory. We newly generated three-dimensional (3D) SLC spheroids from ADSCs using a modified protocol with human recombinant peptide (RCP) petaloid -piece. Morphological analysis, gene expression analysis by qRT-PCR, ELISA measurement of the secretion capabilities of neurotrophic factors, and neurite formation assay were performed to evaluate the functions of these 3D SLCs in vitro. Motor function recovery was measured in a sciatic nerve injury mouse model to analyze the nerve regeneration-promoting effect of 3D SLCs in vivo. The differentiation efficiency and the secretion of neurotrophic factors were enhanced in 3D SLCs compared with conventional SLCs. 3D SLCs could more effectively promote neurite growth and longer neurite extension in a neuron-like SH-SY5Y model. Additionally, 3D SLCs had a better therapeutic effect on nerve regeneration after transplantation into the sciatic nerve injury mouse model. These findings demonstrated that the potential of ADSC-derived SLCs to promote nerve regeneration could be significantly increased using our modified differentiation protocol and by assembling cells into a 3D sphere conformation. Therefore, these cells have great potential and can be used in the clinical treatment of PNI. (Keyword) Adipocytes / Adipose Tissue / Animals / Humans / Mice / Nerve Growth Factors / Peripheral Nerve Injuries / Schwann Cells / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 117435 (Link to Publication Site) ● Publication site (DOI): 10.1177/09636897221093312 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35469470 ● Search Scopus @ Elsevier (PMID): 35469470 ● Search Scopus @ Elsevier (DOI): 10.1177/09636897221093312 (Tokushima University Institutional Repository: 117435, DOI: 10.1177/09636897221093312, PubMed: 35469470)
19.	Luping Gao, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Chie Takasu, Katsuki Miyazaki and Mitsuo Shimada : Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells., PLoS ONE, Vol.16, No.9, e0256755, 2021. (Summary) As a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems. Because the mechanism controlling sorafenib-resistance is not well understood, this study focused on the connection between tumor characteristics and the Nrf2 signaling pathway in a sorafenib-resistant HCC cell line. A sorafenib-resistant HCC cell line (Huh7) was developed by increasing the dose of sorafenib in the culture medium until the target concentration was reached. Cell morphology, migration/invasion rates, and expression of stemness-related and ATP-binding cassette (ABC) transporter genes were compared between sorafenib-resistant Huh7 cells and parental Huh7 cells. Next, a small interfering RNA was used to knock down Nrf2 expression in sorafenib-resistant Huh7 cells, after which cell viability, stemness, migration, and ABC transporter gene expression were examined again. Proliferation, migration, and invasion rates of sorafenib-resistant Huh7 cells were significantly increased relative to the parental cells with or without sorafenib added to the medium. The expression levels of stemness markers and ABC transporter genes were up-regulated in sorafenib-resistant cells. After Nrf2 was knocked down in sorafenib-resistant cells, cell migration and invasion rates were reduced, and expression levels of stemness markers and ABC transporter genes were reduced. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant HCC cells. (Keyword) ATP-Binding Cassette Transporters / Antineoplastic Agents / Carcinoma, Hepatocellular / Cell Line, Tumor / Cell Movement / Cell Proliferation / Cell Survival / Drug Resistance, Neoplasm / Gene Expression / Gene Expression Regulation, Neoplastic / Gene Knockdown Techniques / Humans / Liver Neoplasms / NF-E2-Related Factor 2 / Protein Kinase Inhibitors / Signal Transduction / Sorafenib / Transfection (Tokushima University Institutional Repository) ● Metadata: 117382 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0256755 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34473785 ● Search Scopus @ Elsevier (PMID): 34473785 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0256755 (Tokushima University Institutional Repository: 117382, DOI: 10.1371/journal.pone.0256755, PubMed: 34473785)
20.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 【肝内胆管癌診療の最前線∼ガイドラインReview∼】肝内胆管癌の外科治療:リンパ節郭清しない立場から, Journal of Biliary Tract & Pancreas, Vol.42, No.9, 835-842, 2021. (Summary) 肝内胆管癌に対する治療は根治的外科切除が基本であるが，リンパ節郭清の意義については一定の見解が得られていない．われわれは末梢型肝内胆管癌において，リンパ節転移陰性例では予防的郭清を行わず，陽性例でもサンプリングにとどめている．その理由として，肝のリンパ流にはさまざまな経路があり遠隔・全身のリンパ流とつながっているため，領域リンパ節郭清は単にサンプリングの意義しかないことがあげられる．実際にリンパ節転移陽性例は，リンパ節郭清を行っても予後は極めて不良であり，肝内胆管癌の予後向上のためには手術のみならず化学療法を含めた集学的治療が必要であると考えられる．(著者抄録) (Keyword) 肝内胆管(外科的療法) リンパ行性転移胆管癌(外科的療法,予後,薬物療法) 胆管腫瘍(外科的療法,予後,薬物療法) リンパ節切除アジュバント化学療法ネオアジュバント療法予防的手術生存期間ヒト
21.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Tetsuya Ikemoto and Mitsuo Shimada : Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis., Anticancer Research, Vol.41, No.9, 4637-4644, 2021. (Summary) The aim of this study was to investigate frailty as a prognostic factor in patients with colorectal liver metastasis undergoing hepatectomy. Eighty-seven patients who underwent hepatectomy at our institution were enrolled. Frailty was defined as a score of ·4 on a clinical frailty scale. Patients were divided into frailty (n=29) and non-frailty (n=58) groups. Overall and cancer-specific survival rates were significantly worse in the frailty group compared with the non-frailty group, and multivariate analysis revealed frailty as an independent prognostic factor. Disease-free survival tended to be worse in the frailty group. Fifty-eight patients relapsed after the first hepatectomy. Twenty-one of 58 recurrent patients were allocated to the frailty group. After recurrence, chemotherapy was significantly more frequently performed in the non-frailty group compared with the frailty group. Frailty can predict the prognosis of patients with colorectal liver metastasis undergoing hepatectomy. (Keyword) Adult / Aged / Aged, 80 and over / Colorectal Neoplasms / Drug Therapy / Female / Frailty / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Prognosis / Retrospective Studies / Survival Analysis / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.15277 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34475092 ● Search Scopus @ Elsevier (PMID): 34475092 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.15277 (DOI: 10.21873/anticanres.15277, PubMed: 34475092)
22.	Luping Gao, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shouhei Okikawa, Chie Takasu and Mitsuo Shimada : The BAFF/NF B axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts., Cancer Science, Vol.112, No.9, 3545-3554, 2021. (Summary) The tumor microenvironment affects malignancy in hepatocellular carcinoma (HCC) cells, and cancer-associated fibroblasts (CAFs) play an important role in the microenvironment. As recent studies indicated a difference between CAFs isolated from chemoresistant and non-resistant cancer tissues, therefore we investigated the intracellular mechanism in resistant HCC co-cultured CAFs and interactions between these CAFs with cancer cells. We established a sorafenib-resistant (SR) Huh7 (human HCC) cell line, and characterized it with cytokine assays, then developed CAFs by co-culturing human hepatic stellate cells with resistant or parental Huh7 cells. The 2 types of CAFs were co-cultured with parental Huh7 cells, thereafter the cell viability of these Huh7 cells was checked under sorafenib treatment. The SR Huh7 (Huh7 ) cells expressed increased B-cell activating factor (BAFF), which promoted high expression of CAF-specific markers in Huh7 -co-cultured CAFs, showed activated BAFF, BAFF-R, and downstream of the NF B-Nrf2 pathway, and aggravated invasion, migration, and drug resistance in co-cultured Huh7 cells. When we knocked down BAFF expression in Huh7 cells, the previously increased malignancy and BAFF/NF B axis in Huh7 -co-cultured CAFs reversed, and enhanced chemoresistance in co-cultured Huh7 cells returned as well. In conclusion, the BAFF/NF B pathway was activated in CAFs co-cultured with cell-culture medium from resistant Huh7, which promoted chemoresistance, and increased the malignancy in co-cultured non-resistant Huh7 cells. This suggests that the BAFF/NF B axis in CAFs might be a potential therapeutic target in chemoresistance of HCC. (Keyword) Antineoplastic Agents / B-Cell Activating Factor / Cancer-Associated Fibroblasts / Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Survival / Coculture Techniques / Drug Resistance, Neoplasm / Gene Knockdown Techniques / Humans / Liver Neoplasms / NF-kappa B / Signal Transduction / Sorafenib / Transfection (Tokushima University Institutional Repository) ● Metadata: 116388 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.15041 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34159680 ● Search Scopus @ Elsevier (PMID): 34159680 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15041 (Tokushima University Institutional Repository: 116388, DOI: 10.1111/cas.15041, PubMed: 34159680)
23.	Shuhai Chen, Yuji Morine, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Tetsuya Ikemoto and Mitsuo Shimada : Cancerssociated fibroblastnduced M2olarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor 1 pathway., International Journal of Oncology, Vol.59, No.2, 59, 2021. (Summary) Targeting the tumor stroma is an important strategy in cancer treatment. Cancerssociated fibroblasts (CAFs) and tumorssociated macrophages (TAMs) are two main components in the tumor microenvironment (TME) in hepatocellular carcinoma (HCC), which can promote tumor progression. Plasminogen activator inhibitor 1 (PAI 1) upregulation in HCC is predictive of unfavorable tumor behavior and prognosis. However, the crosstalk between cancer cells, TAMs and CAFs, and the functions of PAI 1 in HCC remain to be fully investigated. In the present study, macrophage polarization and key paracrine factors were assessed during their interactions with CAFs and cancer cells. Cell proliferation, wound healing and Transwell and Matrigel assays were used to investigate the malignant behavior of HCC cells . It was found that cancer cells and CAFs induced the M2 polarization of TAMs by upregulating the mRNA expression levels of CD163 and CD206, and downregulating IL 6 mRNA expression and secretion in the macrophages. Both TAMs derived from cancer cells and CAFs promoted HCC cell proliferation and invasion. Furthermore, PAI 1 expression was upregulated in TAMs after being stimulated with CAFonditioned medium and promoted the malignant behavior of the HCC cells by mediating epithelialesenchymal transition. CAFs were the main producer of C motif chemokine ligand 12 (CXCL12) in the TME and CXCL12 contributed to the induction of PAI 1 secretion in TAMs. In conclusion, the results of the present study suggested that CAFs promoted the M2 polarization of macrophages and induced PAI 1 secretion via CXCL12. Furthermore, it was found that PAI 1 produced by the TAMs enhanced the malignant behavior of the HCC cells. Therefore, these factors may be targets for inhibiting the crosstalk between tumor cells, CAFs and TAMs. (Keyword) Cancer-Associated Fibroblasts / Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Polarity / Cell Proliferation / Coculture Techniques / Disease Progression / Gene Expression Regulation, Neoplastic / Humans / Liver Neoplasms / Macrophage Activation / Plasminogen Activator Inhibitor 1 / Prognosis / Signal Transduction / THP-1 Cells / Tumor Microenvironment / Tumor-Associated Macrophages / Up-Regulation (Tokushima University Institutional Repository) ● Metadata: 117319 (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2021.5239 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34195849 ● Search Scopus @ Elsevier (PMID): 34195849 ● Search Scopus @ Elsevier (DOI): 10.3892/ijo.2021.5239 (Tokushima University Institutional Repository: 117319, DOI: 10.3892/ijo.2021.5239, PubMed: 34195849)
24.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Utility of cone unit liver resection for small hepatocellular carcinoma: a propensity score matched analysis., HPB, Vol.23, No.5, 739-745, 2021. (Summary) Anatomical resection (AR) is performed widely for hepatocellular carcinoma (HCC). However, it is controversial whether typical AR, which removes the whole feeding territory of the tumor-bearing portal branch bordered by the landmark veins, is necessary. The aim of this study was to investigate the utility of small AR, so-called cone unit resection, for small HCC. Between 2007 and 2019, 372 hepatectomies were performed for HCC. Among them, 91 initial resections for small (<5 cm) solitary HCC were performed by typical AR (n = 44) or cone unit AR (n = 47). Propensity score matching was performed and clinicopathological features including prognosis were compared. At baseline, platelet count was higher, and liver function (serum albumin level) and indocyanine green retention at 15 min were better in the typical AR than cone unit AR group. There was no significant difference between the typical AR and cone unit AR group for tumor characteristics, short- and long-term outcomes. Even after propensity score matching (n = 29), the short- and long-term outcomes were also equivalent in between the two groups. There was no difference in prognosis of typical and cone unit AR. Therefore, cone unit AR is a feasible procedure for small HCC. (Keyword) Carcinoma, Hepatocellular / Hepatectomy / Humans / Liver Neoplasms / Propensity Score / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1016/j.hpb.2020.09.010 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32988753 ● Search Scopus @ Elsevier (PMID): 32988753 ● Search Scopus @ Elsevier (DOI): 10.1016/j.hpb.2020.09.010 (DOI: 10.1016/j.hpb.2020.09.010, PubMed: 32988753)
25.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma., Surgery Today, Vol.51, No.12, 1985-1995, 2021. (Summary) To clarify whether the preoperative lymphocyte/C-reactive protein (CRP) ratio (LCR) is a prognostic factor for patients with intrahepatic cholangiocarcinoma (IHCC), and investigate its mechanism via tumor-infiltrating lymphocytes. The subjects of this retrospective study were 42 patients who had undergone hepatectomy for IHCC. We divided the patients into low LCR and high LCR groups (cutoff value: 8780) and analyzed their overall survival (OS) and disease-free survival (DFS) with respect to LCR and other clinicopathological factors. We also investigated the levels of stromal tumor-infiltrating lymphocytes (TILs) and CD8 TILs in surgical specimens, and the relationship between LCR and TILs. A low LCR was identified in 21 patients and was significantly correlated with older age, a high CRP-albumin ratio, and advanced disease stage, and was a prognostic factor for OS and DFS. Multivariate analysis revealed that a low LCR was an independent prognostic factor for worse OS (HR 10.40, P = 0.0077). Although the LCR and levels of stromal TILs were not significantly related, LCR and levels of CD8 TILs were significantly related (P = 0.0297). The preoperative LCR may predict the postsurgical prognosis of patients with IHCC and reflect the CD8 TILs. (Keyword) Bile Duct Neoplasms / Biomarkers, Tumor / C-Reactive Protein / CD8-Positive T-Lymphocytes / Cholangiocarcinoma / Female / Humans / Lymphocyte Count / Lymphocytes, Tumor-Infiltrating / Male / Predictive Value of Tests / Preoperative Period / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-021-02295-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34009433 ● Search Scopus @ Elsevier (PMID): 34009433 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-021-02295-5 (DOI: 10.1007/s00595-021-02295-5, PubMed: 34009433)
26.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Takuya Tokunaga and Masaaki Nishi : Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma., World Journal of Surgical Oncology, Vol.19, No.1, 94, 2021. (Summary) Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be a prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection. One hundred and twenty patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma were enrolled. Frailty was defined as a clinical frailty scale score ·4. Patients were divided into frailty (n = 29) and non-frailty (n=91) groups, and clinicopathological factors were compared between the two groups. The frailty group showed an older age, lower serum albumin concentration, lower prognostic nutritional index, larger tumor diameter, and higher rate of lymph node metastasis than the non-frailty group (p < 0.05). Neutrophil-lymphocyte ratio and modified Glasgow prognostic score tended to be higher in the frailty group. Cancer-specific and disease-free survival rates were significantly poor in the frailty group (p < 0.05). With a multivariate analysis, frailty was an independent prognostic factor of cancer-specific survival. Frailty can predict the prognosis of patients with pancreatic ductal adenocarcinoma who undergo pancreatic resection. (Keyword) Aged / Carcinoma, Pancreatic Ductal / Frailty / Humans / Pancreatectomy / Pancreatic Neoplasms / Prognosis (Tokushima University Institutional Repository) ● Metadata: 116675 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02205-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33781262 ● Search Scopus @ Elsevier (PMID): 33781262 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02205-6 (Tokushima University Institutional Repository: 116675, DOI: 10.1186/s12957-021-02205-6, PubMed: 33781262)
27.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : 【肝胆膵外科における再切除と再手術-最新の治療戦略】肝細胞癌切除後再発に対する再肝切除適応と治療成績, Operation, Vol.75, No.3, 249-256, 2021. (Keyword) 肝細胞癌(外科的療法,予後) 肝切除再手術術後合併症(外科的療法) 腫瘍再発腹腔鏡法癒着(病因,外科的療法) 診療ガイドライン治療成績ヒト (Link to Publication Site) ● Publication site (DOI): 10.18888/op.0000002091 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.18888/op.0000002091 (DOI: 10.18888/op.0000002091)
28.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Preoperative prognostic nutritional index predicts short- and long-term outcomes after liver resection in patients with hepatocellular carcinoma., Oncology Letters, Vol.21, No.2, 153, 2021. (Summary) The prognostic nutritional index (PNI) is one of the immune parameters calculated on the basis of the serum albumin and the total lymphocyte count. The aim of the present study was to investigate the prognostic significance of the PNI for short- and long-term outcomes after liver resection for patients with hepatocellular carcinoma (HCC). Data from 162 surgically treated patients with HCC (without any previous treatment) were retrospectively analyzed. The cutoff value of preoperative PNI was 45.0, which was calculated by a receiver operating characteristic curve for predicting the recurrence of HCC after liver resection. Patients were divided into low (n=86) and high (n=76) PNI groups. In short-term outcomes, patients in the low PNI group were more likely to experience postoperative complications compared with those in the high PNI group. The 5-year disease-free survival (DFS) rate in the low PNI group was significantly lower compared with that in the high PNI group (20.5% vs. 48.7%). In the multivariate analysis, a low PNI was an independent prognostic factor for DFS (HR, 1.65; 95% CI, 1.00-2.71). In conclusion, the preoperative PNI may be a prognostic factor for evaluating short- and long-term outcomes after liver resection in patients with HCC. (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2020.12414 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33552271 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099380892 (DOI: 10.3892/ol.2020.12414, PubMed: 33552271, Elsevier: Scopus)
29.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Takuya Tokunaga, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : The interaction between cancer associated fibroblasts and tumor associated macrophages via the osteopontin pathway in the tumor microenvironment of hepatocellular carcinoma., Oncotarget, Vol.12, No.4, 333-343, 2021. (Summary) Cancer-tumor associated macrophage (TAM)-cancer associated fibroblast (CAF) interactions are an important factor in the tumor microenvironment of hepatocellular carcinoma. Hepatic stellate cells (HSCs) were cultured with cancer cell-conditioned medium (Ca.-CM), TAM-CM and CAF-CM, and the expression of CAF markers were evaluated by RT-PCR. Whether HSCs cultured with Ca.-CM, TAM-CM and CAF-CM contributed to the enhanced malignancy of cancer cells was examined using proliferation, invasion and migration assays. Furthermore, the differences between these three types of CM were evaluated using cytokine arrays. HSCs cultured with Ca.-CM, TAM-CM and CAF-CM showed significantly increased mRNA expression of SMA, FAP and IL-6. All HSCs cultured with each CM exhibited significantly increased proliferation, invasion and migration of cancer cells. The osteopontin concentration was significantly higher in HSCs cultured with TAM-CM than the other CAF-CMs. Osteopontin inhibition significantly reduced osteopontin secretion from HSCs cultured with TAM-CM and suppressed the proliferation and invasion of cancer cells enhanced by HSCs cultured with TAM-CM. We observed enhanced osteopontin secretion from TAMs, and this increased osteopontin further promoted osteopontin secretion from HSCs cultured with TAM-CM, leading to increased malignancy. For the first time, we demonstrated the importance of cancer-TAM-CAF interactions via osteopontin in hepatocellular carcinoma. (Tokushima University Institutional Repository) ● Metadata: 116612 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27881 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33659044 ● Search Scopus @ Elsevier (PMID): 33659044 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27881 (Tokushima University Institutional Repository: 116612, DOI: 10.18632/oncotarget.27881, PubMed: 33659044)
30.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of Frailty in Prognosis After Hepatectomy for Elderly Patients with Hepatocellular Carcinoma., Annals of Surgical Oncology, Vol.28, No.1, 439-446, 2021. (Summary) The concept of frailty becomes important for patients who undergo surgery in this recent aging society. The aim of this study is to investigate the frailty as a prognostic factor in elderly patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. A total of 92 patients over 75 years old who underwent hepatectomy were enrolled in this study. Frailty was defined as clinical frailty scale (CFS) 4. Patients were divided into two groups, i.e., frailty group (n = 21) and no-frailty group (n = 71), and clinicopathological features were compared between them. The frailty group showed significant higher PIVKA-II level and larger tumor diameter (p < 0.05). CRP level and modified Glasgow prognostic score were significantly higher in the frailty group (p < 0.05). The frailty group showed higher rate of postoperative complications of Clavien-Dindo III (p = 0.06) and longer postoperative stay (p = 0.08). Cancer-specific, overall, and disease-free survival rates were significantly worse in the frailty group (p < 0.05). Frailty was detected as an independent prognostic factor on multivariate analysis of cancer-specific survival. Frailty can estimate the prognosis of HCC patients who underwent hepatectomy. (Keyword) Aged / Carcinoma, Hepatocellular / Frail Elderly / Frailty / Hepatectomy / Humans / Liver Neoplasms / Neoplasm Recurrence, Local / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-020-08742-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
31.	Hiroki Mori, Yuji Morine, Kazuaki Mawatari, Ayumi Chiba, Shin-ichiro Yamada, Yu Saitou, Hiroki Ishibashi, Akira Takahashi and Mitsuo Shimada : Bile Metabolites and Risk of Carcinogenesis in Patients With Pancreaticobiliary Maljunction: A Pilot Study., Anticancer Research, Vol.41, No.1, 327-334, 2021. (Summary) Pancreaticobiliary maljunction (PBM), a disease with reflux of pancreatic and bile juice in the pancreaticobiliary tract, is a high-risk factor for biliary tract cancer. The aim of this study was to investigate the mechanism of carcinogenesis in PBM using a metabolomics analysis of bile sampled during surgery. Three patients with PBM without biliary tract cancer, four patients with extrahepatic bile duct cancer (EHBC), and three controls with benign disease were enrolled. Metabolomics analysis of bile samples was performed using capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry to discriminate the amino acid and lipidomic profiles. The principal component analysis in the capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry revealed similar metabolites in patients with PBM and those with EHBC; furthermore, there was a clear difference between patients with PBM or EHBC compared to controls. The amino acid profiles revealed the following 20 potential carcinogenic candidates for PBM: isoleucine, phenylalanine, tyrosine, leucine, tryptophan, arginine, lysine, valine, asparagine, methionine, aspartic acid, serine, threonine, histidine, glutamine, alanine, proline, glutamic acid, and pyruvic acid. The lipidomic profiles revealed the following 11 carcinogenic candidates: lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidyl glycerol, lysophosphatidyl glycerol, triacylglycerol, diacylglycerol, ceramide, sphyngomyeline, fatty acid, hyperforin, and vitamin D. Among these characteristic metabolites, the branched-chain amino acids, methionine and lysophosphatidylcholine are known to be related to carcinogenesis. The bile metabolites were extremely similar in patients with PBM and those with EHBC. Furthermore, amino acid and lipid metabolism was markedly different in patients with PBM or EHBC compared to healthy controls. (Keyword) Bile / Bile Duct Neoplasms / Cell Transformation, Neoplastic / Chromatography, Liquid / Disease Susceptibility / Electrophoresis, Capillary / Female / Humans / Male / Mass Spectrometry / Metabolomics / Pancreaticobiliary Maljunction / Pilot Projects / Risk Assessment / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.14779 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33419827 ● Search Scopus @ Elsevier (PMID): 33419827 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.14779 (DOI: 10.21873/anticanres.14779, PubMed: 33419827)
32.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada and Mitsuo Shimada : Regeneration of caudate lobe after living donor liver transplantation : Comparison with a surrogate model of left lobe graft., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 330-333, 2021. (Summary) Background : The aim of this study is to clarify the regeneration of the CL (caudate lobe) without any reconstructions of short hepatic veins (SHVr) after LDLT (living donor liver transplantation) and compare the regeneration of the CL after right hepatectomy (Rt. Hx), as the surrogate model of extended left lobe graft (Ex LLG) with complete SHVr. Methods : Eleven Ex LLGs with CL were included in this study. SHVr was not performed in all cases. The volumetry was performed before, one month and six months after LDLT. Seven patients who underwent Rt. Hx were also included in this study as the surrogate model. Results : In Ex LLGs with CL, the regeneration rate of the large CL (> 30 ml) was worse than that of small CL (< 30 ml). In the surrogate model, the regeneration rate of the CL was not worse than other segments. However, the regeneration rate of the large CL was also worse than that of small CL even in the presence of complete SHVr. Conclusions : The regeneration of the large CL was worse than that of the small CL regardless of the presence or absence of SHVr, indicating that SHVr in Ex LLG with CL might not be necessary. J. Med. Invest. 68 : 330-333, August, 2021. (Keyword) Hepatectomy / Hepatic Veins / Humans / Liver / Liver Transplantation / Living Donors (Tokushima University Institutional Repository) ● Metadata: 116533 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.330 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759154 ● Search Scopus @ Elsevier (PMID): 34759154 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.330 (Tokushima University Institutional Repository: 116533, DOI: 10.2152/jmi.68.330, PubMed: 34759154)
33.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the CRP-albumin ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 244-255, 2021. (Summary) Background : The C-reactive protein (CRP)-albumin ratio (CAR) was reported as a prognostic factor of resectable hepatocellular carcinoma. The aim of this study was to analyse the significance of CAR in resectable pancreatic cancer. Patients and Methods : 163 patients with curative resection for pancreatic cancer were enrolled in this retrospective study. Cases of non-curative resection were excluded. The CAR was calculated with the preoperative plasma CRP and albumin values, with a cut-off value of 0.06, as calculated in a previous report. Results : Patients in the low CAR group had significantly better overall survival (OS) and disease-free survival (DFS) compared with the high CAR group (P < 0.05). On multivariate analysis, for high CAR, CA19-9 > 300 U /l and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. High CAR was significantly associated with advanced T stage. Conclusion : The CAR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 244-248, August, 2021. (Keyword) Albumins / C-Reactive Protein / Humans / Pancreatic Neoplasms / Prognosis / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116489 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.244 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759138 ● Search Scopus @ Elsevier (PMID): 34759138 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.244 (Tokushima University Institutional Repository: 116489, DOI: 10.2152/jmi.68.244, PubMed: 34759138)
34.	Shuhai Chen, Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective in vitro differentiation of adipose-derived stem cells into Schwann-like cells with folic acid supplementation., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 347-353, 2021. (Summary) Peripheral nerve injury (PNI) after pelvic surgery is a common issue with a significant impact on patients. Autologous nerve grafting is the gold standard treatment for PNI, but this technique cannot be applied to fine nerve fibers in the pelvis. Schwann-like cell (SLC) differentiation is a novel therapeutic strategy for this clinical condition. However, the efficiency of SLC differentiation remains unsatisfactory. We modified an SLC differentiation protocol using adipose-derived stem cells (ADSCs) and folic acid. Morphology, gene expression and secretion of neurotrophic factors were examined to assess the differentiation quality and phenotypic characteristics. Our new modified protocol effectively induced a Schwann cell (SC) phenotype in ADSCs as assessed by morphology and expression of SC markers [S100 calcium-binding protein B (S100B), P < 0.01 ; p75 neurotrophic receptor (p75NTR), P < 0.05]. SLCs produced by the new protocol displayed a repair phenotype with decreased expression of ERBB2 and early growth response protein 2 (EGR2) /ROX20 (P < 0.01). Furthermore, our new protocol enhanced both mRNA expression and secretion of nerve growth factors by SLCs (P < 0.01). This protocol enhanced the SC characteristics and functions of ADSC-derived SLCs. This promising protocol requires further research and may contribute to SC-based nerve regeneration. J. Med. Invest. 68 : 347-353, August, 2021. (Keyword) Adipose Tissue / Cell Differentiation / Cells, Cultured / Dietary Supplements / Folic Acid / Humans / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 116542 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.347 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759157 ● Search Scopus @ Elsevier (PMID): 34759157 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.347 (Tokushima University Institutional Repository: 116542, DOI: 10.2152/jmi.68.347, PubMed: 34759157)
35.	Yuji Morine, Toru Utsunomiya, Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Akihiro Kitagawa, Yuta Kobayashi, Seiichiro Takao, Keisuke Kosai, Koshi Mimori, Yasuhito Tanaka and Mitsuo Shimada : Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma., Oncotarget, Vol.11, No.52, 4803-4812, 2020. (Summary) Genome-wide analysis is widely applied to detect molecular alterations during oncogenesis and tumor progression. We analyzed DNA methylation profiles of hepatocellular carcinoma (HCC), and investigated the clinical role of most heypermethylated of tumor, encodes T-box 15 (TBX15), which was originally involved in mesodermal differentiation. We conducted a genome-wide analysis of DNA methylation of tumor and non-tumor tissue of 15 patients with HCC, and revealed was the most hypermethylated gene of tumor (Beta-value in tumor tissue = 0.52 compared with non-tumor tissue). Another validation set, which comprised 58 HCC with radical resection, was analyzed to investigate the relationships between tumor phenotype and mRNA expression. mRNA levels in tumor tissues were significantly lower compared with those of nontumor tissues ( < 0.0001). When we assigned a cutoff value = 0.5-fold, the overall survival 5-year survival rates of the low-expression group ( = 17) were significantly shorter compared with those of the high-expression group ( = 41) (43.3% vs. 86.2%, = 0.001). Multivariate analysis identified low expression as an independent prognostic factor for overall and disease-free survival. Therefore, genome-wide DNA methylation profiling indicates that hypermethylation and reduced expression of in tumor tissue represents a potential biomarker for predicting poor survival of patients with HCC. (Tokushima University Institutional Repository) ● Metadata: 116613 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27852 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33447348 ● Search Scopus @ Elsevier (PMID): 33447348 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27852 (Tokushima University Institutional Repository: 116613, DOI: 10.18632/oncotarget.27852, PubMed: 33447348)
36.	Yuuma Wada, Kazunori Tokuda, Yuji Morine, Shohei Okikawa, Shoko Yamashita, Tetsuya Ikemoto, Satoru Imura, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The inhibitory effect of TU-100 on hepatic stellate cell activation in the tumor microenvironment., Oncotarget, Vol.11, No.49, 4593-4604, 2020. (Summary) The tumor microenvironment is involved in acquiring tumor malignancies of colorectal liver metastasis (CRLM). We have reported that TU-100 (Daikenchuto) suppresses hepatic stellate cell (HSC) activation in obstructive jaundice. In this study, we report new findings as the direct and indirect inhibitory effects of TU-100 on cancer cell growth through the suppression of HSC activation. The HSCs (LX2) were cultured in colon cancer cells (HCT116 and HT29)-conditioned medium (CM) with or without TU-100 treatment (90, 270, 900 g/ml). Activated HSCs (aHSCs) were detected by -SMA and IL-6 mRNA expressions and cytokine arrays of HSC's culture supernatants. Cancer cell growth was analyzed for proliferation and migration ability, compared with TU-100 treatment. To investigate the direct anti-tumor effect of TU-100, cancer cells were cultured in the presence of aHSC-CM and TU-100 (90, 270, 900) or aHSC-CM alone, and assessed autophagosomes, conversion to LC3-II protein, and Beclin-1 mRNA expression. Colon cancer-CM significantly increased -SMA and IL-6 mRNA expressions of aHSC. -SMA and IL-6 mRNA expressions of aHSC, and IL-6 secretions from aHSCs were significantly decreased with TU-100 (270, 900) treatment, compared to colon cancer-CM alone. Compared with normal culture medium, aHSC-CM led to a significantly increased cell number and modified HSC-CM (TU-100; 270, 900) significantly suppressed cancer cell growth and migration. TU-100 (900) treatment induced autophagy and significantly promoted the autophagic cell death. TU-100 inhibited colon cancer cell malignant potential by both suppressing HSC activation and inducing directly autophagy of cancer cells. (Tokushima University Institutional Repository) ● Metadata: 116616 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27835 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33346211 ● Search Scopus @ Elsevier (PMID): 33346211 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27835 (Tokushima University Institutional Repository: 116616, DOI: 10.18632/oncotarget.27835, PubMed: 33346211)
37.	Shin-ichiro Yamada, Yuji Morine, Hiroki Ishibashi and Mitsuo Shimada : 【臨床に役立つ胆と膵の解剖学】膵・胆管合流異常の解剖と病型分類, Journal of Biliary Tract & Pancreas, Vol.41, No.11, 1085-1092, 2020. (Summary) 膵・胆管合流異常(pancreaticobiliary maljunction:PBM)は，解剖学的に膵管と胆管が十二指腸壁外で合流する先天性の形成異常であり，膵液と胆汁の相互逆流により高率な胆道発癌や膵炎をはじめとしたさまざまな病態を引き起こす．PBMの発生には，腹側膵原基と背側膵原基が癒合する以前の，下部胆管と腹側膵の異常が影響し，背側膵の関与はないと考えられている．PBMの分類においては胆管拡張の有無がとくに重要であり，拡張があるもの(先天性胆道拡張症)とないもの(胆道非拡張型)に分けられ，さらに胆管と膵管の合流形式などによってこれまでいくつかの分類が報告されている．また，共通管が6mm以上で合流部に括約筋作用が及ぶ例は膵胆管高位合流と定義され，PBMとは異なる病態として扱われる．今後の課題として，胆管拡張の定義や型分類の統一，高位合流との鑑別があげられる．(著者抄録) (Keyword) 局所解剖学分類 *膵胆管合流異常胆道拡張症病態生理ヒト
38.	Tetsuya Ikemoto, Kazunori Tokuda, Yuuma Wada, Luping Gao, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells., Pancreas, Vol.49, No.9, 1225-1231, 2020. (Summary) We aimed to determine whether responsive insulin-producing cells (IPCs) could be generated from adipose-derived stem cells (ADSCs) isolated from patients with type 1 diabetes mellitus (T1DM). We isolated ADSCs from adipose tissue of 4 patients (one patient with T1DM and 3 nondiabetic patients), who underwent surgery and differentiated them into IPCs with using a 2-step xeno-antigen free, 3-dimensional culture method. Characteristics of isolated ADSCs, in vitro cell quality, programmed cell death ligand-1 (PDL-1) expression, and transplantation into streptozotocin induced diabetic nude mice were investigated. Adipose-derived stem cells from T1DM patients and commercially obtained ADSCs showed the same surface markers; CD31CD34CD45CD90CD105CD146. Moreover, the generated IPCs at day 21 demonstrated appropriate autonomous insulin secretion (stimulation index, 3.5; standard deviation, 0.8). Nonfasting blood glucose concentrations of IPC-transplanted mice were normal at 30 days. The normalized rate of IPC-transplanted mice was significantly higher than that of the sham-operated group (P < 0.05). Insulin-producing cells generated from T1DM adipose tissue expressed high levels of PDL-1. Insulin-producing cells obtained from adipose tissue of T1DM patients are capable of secreting insulin long-term and achieve normoglycemia after transplantation. Expression of PDL-1 suggests the potential for immune circumvention. (Link to Publication Site) ● Publication site (DOI): 10.1097/MPA.0000000000001663 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32898009 ● Search Scopus @ Elsevier (PMID): 32898009 ● Search Scopus @ Elsevier (DOI): 10.1097/MPA.0000000000001663 (DOI: 10.1097/MPA.0000000000001663, PubMed: 32898009)
39.	Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shin-ichiro Yamada and Mitsuo Shimada : HIF-1 expression in liver metastasis but not primary colorectal cancer is associated with prognosis of patients with colorectal liver metastasis., World Journal of Surgical Oncology, Vol.18, No.1, 241, 2020. (Summary) The role of hypoxia-inducible factor-1 (HIF-1 ) in primary colorectal cancer (CRC) and colorectal liver metastasis (CRLM) has remained unclear. The aim of this study was to investigate HIF-1 expression and its association with prognosis in patients with CRLM with a focus on hepatic stellate cells (HSCs). Colon cancer cells were cultured in HSC-conditioned medium (CM), and HIF-1 expression and cell migration were analyzed. Seventy-five patients with CRLM who underwent an initial curative hepatectomy were enrolled. We examined HIF-1 expressions and patient prognosis between primary CRCs and the matched liver metastatic specimens. Activated HSCs induced HIF-1 mRNA and protein expression in colon cancer cells (p < 0.01) and promoted cell migration (p < 0.01). The positive rates of HIF-1 expression in primary CRCs and liver metastases were 68.0 and 72.0%, respectively. There were no differences in overall (OS) and disease-free survival (DFS) of HIF-1 expression in primary CRC. However, HIF-1 expression in liver metastasis correlated to poor prognosis in both OS and DFS. Furthermore, patients with HIF-1 positive expression in liver metastasis had poor prognosis. HIF-1 expression in liver metastasis determines poor prognosis of CRLM patients. HSCs might play a key role in aggressive phenotypes of tumor cells. (Keyword) Colonic Neoplasms / Colorectal Neoplasms / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / Prognosis (Tokushima University Institutional Repository) ● Metadata: 116676 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-020-02012-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32895059 ● Search Scopus @ Elsevier (PMID): 32895059 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-020-02012-5 (Tokushima University Institutional Repository: 116676, DOI: 10.1186/s12957-020-02012-5, PubMed: 32895059)
40.	Kazunori Tokuda, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma., International Journal of Clinical Oncology, Vol.25, No.12, 2083-2089, 2020. (Summary) Intrahepatic cholangiocarcinoma (IHCC) has a poor prognosis, and surgery remains the only effective treatment. However, tumor recurrence after primary hepatectomy is common. We examined the significance of repeat surgery for IHCC. We collected data for all patients with IHCC between 1992 and 2018 (n = 67) in our database. Fifty-three (79.1%) of all 67 patients experienced recurrence after primary hepatectomy and we analyzed data for those 53 recurrent patients. We divided recurrent patients into a repeat surgery group (n = 9), chemotherapy group (n = 19), and best supportive care group (n = 25). We analyzed differences in patients' clinicopathological factors, including prognosis, between the three groups. The IHCC recurrence rate after hepatectomy in our institution was 79.1%. Of the 53 patients with recurrence, nine underwent repeat surgery (17.0%). The characteristics of the patients undergoing repeat surgery was lower stage at primary hepatectomy. Recurrence sites in the repeat surgery group were liver (n = 6), lung (n = 2), and adrenal gland (n = 1), as a single nodule. The period between primary hepatectomy and recurrence was comparatively longer in the repeat surgery group, at 1.8 years. The prognosis in patients undergoing repeat surgery was significantly better compared with the other groups. Not undergoing repeat surgery (hazard ratio: 5.506; p = 0.0077) and positive lymph node metastasis (hazard ratio: 2.207; p = 0.0242) were independent poor prognostic factors. Repeat surgery should be considered in patients with IHCC with a single recurrence site and negative lymph node metastasis at primary surgery and at least more than 6 months of disease-free period after primary surgery. (Keyword) Adrenal Gland Neoplasms / Adrenalectomy / Adult / Aged / Aged, 80 and over / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Female / Hepatectomy / Humans / Liver Neoplasms / Lung Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Neoplasm Recurrence, Local / Prognosis / Proportional Hazards Models / Reoperation / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-020-01775-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32869120 ● Search Scopus @ Elsevier (PMID): 32869120 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-020-01775-x (DOI: 10.1007/s10147-020-01775-x, PubMed: 32869120)
41.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : Impact of using a perioperative artificial endocrine pancreas in pancreatic resection., Annals of Gastroenterological Surgery, Vol.4, No.5, 591-596, 2020. (Summary) Pancreatectomy causes both hyperglycemia, secondary to surgical stress, and pancreatic diabetes, which leads to difficult-to-control postoperative blood glucose levels. We investigated whether using an artificial pancreas perioperatively to provide appropriate blood glucose control could reduce postoperative complications following pancreatectomy. We retrospectively enrolled 52 patients who underwent pancreatectomy at Tokushima University Hospital from 2015 to 2019. The most recent 26/52 patients received perioperative blood glucose control using an artificial pancreas. Postoperative blood glucose control with manual insulin injections based on a sliding scale was performed in the earlier 26 patients (controls). We compared surgical outcomes between the artificial pancreas group and the control group. There was no significant difference in patients' white blood cell or neutrophil counts, prognostic nutritional index, neutrophil-lymphocyte ratio, and C-reactive protein-to-albumin ratio on postoperative day 1; however, lymphocyte counts were higher in the artificial pancreas group. The number of serious complications of Clavien-Dindo grade >IIIa was significantly lower in the artificial pancreas group ( < .05). Using an artificial pancreas for perioperative blood glucose control in patients undergoing pancreatectomy decreased the number of serious complications through proper management of blood glucose levels without hypoglycemia, and may influence peripheral lymphocytes. (Tokushima University Institutional Repository) ● Metadata: 116476 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12374 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33005854 ● Search Scopus @ Elsevier (PMID): 33005854 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12374 (Tokushima University Institutional Repository: 116476, DOI: 10.1002/ags3.12374, PubMed: 33005854)
42.	Katsuki Miyazaki, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Pancreatoduodenectomy co-morbid with celiac axis compression syndrome: a report of three cases., Surgical Case Reports, Vol.6, No.1, 113, 2020. (Summary) Celiac axis compression syndrome (CACS) is a relatively rare disease. Because of the nature of the blood flow in the celiac region when a pancreatoduodenectomy (PD) is performed for CACS, the celiac region can become ischemic. The aim of this study is to report on the importance of pre-operative diagnosis of CACS in terms of the outcomes for patients post-operatively. In this study, three 3 cases of PD co-morbid with CACS are reported: one intra-operative diagnosis case and two pre-operative diagnosis cases. The one case, not diagnosed with CACS prior to the operation, had a hard post-operative course because of complication caused by ischemia of the celiac region compared with the two cases diagnosed prior to the operation, who had a good post-operative course because of pre-operative or intra-operative intervention. Post-operative complications due to CACS are preventable by pre-operative diagnosis and appropriate interventions. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-020-00878-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32449014 ● Search Scopus @ Elsevier (PMID): 32449014 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-020-00878-x (DOI: 10.1186/s40792-020-00878-x, PubMed: 32449014)
43.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.27, No.7, 388-395, 2020. (Summary) We evaluated apparent diffusion coefficient (ADC) of diffusion-weighted image MRI as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma (IHCC). We enrolled 26 patients who had undergone hepatic resections for mass-forming-type IHCC in this study, and calculated their mean ADC, using diffusion-weighted image MRI (b: 0, 20, 800 seconds/mm ; 1.5 T MRI). Patients were divided into the ADC and the ADC groups at the median ADC value (n = 13 for both). We also immunohistochemically evaluated hypoxia-inducible factor (HIF)-1 in tumor tissue. Median age in the ADC was older (P = .03), and showed significant higher rate of scirrhous tumor (P = .02). The 5-year overall survival rate in the ADC group was significantly worse than in the ADC group (P = .04). In multivariate analysis, hilar tumor, portal vein invasion and low ADC were independent prognostic factors (P < .05). The ADC group also had a higher rate of high HIF-1 expression than the ADC group (P < .05). Representative case of ADC group showed rich stroma and high HIF-1 expression. The ADC values in MRIs can predict IHCC prognosis, and correlated with stromal density and HIF-1 expression. (Keyword) Aged / Algorithms / Bile Duct Neoplasms / Biomarkers, Tumor / Cholangiocarcinoma / Contrast Media / Diffusion Magnetic Resonance Imaging / Female / Hepatectomy / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Male / Neoplasm Invasiveness / Prognosis / Survival Rate / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.732 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32162483 ● Search Scopus @ Elsevier (PMID): 32162483 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.732 (DOI: 10.1002/jhbp.732, PubMed: 32162483)
44.	Yu Saitou, Maki Sugimoto, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : Intraoperative 3D Hologram Support With Mixed Reality Techniques in Liver Surgery., Annals of Surgery, Vol.271, No.1, e4-e7, 2020. (Summary) The aim of this study was to investigate the potential of an intraoperative 3D hologram, which was a computer graphics model liver, with mixed reality techniques in liver surgery. The merits for the application of a hologram for surgical support are: 1) no sterilized display monitor; 2) better spatial awareness; and 3) 3D images shared by all the surgeons. 3D polygon data using preoperative computed tomography data was installed into head mount displays, HoloLens (Microsoft Corporation, Redmond, WA). In a Wi-Fi-enabled operative room, several surgeons wearing HoloLens succeeded in sharing the same hologram and moving that hologram from respective operators' angles by means of easy gesture-handling without any monitors. The intraoperative hologram contributed to better imagination of tumor locations, and for determining the parenchymal dissection line in the hepatectomy for the patients with more than 20 multiple colo-rectal liver metastases. In another case, the hologram enabled a safe Gliisonean pedicle approach for hepato-cellular carcinoma with a hilar anatomical anomaly. Surgeons could easily compare the real patient's anatomy and that of the hologram just before the hepatic hilar procedure. This initial experience suggested that an intraoperative hologram with mixed reality techniques contributed to "last-minute simulation," not for "navigation." The intraoperative hologram might be a new next-generation operation-supportive tool in terms of spatial awareness, sharing, and simplicity. (Tokushima University Institutional Repository) ● Metadata: 114184 (Link to Publication Site) ● Publication site (DOI): 10.1097/SLA.0000000000003552 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31425293 ● Search Scopus @ Elsevier (PMID): 31425293 ● Search Scopus @ Elsevier (DOI): 10.1097/SLA.0000000000003552 (Tokushima University Institutional Repository: 114184, DOI: 10.1097/SLA.0000000000003552, PubMed: 31425293)
45.	Kazunori Tokuda, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Shoko Yamashita, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : The Fragility of Cryopreserved Insulin-producing Cells Differentiated from Adipose-tissue-derived Stem Cells., Cell Transplantation, Vol.29, 963689720954798, 2020. (Summary) The aim of our study is to determine whether insulin-producing cells (IPCs) differentiated from adipose-tissue-derived stem cells (ADSCs) can be cryopreserved. Human ADSCs were differentiated into IPCs using our two-step protocol encompassing a three-dimensional culture and xenoantigen-free method. Thereafter, IPCs were frozen using three different methods. First, IPCs were immediately frozen at -80 C (-80 C group). Second, IPCs were initially placed into a Bicell freezing container before freezing at -80 C (BICELL group). Third, a vitrification method for oocytes and embryos was used (CRYOTOP group). Cell counting kit-8 (CCK-8) assay showed that cell viability was decreased in all groups after cryopreservation ( < 0.01). Corroboratively, the amount of adenosine triphosphate was markedly decreased after cryopreservation in all groups ( < 0.01). Immunofluorescence staining showed a reduced positive staining area for insulin in all cryopreservation groups. Furthermore, 4',6-diamidino-2-phenylindole and merged immunofluorescence images showed that cryopreserved cells appeared to be randomly reduced in the -80 C group and CRYOTOP group, while only the central region was visibly reduced in the BICELL group. Using immunohistochemical staining, IPCs after cryopreservation were shown to be positive for cleaved caspase-3 antibody in all groups. Finally, insulin secretion following glucose stimulation was significantly reduced in IPCs from all groups after cryopreservation ( < 0.01). In conclusion, IPCs may be too fragile for cryopreservation with accomplished methods and further investigations for a suitable preservation method are required. (Keyword) Adenosine Triphosphate / Adipose Tissue / Caspase 3 / Cell Differentiation / Cell Shape / Cell Survival / Cryopreservation / Dithizone / Glucose / Humans / Insulin / Insulin Secretion / Insulin-Secreting Cells / Staining and Labeling / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 116513 (Link to Publication Site) ● Publication site (DOI): 10.1177/0963689720954798 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32878465 ● Search Scopus @ Elsevier (PMID): 32878465 ● Search Scopus @ Elsevier (DOI): 10.1177/0963689720954798 (Tokushima University Institutional Repository: 116513, DOI: 10.1177/0963689720954798, PubMed: 32878465)
46.	Shogo Oota, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Shoko Iwahashi, Yoshimi Bando and Mitsuo Shimada : Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1 for Intrahepatic Cholangiocarcinoma., Anticancer Research, Vol.39, No.11, 6025-6033, 2019. (Summary) Carbohydrate antigen 19-9 (CA19-9) is a poor prognostic marker in intrahepatic cholangiocarcinoma (IHCC). Previous studies have shown a link between hypoxia and CA19-9 in cancer, and we have previously demonstrated a correlation between HDAC1 and HIF-1 in IHCC. Here, we evaluated the expression and correlation of CA19-9 with HIF-1 and HDAC in IHCC. This study included 62 patients with IHCC who underwent primary hepatectomy at our department. Clinicopathological characteristics were examined. Immunohistochemical expression of HIF-1 and HDAC1 in specimens was quantitatively evaluated. Patients with high preoperative serum CA19-9 levels showed clinicopathological characteristics associated with tumour progression. High CA19-9 levels were associated with worse overall and recurrence-free survival. Univariate and multivariate analysis detected high CA19-9 levels as an independent poor prognostic factor for IHCC. Serum CA19-9 was significantly correlated with both HIF-1 and HDAC1 expression. High serum CA19-9 level is a poor prognostic factor for overall survival in IHCC and correlates with HIF-1 and HDAC1 expression. (Keyword) Aged / Bile Duct Neoplasms / Biomarkers, Tumor / CA-19-9 Antigen / Cholangiocarcinoma / female / Follow-Up Studies / Gene Expression Regulation, Neoplastic / Histone Deacetylase 1 / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Liver Neoplasms / male / Neoplasm Recurrence, Local / Prognosis / Survival Rate (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13808 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31704828 ● Search Scopus @ Elsevier (PMID): 31704828 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13808 (DOI: 10.21873/anticanres.13808, PubMed: 31704828)
47.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The Differences in the Characteristics of Insulin-producing Cells Using Human Adipose-tissue Derived Mesenchymal Stem Cells from Subcutaneous and Visceral Tissues., Scientific Reports, Vol.9, No.1, 13204, 2019. (Summary) The aim of this study was to investigate the characteristics of insulin producing cells (IPCs) differentiated from adipose-tissue derived stem cells (ADSCs) isolated from human subcutaneous and visceral adipose tissues and identify ADSCs suitable for differentiation into efficient and functional IPCs. Subcutaneous and visceral adipose tissues collected from four (4) patients who underwent digestive surgeries at The Tokushima University (000035546) were included in this study. The insulin secretion of the generated IPCs was investigated using surface markers by: fluorescence activated cell sorting (FACS) analysis; cytokine release; proliferation ability of ADSCs; in vitro (glucose-stimulated insulin secretion: (GSIS) test/in vivo (transplantation into streptozotocin-induced diabetic nude mice). The less fat-related inflammatory cytokines secretions were observed (P < 0.05), and the proliferation ability was higher in the subcutaneous ADSCs (P < 0.05). Insulin expression and GISI were higher in the subcutaneous IPCs (P < 0.01 and P < 0.05, respectively). The hyperglycaemic state of all mice that received IPCs from subcutaneous fat tissue converted into normo-glycaemia in thirty (30) days post-transplantation (4/4,100%). Transplanted IPCs were stained using anti-insulin and anti-human leukocyte antigen antibodies. The IPCs generated from the ADSCs freshly isolated from the human fat tissue had sufficient insulin secreting ability in vitro and in vivo. (Tokushima University Institutional Repository) ● Metadata: 114942 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-019-49701-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31519950 ● Search Scopus @ Elsevier (PMID): 31519950 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-019-49701-0 (Tokushima University Institutional Repository: 114942, DOI: 10.1038/s41598-019-49701-0, PubMed: 31519950)
48.	Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Chie Takasu, Jun Higashijima, Satoru Imura and Mitsuo Shimada : Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis., Anticancer Research, Vol.39, No.9, 5089-5096, 2019. (Summary) We evaluated the clinical impact of FOLFOXIRI regimen aiming for conversion surgery in patients with unresectable multiple colorectal liver metastasis (CRLM). A total of 42 patients with unresectable multiple CRLM who received chemotherapy with molecular agents were included in the analysis. The clinical results of FOLFOXIRI with other regimens were compared. The total conversion rate of 42 unresectable CRLM was 48.1%, and conversion cases had a better prognosis. Clinicopathological characteristics of conversion cases were more frequent in FOLFOXIRI induction, liver limited disease and maximum diameter number (MDN) over 70. FOLFOXIRI achieved a higher conversion rate compared to other regimens (72.2% vs. 37.5%, p=0.0334), and significantly reduced the medication period until conversion surgery (median 5.8 courses) with a higher tumour necrotic rate. Consequently, the overall survival of conversion cases with FOLFOXIRI was better than that with other regimens (p=0.0055). FOLFOXIRI plus molecular agents might provide a higher probability of conversion surgery with a prognostic benefit. (Keyword) Antineoplastic Combined Chemotherapy Protocols / Camptothecin / Colorectal Neoplasms / Combined Modality Therapy / Conversion to Open Surgery / female / Fluorouracil / Hepatectomy / Humans / Kaplan-Meier Estimate / Leucovorin / Liver Neoplasms / male / Neoplasm Grading / Neoplasm Staging / Organoplatinum Compounds / Prognosis / Treatment Outcome / Tumor Burden (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13703 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31519620 ● Search Scopus @ Elsevier (PMID): 31519620 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13703 (DOI: 10.21873/anticanres.13703, PubMed: 31519620)
49.	Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Toshiaki Yoshimoto, Koichi Tsuneyama and Mitsuo Shimada : Two cases of non-mucinous cystadenomas of the pancreas with pancreatobiliary phenotype and ovarian-like stroma., Surgical Case Reports, Vol.5, No.1, 117, 2019. (Summary) Diagnosis of cystic tumor of the pancreas is based on the World Health Organization criteria that classify pancreatic cystadenomas into four types: intra-ductal papillary mucinous neoplasms, mucinous cystic neoplasms (MCNs), serous cystic neoplasms, and solid pseudo-papillary neoplasms depending on their secretion and presence of ovarian-like stroma. Recently, Albores-Saavedra identified non-mucinous cystadenomas of the pancreas with pancreato-biliary phenotype and ovarian-like stroma. This precipitated examination of the proportions of these rare tumors in patients treated at Tokushima University Hospital. Case 1 was a 40-year-old woman with a cystic tumor in the tail of the pancreas. Computed tomography (CT) revealed a diffuse and non-enhanced cystic tumor in the tail of the pancreas. This tumor was diagnosed as a simple cyst at this point. However, 2ears later, the tumor had increased in size by 3m. Thus, laparoscopic distal pancreatectomy was performed. The content of the cyst was serous. The epithelial cells were lined with a single layer of cuboidal cells and the tumor had ovarian-like stroma pathologically. The final pathological diagnosis was non-mucinous cystadenoma of the pancreas with ovarian-like stroma. In Case 2, a cystic tumor in the pancreas was found by medical examination in a woman in her sixties who presented without symptoms. CT showed a 1.5-cm cystic tumor in the tail and body of the pancreas and a septum in the cyst. Nine years later, the tumor had grown to 2.4m in diameter and had a clear septum in the cyst. This tumor was diagnosed preoperatively as MCN. Thus, laparoscopic distal pancreatectomy was performed. The cyst contained serous fluid. Microscopic examination showed no ovarian-like stroma and the epithelial cells were lined by a single layer of cuboidal cells. The final pathological diagnosis was non-mucinous cystadenoma of the pancreas with ovarian-like stroma. Accurate preoperative diagnosis of this type of pancreatic cystic tumor may be difficult, although it occurs more often than expected. Non-mucinous cystadenomas of the pancreas with ovarian-like stroma need to be considered as a differential diagnosis. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-019-0673-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31338648 ● Search Scopus @ Elsevier (PMID): 31338648 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-019-0673-y (DOI: 10.1186/s40792-019-0673-y, PubMed: 31338648)
50.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging., PLoS ONE, Vol.14, No.1, e0210579, 2019. (Summary) Dynamic magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) can be used not only to detect liver tumors but also to estimate liver function. The aim of this study was to establish a new EOB-MRI-based formula to determine the resection limit in patients undergoing hepatectomy. Twenty-eight patients with a normal liver (NL group) and five with an unresectable cirrhotic liver (UL group) who underwent EOB-MRI were included. Standardized liver function (SLF) was calculated based on the signal intensity (SI), the volume of each subsegment (S1-S8), and body surface area. A formula defining the resection limit was devised based on the difference in the SLF values of patients in the NL and UL groups. The formula was validated in 50 patients who underwent EOB-MRI and hepatectomy. The average SLF value in the NL and UL groups was 2038 and 962 FV/m2, respectively. The difference (1076 FV/m2) was consistent with a 70% in resection volume. Thus, the resection limit for hepatectomy was calculated as a proportion of 70%: 70 (SLF-962)/1076 (%). The one patient who underwent hepatectomy over the resection limit died due to liver failure. In other 49 patients, in whom the resection volume was less than the resection limit, procedures were safely performed. Our formula for resection limit based on EOB-MRI can improve the safety of hepatectomy. (Tokushima University Institutional Repository) ● Metadata: 113041 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0210579 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30682046 ● Search Scopus @ Elsevier (PMID): 30682046 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0210579 (Tokushima University Institutional Repository: 113041, DOI: 10.1371/journal.pone.0210579, PubMed: 30682046)
51.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa, Jun Higashijima, Chie Takasu and Mitsuo Shimada : Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases., In Vivo, Vol.31, No.3, 419-423, 2017. (Summary) Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM. (Keyword) Adult / Aged / Aged, 80 and over / Cell Differentiation / Colorectal Neoplasms / Female / Follow-Up Studies / Hepatectomy / Humans / Liver Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Multivariate Analysis / Prognosis / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28438872 ● Search Scopus @ Elsevier (PMID): 28438872 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.11076 (DOI: 10.21873/invivo.11076, PubMed: 28438872)
52.	Masato Yoshikawa, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition., Anticancer Research, Vol.37, No.3, 1169-1175, 2017. (Summary) Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis. (Keyword) Adult / Aged / Aged, 80 and over / Antigens, CD / Antigens, CD34 / Cadherins / Carcinoembryonic Antigen / Carcinoma, Hepatocellular / Cell Adhesion Molecules / Disease-Free Survival / Epithelial-Mesenchymal Transition / Female / Follow-Up Studies / Humans / Immunohistochemistry / Liver Neoplasms / Male / Microcirculation / Middle Aged / Neovascularization, Pathologic / Predictive Value of Tests / Preoperative Period / Prognosis / Recurrence / Vimentin (Tokushima University Institutional Repository) ● Metadata: 112034 (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.11430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28314278 ● Search Scopus @ Elsevier (PMID): 28314278 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.11430 (Tokushima University Institutional Repository: 112034, DOI: 10.21873/anticanres.11430, PubMed: 28314278)
53.	M Davaadorj, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Mitsuo Shimada : Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma., EJSO - European Journal of Surgical Oncology, Vol.43, No.2, 344-350, 2017. (Summary) Secreted Frizzled-Related Protein-1 (SFRP1) is a well-known negative regulator of the wingless type (Wnt)- -catenin pathway and its inactivation plays an important role in the development and progression of many cancers. In this study, we aimed to determine the clinical significance of SFRP1 expression in intrahepatic cholangiocarcinoma (IHCC) and to define the relationship to Wnt- -catenin pathway. Fifty IHCC patients who had liver resection were enrolled in this study. SFRP1 protein expression was examined by immunohistochemistry in tumor tissues. The patients were divided into two groups: SFRP1 positive (n = 30) and negative (n = 20). Clinicopathological characteristics were analyzed. SFRP1 significantly correlated with curability (Cur A, B vs. C, p = 0.029); and recurrent pattern (intrahepatic vs. extrahepatic, p = 0.010). The negative SFRP1 group had significantly poorer prognosis, and 5-year survival rates were 8.1% of the negative SFRP1 group and 44.6% of the positive SFRP1 group, respectively. Moreover, the disease-free survival rate in the negative SFRP1 group was significantly poorer (p < 0.001). Multivariate analysis revealed that loss of SFRP1served as an independent prognostic factor in IHCC for both overall (HR, 2.923; 95% CI, 1.30-6.56; p = 0.009) and disease-free (HR, 2.631; 95% CI, 1.31-5.27; p = 0.006) survival. In addition, SFRP1 expression negatively correlated to -catenin expression (p = 0.005). Those results suggested that the loss of SFRP1 could be a poor prognostic factor for IHCC, through the Wnt- -catenin pathway. (Keyword) Aged / Biomarkers, Tumor / Cholangiocarcinoma / Female / Hepatectomy / Humans / Immunohistochemistry / Japan / Liver Neoplasms / Male / Prognosis / Proteins / Survival Rate (Tokushima University Institutional Repository) ● Metadata: 110034 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejso.2016.11.017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28062160 ● Search Scopus @ Elsevier (PMID): 28062160 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejso.2016.11.017 (Tokushima University Institutional Repository: 110034, DOI: 10.1016/j.ejso.2016.11.017, PubMed: 28062160)

Review, Commentary:

1.	Yoichiro Kawashita, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shuichi Iwahashi, Shin-ichiro Yamada, Jun Higashijima, Satoru Imura, Hirohisa Ogawa, Toshiyuki Yagi and Mitsuo Shimada : Loss of Fbxw7 expression is a predictor of recurrence in colorectal liver metastasis., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.24, No.10, 576-583, Oct. 2017. (Summary) Fbxw7 is a tumor suppressor through ubiquitination and degradation of multiple oncoproteins. Loss of Fbxw7 is frequently observed in various human cancers. In this study, we examined the role of Fbxw7 expression in colorectal liver metastasis (CRLM) and its mechanism. Fifty-six patients with CRLM who undergo curative resection were enrolled. Fbxw7 in tumor tissue was determined by immunohistochemistry. Patients were divided into two groups, the Fbxw7 high and low groups. Clinicopathological factors including miR-223 expression were compared between the high (n = 32) and low Fbxw7 groups (n = 24). Fbxw7 expression in tumor tissues was significantly lower than that in normal tissues. The disease-free survival in the low Fbxw7 group was significantly worse than that in the high Fbxw7 group, and 3 years disease-free survival of the low and high Fbxw7 groups were 12.5% and 47.0%, respectively (P = 0.023). On multivariate analysis, loss of Fbxw7 was detected as one of the independent risk factors for recurrence of CRLM (hazard ratio: 2.390, P = 0.017). Likewise, Fbxw7 expression inversely correlated to miR-223 expression (P = 0.017). Loss of Fbxw7 in tumor tissues could be a reliable predictor of recurrence after hepatectomy in patients with CRLM, and miR-223 might be a possible regulator of Fbxw7. (Tokushima University Institutional Repository) ● Metadata: 110995 (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.500 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28846828 ● Search Scopus @ Elsevier (PMID): 28846828 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.500 (Tokushima University Institutional Repository: 110995, DOI: 10.1002/jhbp.500, PubMed: 28846828)
2.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto and Atsushi Takata : Effective stepwise training and procedure standardization for young surgeons to perform laparoscopic left hepatectomy., Surgical Endoscopy, Vol.31, No.6, 2623-2629, Dec. 2016. (Summary) Laparoscopic hepatectomy remains one of the most difficult procedures for young surgeons to perform. We recently developed a new training method and standardization procedure for teaching young surgeons to perform laparoscopic left hepatectomy (Lap-LHx). The aim of this study was to assess the effectiveness of our method. In 2004, we standardized a laparoscopic procedure for Lap-LHx, using a laparoscopy-assisted method as a stepping stone. The laparoscopic training method comprised the following three steps: (1) training in fundamental procedures using a dry box and checking by mentors; (2) detailed preoperative simulation using Vincent three-dimensional software for each patient; and (3) self-assessment including understanding of relevant anatomy and completion grade for each procedure using a check sheet and feedback by both mentors and a professor. Twenty-three Lap-LHx procedures performed during the study period were divided into two groups: those performed by young non-board-certified surgeons (n = 9) and those performed by senior board-certified surgeons (n = 14). The blood loss and operative time were similar in the young surgeon (194 g and 336 min, respectively) and senior surgeon groups (208 g and 322 min, respectively). Our standardized Lap-LHx procedure and stepwise training to perform it enable young surgeons to perform Lap-LHx as confidently and safely as more experienced surgeons. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-016-5273-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27928671 ● Search Scopus @ Elsevier (PMID): 27928671 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-016-5273-3 (DOI: 10.1007/s00464-016-5273-3, PubMed: 27928671)
3.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou and Shin-ichiro Yamada : 【最新肝胆膵高難度外科手術アトラス】高難度外科手術手技肝臓肝下部下大静脈再建を伴う肝切除, Operation, Vol.70, No.4, 431-438, Mar. 2016. (Keyword) *下大静脈(外科的療法)
4.	Yuji Morine, Mitsuo Shimada, Hiroki Ishibashi, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : 【膵・胆管合流異常の診断基準の改訂をめぐって】膵・胆管合流異常の診断の最前線胆汁中アミラーゼ値, Journal of Biliary Tract & Pancreas, Vol.35, No.10, 921-925, Oct. 2014. (Keyword) 和文論文

Proceeding of International Conference:

1.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : Preoperative weight loss program for HCC patients with high body mass index in hepatectomy., APASL 2024 Kyoto(アジア太平洋肝臓学会), Kyoto, Mar. 2024.
2.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki and Mitsuo Shimada : New onlocogical resectability of CRLM and multidisciplinary treatment strategy, APASL 2024 Kyoto(アジア太平洋肝臓学会), Kyoto, Mar. 2024.
3.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Preoperative weight loss program for hepatocellular carcinoma patients with high body mass index in hepatectomy., ASCO-GI 2024, San Francisco, Jan. 2024.
4.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : Computed Tomography in Patients with Mass-Forming Intrahepatic Cholangiocarcinoma, IHPBA2020, Melbourne, Nov. 2020.
5.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Shin-ichiro Yamada : Treatment Strategy for Synchronous Liver Metastases from Colorectal Cancer, IHPBA2020, Melbourne, Nov. 2020.
6.	Kazunori Tokuda, Mitsuo Shimada, Tetsuya Ikemoto, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura and Yuji Morine : The investigation of optimal transplantation site of insulin producing cell differentiated from human adipose derived stem cell., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.194 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.194 (DOI: 10.1016/j.jcyt.2020.03.194)
7.	Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective 3D culture of hepatocyte like cells from human adipose derived mesenchymal stem cells., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.178 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.178 (DOI: 10.1016/j.jcyt.2020.03.178)
8.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura and Yuji Morine : The generation of effective insulin-producing cells from ADSC derived from type 1 diabetes mellitus patients., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.147 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.147 (DOI: 10.1016/j.jcyt.2020.03.147)
9.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty in prognosis after hepatectomy in older patients with hepatocellular carcinoma., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-020-08742-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
10.	Yusuke Arakawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Evaluation of the ratio of plasma fibrinogen to platelet in resectable pancreatic cancer., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.756 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.756 (DOI: 10.1200/JCO.2020.38.4_suppl.756)
11.	Masato Yoshikawa, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, IASGO2019, Bangkok, Oct. 2019.
12.	Yu Saitou, Shogo Oota, Tetsuya Ikemoto, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Shin-ichiro Yamada and Mitsuo Shimada : THE NEW ROLE OF ZINC ION IN INSULIN-PRODUCING CELLS DIFFERENTIATION FROM ADIPOSE DERIVED MESENCHYMAL STEM CELLS., ESOT2019, Copenhagen, Sep. 2019.
13.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Feng Rui, Shin-ichiro Yamada, Shuichi Iwahashi, Yuji Morine and Satoru Imura : THE POTNETIALLY CLINICAL APPLICATION OF XENO-ANTIGEN FREE DIFFERENTIATION PROTOCOL FOR INSULINPRODUCING CELLS USING HUMAN RECOMBINANT PEPTIDE PETALOID Μ-PIECE FROM ADIPOSE-TISSUE DERIVED MESENCHYMAL STEM CELL, ESOT2019, Copenhagen, Sep. 2019.
14.	Mitsuo Shimada, Tetsuya Ikemoto, Yuuma Wada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Shogo Oota : Characteristic difference of adiposederived mesenchymal stem cells from subcutaneous and visceral fat tissue for generating insulin-producing cell, ESOT2019, Copenhagen, Sep. 2019.
15.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : Standardization of surgical technique in laparoscopic distal pancreatectomy, SAGES 2019, Baltimore, Apr. 2019.
16.	Shin-ichiro Yamada, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto, Masaaki Nishi and Chie Takasu : Prognostic Prediction of Mass-Forming Intrahepatic Cholangiocarcinoma from Diffusion Weighted Image of Magnetic Resonance Image, SSO's 72nd Annual Cancer Symposium, San Diego, Mar. 2019.
17.	Shogo Oota, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : The feasibility of hepatectomy for the super-elderly patients with HCC., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.274 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.274 (DOI: 10.1200/JCO.2019.37.4_suppl.274)
18.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and 馮睿 : The effect of hepatic stellate cells on hepatocellular carcinoma progression., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.265 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.265 (DOI: 10.1200/JCO.2019.37.4_suppl.265)
19.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Validity of hepatic cone-unit resection for hepatocellular carcinoma., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.228 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.228 (DOI: 10.1200/JCO.2019.37.4_suppl.228)
20.	Mitsuo Shimada, Hiroki Teraoku, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu and Shin-ichiro Yamada : Role of central hypovascularity in the hepatic arterial phase of dynamic CT on mass-forming intrahepatic cholangiocarcinoma., ASCO-GI, San Francisco, Jan. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2019.37.4_suppl.205 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2019.37.4_suppl.205 (DOI: 10.1200/JCO.2019.37.4_suppl.205)
21.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : The approach for establishing safe, reliable and rapid pancreatoduodenectomy, 第9回日本・モンゴル国際消化器癌シンポジウム, Aug. 2018.
22.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Current status and effect of laparoscopic training for young surgeon, 40th World Congress of the International College of Surgeons (ICS 2016), Kyoto, Oct. 2016.
23.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : Elevated preoperative serum CEA levels in patients with HCC is associated with prognosis and EMT, 第8回日本・モンゴル消化器癌国際シンポジウム, ウランバートル, Aug. 2016.
24.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The effect od HDACi in ADSC differentiation in to insulin producing cells., Transplantation Science Symposium (TSS) Asian Regional Meeting 2016, Tokyo, Apr. 2016.
25.	Satoru Imura, Takuya Tokunaga, Masayuki Sumitomo, Shin-ichiro Yamada, Chie Takasu, Yu Saitou, Jun Higashijima, Kouzou Yoshikawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Usefulness of telementoring system to develop laparoscopic surgery in rural hospital, Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
26.	Shin-ichiro Yamada and Mitsuo Shimada : Recurrent feature after radiofrequency ablation herapy for hepatocelluar carcinoma : Risk of increasing malignant behavior., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.
27.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : Treatment strategy for intrahepatic cholangiocarcinoma: From optimal surgical management to adjuvant therapy., 2016 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2016.
28.	Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Jun Higashijima and Chie Takasu : Folfoxiri regimen brings early ``conversion'' and better long-term outcome in patients with initially unresectable colorectal liver metastases, 46th World Congress of Surgery (WCS)2015, Aug. 2015.
29.	Shin-ichiro Yamada : Recurrent feature after radiofrequency ablation therapy for hepatocelluar carcinoma-Risk of increasing malignant behavior, The 6th Asia-Pacific Primary Liver Cancer Expert Meeting(APPLE2015), Jul. 2015.
30.	Teraoku Hiroki, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Daichi Ishikawa and Yoshikawa Masato : The expression of Ki-67 is a useful prognostic factor in patients with colorectal liver metastasis, IASGO 2015 post graduate course, Tokyo, Jun. 2015.
31.	Shin-ichiro Yamada : Successful resected case of hilar cholangiocarcinoma with right-sided round ligament., A-PHPBA 2015, Mar. 2015.
32.	Shin-ichiro Yamada : Successful resected case of hilar cholangiocarcinoma with right-sided round ligament., A-PHPBA, Mar. 2015.
33.	良元俊昭, GY Wubetu, Shin-ichiro Yamada, 石川大地, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Impact of STAT4 expression on cellular immunity and prognosis in hepatocellular carcinoma., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
34.	Shuichi Iwahashi, Yismaw Gizachew, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 吉川雅登, 寺奥大貴 and Mitsuo Shimada : The antitumor effect of epigallocatechin-3-gallate on gastroenterological cancer., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
35.	Satoru Imura, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Hiroshi Shibata and Hidenori Miyake : Long-term survivors after sorafenib therapy in unresectable hepatocellular carcinoma., ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.
36.	Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登, Jun Higashijima and Chie Takasu : Impact of FOLFOXIRI regimen on early ``Conversion'' and long-term outcome in patients with initially unresectable colorectal liver metastases, ASCO-GI 2015 Gastrointestinal Cancers Symposium, Jan. 2015.

Proceeding of Domestic Conference:

1.	Takuya Tokunaga, Yuhei Waki, Hiroki Ishibashi, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : ADSCから分化したSchwann cell-like cellが神経修復へ与える影響に関する基礎的検討, 第23回日本再生医療学会総会, Mar. 2024.
2.	Yuhei Waki, Yu Saitou, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導した肝細胞様細胞の尿素サイクル異常症モデルマウスへの移植効果, 第23回日本再生医療学会総会, Mar. 2024.
3.	Yu Saitou, Tetsuya Ikemoto, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 脂肪由来幹細胞から分化誘導した肝細胞様細胞の免疫原性獲得に関する研究, 第23回日本再生医療学会総会, Mar. 2024.
4.	Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療を用いた新たな膵β細胞(insulin producing cell:IPC)移植戦略の樹立に関する研究, 第23回日本再生医療学会総会, Mar. 2024.
5.	Hiroki Teraoku, Yuhei Waki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 腫瘍関連マクロファージ(TAM)とのcrosstalkを介したLenvatinib耐性肝細胞癌における悪性度獲得機序, 第56回制癌剤適応研究会, Feb. 2024.
6.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : Atezolizmab+Bevacizumab療法ならびにTremelimumab+Durvalumab療法により縮小が得られ肝切除を施行し得たVp4を伴う進行肝細胞癌の一例, 第29回日本肝がん分子標的治療研究会, Jan. 2024.
7.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Mitsuo Shimada : 切除可能境界膵癌における集学的治療の意義, 第120回日本消化器病学会四国支部例会, Dec. 2023.
8.	Shin-ichiro Yamada : 腹腔鏡下胆嚢摘出術における内視鏡ホルダロボットEMAROの有用性に関する検討, 第36回日本内視鏡外科学会総会, Dec. 2023.
9.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 腹腔鏡下肝切除におけるPitfall -心房細動アブレーション後医原性心房中隔欠損を介した奇異性塞栓症-, 第36回日本内視鏡外科学会総会, Dec. 2023.
10.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 最大腫瘍径×個数を用いた新たなresectabilityと治療戦略の提唱, 第45回日本肝臓学会西部会, Dec. 2023.
11.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝内胆管癌における新たな予後予測 - MRI拡散強調画像と腫瘍浸潤リンパ球 –, 第45回日本肝臓学会西部会, Dec. 2023.
12.	Yuuma Wada, Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Hiroki Teraoku, Kouzou Yoshikawa, Takuya Tokunaga, Toshihiro Nakao, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto and Mitsuo Shimada : 肝細胞癌におけるエクソソームmiRNAを介したLenvatinib耐性機序の検討, 第34回日本消化器癌発生学会総会, Nov. 2023.
13.	Yuhei Waki, Yuji Morine, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : 肝細胞癌微小環境におけるNrf2シグナルを介した癌細胞とTAMの相互作用, 第34回日本消化器癌発生学会総会, Nov. 2023.
14.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第34回日本消化器癌発生学会総会, Nov. 2023.
15.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 80歳以上の高齢者膵癌に対する膵頭十二指腸切除の治療成績, 第85回日本臨床外科学会総会, Nov. 2023.
16.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 大腸癌多発肝転移における最大腫瘍径×個数を用いた肝切除基準と集学的治療方針の提唱, 第85回日本臨床外科学会総会, Nov. 2023.
17.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : EOB予備能評価に基づいた至適肝切除, JDDW 2023, Nov. 2023.
18.	Yuhei Waki, Yuji Morine, Takayuki Noma, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto and Mitsuo Shimada : 微小環境におけるエクソソームを介した薬剤肝細胞癌の悪性度増強と耐性機序の解明, 第61回日本癌治療学会学術集会, Oct. 2023.
19.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 再発肝細胞癌に対する肝切除成績, 第61回日本癌治療学会学術集会, Oct. 2023.
20.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 膵・胆管合流異常における胆道上皮PD-L1発現, 第46回日本膵・胆管合流異常研究会, Sep. 2023.
21.	Hiroki Teraoku, Yu Saitou, 杉本真樹, Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto and Mitsuo Shimada : 胆道手術における3D胆道造影Extended realityによる手術支援, 第17回肝癌治療ナビゲーション研究会, Aug. 2023.
22.	Yu Saitou, 杉本真樹, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝胆膵手術支援の新展開-Extended reality・ホログラム・メタバース-, 第50回日本膵切研究会, Aug. 2023.
23.	Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 症例, 第59回日本肝癌研究会, Jul. 2023.
24.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌における微小環境クロストークによるLenvatinib耐性機序の検討, 第59回日本肝癌研究会, Jul. 2023.
25.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第59回日本肝癌研究会, Jul. 2023.
26.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Shoko Yamashita and Koichi Tsuneyama : 組織発生学的特徴からみた肝内胆管癌の病理診断, 第59回日本肝癌研究会, Jul. 2023.
27.	Yuhei Waki, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Takayuki Noma, Tetsuya Ikemoto and Mitsuo Shimada : 内科的治療後再発・遺残肝細胞に対するRescue肝切除の意義, 第78回日本消化器外科学会総会, Jul. 2023.
28.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Hiroki Teraoku : 徳島大学病院全体と消化器・移植外科のFRT回避に係る連携とOODAループ, 第78回日本消化器外科学会総会, Jul. 2023.
29.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Takayuki Noma and Mitsuo Shimada : EOBによる肝予備能評価と最大腫瘍径×個数を用いた肝切除限界の提唱, 第78回日本消化器外科学会総会, Jul. 2023.
30.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 高齢者膵癌に対する膵頭十二指腸切除術の適応と限界, 第78回日本消化器外科学会総会, Jul. 2023.
31.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性 - ERAS導入による手術成績の向上 –, 第78回日本消化器外科学会総会, Jul. 2023.
32.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第78回日本消化器外科学会総会, Jul. 2023.
33.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto, Sonoko Yasui-Yamada, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性-ERAS導入による手術成績の向上 –, 日本外科代謝栄養学会第60回学術集会, Jul. 2023.
34.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, 仲須千春 and Mitsuo Shimada : PD-L1 expression of biliary epithelium in pancreaticobiliary maljunction, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
35.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : New strategy for CRLM using Maximum Diameter x Number: MDN, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
36.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto, Shin-ichiro Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : Preoperative weight loss program for high body mass index patients undergoing liver resection for hepatocellular carcinoma - Surgical outcomes of ERAS protocol, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
37.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki and Hiroki Teraoku : Establishment of investigator initiated clinical trial as a future cell transplantation for to complement existing transplantations, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
38.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : Reconsideration of indication of hepatic for advanced hepatocellular carcinoma and significance of conversion surgery, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
39.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 肝細胞癌におけるNrf2/VEGFシグナルを介したTumor-associated macrophage (TAM)との相互作用, 第44回癌免疫外科研究会, Jun. 2023.
40.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 術前の心構え「AWA spirits」に基づいたtraining systemによる肝胆膵外科の若手教育, 日本消化器病学会四国支部第119回例会, Jun. 2023.
41.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : StageIII/IVa肝細胞癌におけるMRI拡散強調画像ADC値とTumor infiltrative lymphocyte (TIL), 第59回日本肝臓学会総会, Jun. 2023.
42.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, 第59回日本肝臓学会総会, Jun. 2023.
43.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第48回日本外科系連合学会学術集会, Jun. 2023.
44.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌における至適肝切除適応の再考とConversion surgeryの意義, 第48回日本外科系連合学会学術集会, Jun. 2023.
45.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 徳島大学病院における医療安全管理上の患者アドボカシーの実情と展望, 第48回日本外科系連合学会学術集会, Jun. 2023.
46.	Hiroki Mori, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Takayuki Noma : EOB予備能評価に基づいた至適肝切除, 第123回日本外科学会定期学術集会, Apr. 2023.
47.	Hiroki Mori, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and Takayuki Noma : EOB予備能評価に基づいた至適肝切除, 第123回日本外科学会定期学術集会, Apr. 2023.
48.	Shin-ichiro Yamada : Nrf2を基軸とした癌微小環境ストロークによる肝細胞癌レンバチニブ耐性機序の解明に関する研究, 第123回日本外科学会定期学術集会, Apr. 2023.
49.	Takayuki Noma, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 再発肝細胞癌に対する肝切除の意義, 第123回日本外科学会定期学術集会, Apr. 2023.
50.	Hiroki Teraoku, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Sonoko Yasui-Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肝細胞癌における肥満患者への術前栄養運動介入の有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
51.	Yuhei Waki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and 仲須千春 : Lenvatinib耐性肝細胞癌における癌微小環境を介した悪性度獲得機序の解明, 第123回日本外科学会定期学術集会, Apr. 2023.
52.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療によるインスリン産生細胞自家移植戦略は1型糖尿病治療を変える, 第123回日本外科学会定期学術集会, Apr. 2023.
53.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Yuhei Waki, Hiroki Teraoku and 仲須千春 : EOBによる肝予備能評価と最大腫瘍径×個数を用いた肝切除限界の提唱, 第123回日本外科学会定期学術集会, Apr. 2023.
54.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku, Takashi Iwata and Mitsuo Shimada : 消化器外科ナビゲーションの新展開 -Extended reality・ホログラム・メタバース –, 第123回日本外科学会定期学術集会, Apr. 2023.
55.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌における至適肝切除適応の再考とConversion surgeryの意義, 第123回日本外科学会定期学術集会, Apr. 2023.
56.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 大腸癌肝転移における切除不能の定義とコンバージョンを目指した治療戦略, 第109回日本消化器病学会総会, Apr. 2023.
57.	Yuhei Waki, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ADSCから分化したinsulin producing cell移植時の自己免疫による影響に関する検討, 第22回日本再生医療学会総会, Mar. 2023.
58.	Yu Saitou, 陳述海, Yuhei Waki, Tetsuya Ikemoto, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を用いた新たな肝細胞様細胞移植の樹立にむけて, 第22回日本再生医療学会総会, Mar. 2023.
59.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 間葉系幹細胞を用いた新たなβ細胞補填治療法樹立に向けて, 第22回日本再生医療学会総会, Mar. 2023.
60.	Yuhei Waki, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療によって作成されたinsulin producing cell移植後の自己免疫による影響に関する基礎的検討, 第50回日本膵・膵島移植学会学術集会, Mar. 2023.
61.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Yuhei Waki, Hiroki Teraoku, Yuuma Wada, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いたβ細胞補填治療法に関する膵島移植とのクロストーク, 第50回日本膵・膵島移植学会学術集会, Mar. 2023.
62.	Hiroki Teraoku, Yuhei Waki, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : Lenvatinib耐性肝細胞癌におけるNrf2を介した悪性度上昇と薬剤耐性獲得機序の検討, 第55回制癌剤適応研究会, Feb. 2023.
63.	Yuhei Waki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : Lenvatinib耐性肝細胞癌における癌微小環境を介した悪性度獲得と薬剤耐性獲得機序の解明, 第27回日本肝がん分子標的治療研究会, Jan. 2023.
64.	Shin-ichiro Yamada, Yuji Morine, Yu Saitou, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 肝細胞癌BCLC intermediate stageにおけるMaximum tumor diameter × number の意義, 第27回日本肝がん分子標的治療研究会, Jan. 2023.
65.	Hiroki Mori, Yuji Morine, Hiroki Ishibashi, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 慢性炎症状態の膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第33回日本消化器癌発生学会総会, Nov. 2022.
66.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Yuhei Waki, Takayuki Noma and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義と集学的治療戦略, 第84回日本臨床外科学会総会, Nov. 2022.
67.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第84回日本臨床外科学会総会, Nov. 2022.
68.	Tetsuya Ikemoto, Mitsuo Shimada, Shin-ichiro Yamada, Hiroki Teraoku, Yu Saitou and Yuji Morine : de novo B型肝炎管理体制構築に向けた取り組み, 第84回日本臨床外科学会総会, Nov. 2022.
69.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Sonoko Yasui-Yamada, 西麻希, Hiroshi Sakaue, 鎌田基夢, Tetsuya Matsuura and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第118回日本消化器病学会四国支部例会, Nov. 2022.
70.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 仲須千春, 髙橋叡, Takayuki Noma and Mitsuo Shimada : StageIII/IV肝細胞癌における拡散強調画像ADC値の意義, 第33回日本消化器癌発生学会総会, Nov. 2022.
71.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移における発育形式と予後に関する検討, 第84回日本臨床外科学会総会, Nov. 2022.
72.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yuhei Waki and Mitsuo Shimada : Nrf2を基軸とした癌微小環境クロストークによる肝細胞癌Lenvatinib耐性機序解明に関する研究, 第33回日本消化器癌発生学会総会, Nov. 2022.
73.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌におけるlymphocyte/C-reactive protein ratio(LCR)の有用性, JDDW 2022, Oct. 2022.
74.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者膵癌切除例におけるフレイルの影響に関する検討, JDDW 2022, Oct. 2022.
75.	仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌におけるNrf2に着目したレンバチニブ耐性獲得機序についての検討, 第60回日本癌治療学会学術集会, Oct. 2022.
76.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 仲須千春 and Mitsuo Shimada : 肝癌微小環境におけるNrf2/VEGFシグナルを介した肝癌細胞とTAMの相互作用, 第60回日本癌治療学会学術集会, Oct. 2022.
77.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, Toshiaki Yoshimoto, 西麻希, Hiroshi Sakaue and Mitsuo Shimada : 肥満肝細胞癌患者に対する術前栄養運動介入の有用性 -ERAS導入による手術成績の向上-, 第60回日本癌治療学会学術集会, Oct. 2022.
78.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 高齢者膵癌切除例の予後におけるフレイルの影響に関する検討, 第60回日本癌治療学会学術集会, Oct. 2022.
79.	Tetsuya Ikemoto, Takuya Tokunaga, Yuhei Waki, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Schwann-like cell分化誘導による末梢神経損傷修復に関する基礎的検討, 第60回日本癌治療学会学術集会, Oct. 2022.
80.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第60回日本癌治療学会学術集会, Oct. 2022.
81.	Yuhei Waki, Yu Saitou, Tetsuya Ikemoto, 陳術海, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出-肝不全・代謝性肝疾患に対する肝移植から細胞治療へ, 第58回日本移植学会総会, Oct. 2022.
82.	Yu Saitou, Mitsuo Shimada, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植ドナー不足解消にむけての普及啓発活動 - 医療系学生に対するドナーアクション(命の授業)の必要性 –, 第58回日本移植学会総会, Oct. 2022.
83.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いた移植治療確立へ向けた戦略∼新たなβ細胞補充治療法, 第58回日本移植学会総会, Oct. 2022.
84.	Hiroki Mori, Yuji Morine, Hiroki Ishibashi, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 慢性炎症化下の膵・胆管合流異常におけるNLRP3活性化を介した腫瘍微小環境と発癌に関する検討, 第45回日本膵・胆管合流異常研究会, Sep. 2022.
85.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌腫瘍微小環境におけるNrf2/VEGFシグナルを介した癌細胞とTAMの相互作用, 第81回日本癌学会学術総会, Sep. 2022.
86.	Takayuki Noma, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 再発膵癌に対する残膵切除の治療成績, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
87.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Takayuki Noma and Mitsuo Shimada : 大腸癌肝転移におけるresectabilityの定義と集学的治療戦略, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
88.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
89.	Yu Saitou, 杉本真樹, Yuji Morine, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第16回肝癌治療ナビゲーション研究会, Sep. 2022.
90.	仲須千春, Mitsuo Shimada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and 沖川昌平 : MRI拡散強調画像から見たミラノ基準内肝細胞癌の予後予測に関する検討, 第77回日本消化器外科学会総会, Jul. 2022.
91.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 膵癌残膵再発に対する残膵切除の治療成績, 第77回日本消化器外科学会総会, Jul. 2022.
92.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Toshiaki Yoshimoto, 西麻希, Hiroshi Sakaue and Mitsuo Shimada : 肥満を有する肝細胞癌患者に対する術前栄養運動介入の有用性, 第77回日本消化器外科学会総会, Jul. 2022.
93.	Tetsuya Ikemoto, Yu Saitou, Mitsuo Shimada, 沖川昌平, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 再生医療を用いた細胞移植治療確立へ向けた戦略∼移植外科医・レシピエント双方の負担軽減という視点から, 第77回日本消化器外科学会総会, Jul. 2022.
94.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義とBRに対する集学的治療戦略, 第77回日本消化器外科学会総会, Jul. 2022.
95.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第77回日本消化器外科学会総会, Jul. 2022.
96.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Yasuhiro Hamada, 沖川昌平 and Mitsuo Shimada : 肝細胞癌におけるmiRNA-132, 142-5pを介したLenvatinib耐性機序の検討, 第77回日本消化器外科学会総会, Jul. 2022.
97.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku and Mitsuo Shimada : 肝細胞癌におけるSorafenib/Lenvatinib耐性機序の検討, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
98.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
99.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除を中心とした治療戦略, 第31回日本癌病態治療研究会, Jun. 2022.
100.	Yu Saitou, Yuji Morine, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第117回日本消化器病学会四国支部例会, Jun. 2022.
101.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 消化器・移植外科から発信する手術室医療安全, 第47回日本外科系連合学会学術集会, Jun. 2022.
102.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Associations between the ADC values based on MRI diffusion-weighted images and tumor-infiltrative lymphocytes in Stage III / IV hepatocellular carcinoma, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
103.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou and Hiroki Teraoku : Impact of frailty on resected pancreatic cancer in elderly patients, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
104.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Masaaki Nishi, Hiroshi Sakaue and Mitsuo Shimada : Weight loss program for high body mass index patients undergoing liver resection for hepatocellular carcinoma, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
105.	Tetsuya Ikemoto, Yu Saitou, Mitsuo Shimada, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : Establishment of investigator initiated clinical trial for insulin producing cells from ADSC with Tokushima protocol to complement pancreas/islet transplantation., 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
106.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : Role of surgical resection for advanced hepatocellular carcinoma focused on conversion surgery in MTA era, 第34回日本肝胆膵外科学会・学術集会, Jun. 2022.
107.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第31回日本コンピュータ外科学会大会, Jun. 2022.
108.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Significance of the ADC values based on MRI DWI in Stage / HCC, 第67回国際外科学会日本部会総会, Jun. 2022.
109.	Chie Takasu, 仲須千春, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 肝細胞癌におけるmiRNA-X,Yを介したLenvatinib耐性機序の検討, 第26回日本肝がん分子標的治療研究会, Jun. 2022.
110.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 症例, 第58回日本肝癌研究会, May 2022.
111.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 大腸癌肝転移におけるoncological/liver functional resectabilityの定義とBRに対する集学的治療戦略, 第58回日本肝癌研究会, May 2022.
112.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する肝切除の意義, 第58回日本肝癌研究会, May 2022.
113.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した肝胆道手術支援, 第58回日本肝癌研究会, May 2022.
114.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Tetsuya Ikemoto and Mitsuo Shimada : 再発肝細胞癌に対する肝切除の意義, 第58回日本肝癌研究会, May 2022.
115.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, 沖川昌平 and 山下祥子 : 高齢者膵癌切除例におけるフレイルの影響に関する検討, 第108回日本消化器病学会総会, Apr. 2022.
116.	髙橋叡, Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Stage III/IV 肝細胞癌におけるMRI拡散強調画像をもとにしたADC値の有用性に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
117.	仲須千春, 山下祥子, Yuji Morine and Shin-ichiro Yamada : 肝細胞癌の腫瘍微小環境形成における癌関連線維芽細胞の役割, 第122回日本外科学会定期学術集会, Apr. 2022.
118.	Hiroki Teraoku, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 沖川昌平, Tetsuya Ikemoto and Mitsuo Shimada : Borderline resectableに着目した切除可能分類に基づく膵癌治療成績に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
119.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 膵癌切除例における早期再発の危険因子に関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
120.	荒川悠佑, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 切除可能膵癌における術後予後予測因子としてのCRP・アルブミン比(CAR)の有用性, 第122回日本外科学会定期学術集会, Apr. 2022.
121.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, 宮崎克己 and Mitsuo Shimada : 術中ホログラム胆道造影を駆使した胆道手術支援, 第122回日本外科学会定期学術集会, Apr. 2022.
122.	Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, 沖川昌平, Hiroki Teraoku, Shin-ichiro Yamada and Yuji Morine : 自己脂肪から作成したインスリン産生細胞自家移植が拓く再生医療の未来, 第122回日本外科学会定期学術集会, Apr. 2022.
123.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, 沖川昌平 and Mitsuo Shimada : 間葉系幹細胞から肝細胞様細胞の誘導におけるNrf2の働きに関する検討, 第122回日本外科学会定期学術集会, Apr. 2022.
124.	Tetsuya Ikemoto, Takuya Tokunaga, Yu Saitou, Shohei Okikawa, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導したSchwann-like cellに関する研究, 第21回日本再生医療学会総会, Mar. 2022.
125.	Shohei Okikawa, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, NAKASU Chiharu and Mitsuo Shimada : VEGF阻害はTAMの機能を減弱させる, 第25回日本肝がん分子標的治療研究会, Jan. 2022.
126.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 肝癌微小環境においてTAMを介したNrf2/VEGFシグナルが悪性度増強に関与する, 第44回日本肝臓学会西部会, Dec. 2021.
127.	Hiroki Teraoku, Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto, Yu Saitou and Mitsuo Shimada : 腹腔鏡下膵体尾部切除の手術手技と定型化, 第34回日本内視鏡外科学会総会, Dec. 2021.
128.	Chie Takasu, Gao Luping, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : Nrf2を介した微小環境クロストークによる肝細胞癌薬剤耐性機序解明に関する研究, 第32回日本消化器癌発生学会総会, Nov. 2021.
129.	Chie Takasu, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Mitsuo Shimada : 大腸癌肝転移における免疫逃避機構の働き, 第83回日本臨床外科学会総会, Nov. 2021.
130.	Shohei Okikawa, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, NAKASU Chiharu and Mitsuo Shimada : VEGF阻害はTAMの悪性度を減じる, 第32回日本消化器癌発生学会総会, Nov. 2021.
131.	Hiroki Teraoku, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝細胞癌におけるNrf2-PINK-1axisを介したLenvatinib耐性機序の検討, 第32回日本消化器癌発生学会総会, Nov. 2021.
132.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第32回日本消化器癌発生学会総会, Nov. 2021.
133.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa and Mitsuo Shimada : 肝細胞癌におけるソラフェニブ耐性獲得機序に関する検討, 第32回日本消化器癌発生学会総会, Nov. 2021.
134.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Shin-ichiro Yamada, Hiroki Teraoku, Takashi Iwata and Mitsuo Shimada : 消化器外科におけるホログラム次世代手術支援, 第30回日本コンピュータ外科学会大会, Nov. 2021.
135.	Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : One stop shop を目指したEOB-MRIによる部分肝機能評価，切除限界予測と腫瘍悪性度の評価に関する検討, 第116回日本消化器病学会四国支部例会, Nov. 2021.
136.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 再発膵癌に対する残膵切除の治療成績, 第83回日本臨床外科学会総会, Nov. 2021.
137.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション, 第83回日本臨床外科学会総会, Nov. 2021.
138.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 徳島大学の肝胆膵外科における若手教育, 第83回日本臨床外科学会総会, Nov. 2021.
139.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : 地方から世界に通用する一流の外科医を目指した取り組み, 第83回日本臨床外科学会総会, Nov. 2021.
140.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第83回日本臨床外科学会総会, Nov. 2021.
141.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Yu Saitou, Shin-ichiro Yamada and Hiroki Teraoku : 外科医をも守る消化器・移植外科から発信する手術室医療安全, 第83回日本臨床外科学会総会, Nov. 2021.
142.	Shoko Yamashita, Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 膵・胆管合流異常におけるNLRP3を介した腫瘍微小環境と発癌に関する検討, 第57回日本胆道学会学術集会, Oct. 2021.
143.	Shohei Okikawa, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第57回日本胆道学会学術集会, Oct. 2021.
144.	Shin-ichiro Yamada, Katsuki Miyazaki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita and Mitsuo Shimada : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第57回日本胆道学会学術集会, Oct. 2021.
145.	Shohei Okikawa, Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto and Mitsuo Shimada : VEGF inhibition reduce TAM's malignant potential, 第80回日本癌学会学術総会, Sep. 2021.
146.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : The role of BAFF/BAFF receptor in microenvironment of sorafenib resistant he patocellular carcinoma, 第80回日本癌学会学術総会, Sep. 2021.
147.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : 生体肝移植術後短期長期成績に関する検討, 第57回日本移植学会総会, Sep. 2021.
148.	Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を基にした機能的肝細胞様細胞の分化誘導, 第57回日本移植学会総会, Sep. 2021.
149.	Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Shohei Okikawa, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療を用いたインスリン産生細胞自家移植による1型糖尿病根治治療確立へ向けた戦略, 第57回日本移植学会総会, Sep. 2021.
150.	Shin-ichiro Yamada, Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Hiroki Teraoku, 杉本真樹 and Mitsuo Shimada : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション-マイクロ波手術デバイスAcrosurg®使用経験も含めて-, 第15回肝がんナビゲーション研究会, Sep. 2021.
151.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出-肝不全・代謝性肝疾患に対する肝移植から細胞治療へ-, 第263回徳島医学会学術集会(令和3年度夏期), Aug. 2021.
152.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Katsuki Miyazaki, Kazunori Tokuda, Shohei Okikawa, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第57回日本肝癌研究会, Jul. 2021.
153.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第57回日本肝癌研究会, Jul. 2021.
154.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第57回日本肝癌研究会, Jul. 2021.
155.	TAKAHASHI Akira, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第76回日本消化器外科学会総, Jul. 2021.
156.	NAKASU Chiharu, Tetsuya Ikemoto, Takuya Tokunaga, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞からSchwann-like cellの効果的分化誘導方法の研究, 第76回日本消化器外科学会総会, Jul. 2021.
157.	Shoko Yamashita, Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 膵・胆管合流異常におけるNLRP3活性化と発癌に関する検討, 第76回日本消化器外科学会総会, Jul. 2021.
158.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第76回日本消化器外科学会総会, Jul. 2021.
159.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝細胞癌の腫瘍微小環境におけるOsteopontinを介したCAF-TAM interactionについての検討, 第76回日本消化器外科学会総会, Jul. 2021.
160.	Yuuma Wada, Yuji Morine, Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Masaaki Nishi, Shin-ichiro Yamada, Kazunori Tokuda, Hiroki Teraoku and Mitsuo Shimada : 癌微小環境における大建中湯の癌細胞増殖抑制効果, 第76回日本消化器外科学会総会, Jul. 2021.
161.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第76回日本消化器外科学会総会, Jul. 2021.
162.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Hiroki Teraoku, Shohei Okikawa, Shin-ichiro Yamada, Satoru Imura and Yuji Morine : 消化器外科領域の幹細胞トランスレーショナルリサーチにおける医工連携, 第76回日本消化器外科学会総会, Jul. 2021.
163.	Hiroki Teraoku, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 両葉多発大腸癌肝転移に対する肝切除適応基準とConversion Surgery, 第76回日本消化器外科学会総会, Jul. 2021.
164.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第76回日本消化器外科学会総会, Jul. 2021.
165.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第115回日本消化器病学会四国支部例会, Jun. 2021.
166.	Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 切除不能肝細胞癌に対するConversion・Salvage surgeryを目指した治療戦略, 第57回日本肝臓学会総会, Jun. 2021.
167.	Yu Saitou, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出- 肝不全・代謝性肝疾患に対する肝移植から細胞移植へ –, 第57回日本肝臓学会総会, Jun. 2021.
168.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 小胞体ストレス応答に着目した非アルコール性脂肪肝炎の肝切除後肝再生/肝不全に関する研究, 第47回日本急性肝不全研究会, Jun. 2021.
169.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Kazunori Tokuda, Koichi Tsuneyama and Mitsuo Shimada : Endoplasmic reticulum stress response deficiency is a major cause of poor liver regeneration after hepatectomy in nonalcoholic steatohepatitis, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
170.	Hiroki Teraoku, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Katsuki Miyazaki : Significance of frailty for eldery patients in HPB surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
171.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : Treatment strategy of multiple colorectal liver metastasis-Criteria for upfront surgery and Conversion Surgery-, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
172.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography in biliary surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
173.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Katsuki Miyazaki : Clinical application of auto-transplantation of generated insulin-producing cells from ADSC with Tokushima protocol, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
174.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝門部領域胆管癌の切除成績と術後補助療法の意義, 第121回日本外科学会定期学術集会, Apr. 2021.
175.	Kanto Yamasaki, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : 術中Real-time 3D胆管造影を併用した胆道手術, 第121回日本外科学会定期学術集会, Apr. 2021.
176.	TAKAHASHI Akira, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞ADSCからのSuper HLC (肝細胞様細胞)の創出, 第121回日本外科学会定期学術集会, Apr. 2021.
177.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Adipose derived stem cellから作製したInsulin producing cellの臨床応用に向けた保存方法に関する研究, 第121回日本外科学会定期学術集会, Apr. 2021.
178.	Yu Saitou, Tetsu Tomonari, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Tetsuji Takayama and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療 - 分子標的治療薬使用によるConversion Surgery –, 第121回日本外科学会定期学術集会, Apr. 2021.
179.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 非アルコール性脂肪性肝疾患(NAFLD)における肝切除後肝再生機能不全に関する研究- 小胞体ストレス応答不全の観点より -, Apr. 2021.
180.	Shoko Yamashita, Yuji Morine, Hiroki Ishibashi, Satoru Imura, Tetsuya Ikemoto, Hiroki Mori, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 膵・胆管合流異常における腫瘍微小環境と発癌に関する検討, 第121回日本外科学会定期学術集会, Apr. 2021.
181.	Hiroki Teraoku, Gao Luping, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌におけるSorafenib耐性獲得機序に関する検討, 第121回日本外科学会定期学術集会, Apr. 2021.
182.	Shohei Okikawa, Yuji Morine, Kazunori Tokuda, Yu Saitou, Shin-ichiro Yamada, Shoko Yamashita, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 腫瘍微小環境におけるOsteopontinの意義, 第121回日本外科学会定期学術集会, Apr. 2021.
183.	Shin-ichiro Yamada, 陳術海, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌微小環境におけるPAI-1発現の意義に関する検討, Apr. 2021.
184.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Satoru Imura and Yuji Morine : 再生医療を用いたインスリン枯渇状態の患者に対する自律的インスリン分泌細胞自己移植に関するAMED橋渡し研究, 第121回日本外科学会定期学術集会, Apr. 2021.
185.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から作製したインスリン産生細胞の至適保存方法に関する研究, 第20回日本再生医療学会総会, Mar. 2021.
186.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出, 第20回日本再生医療学会総会, Mar. 2021.
187.	Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導したSchwann-like cellの基礎的検討, 第20回日本再生医療学会総会, Mar. 2021.
188.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 徳島大学の肝胆膵外科における若手教育-特に内視鏡手術に焦点をあてて-, 第33回日本内視鏡外科学会, Mar. 2021.
189.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出- 肝不全・代謝性肝疾患に対する肝移植から細胞治療へ -, 第262回徳島医学会学術集会, Mar. 2021.
190.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty for elderly patients in HPB surgery, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
191.	Yu Saitou, Tetsuya Ikemoto, Yusuke Arakawa, Luping Gao, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective 3D culture of hepatocyte like cells human adipose derived mesenchymal stem cells, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
192.	Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography and indocyanine green navigation, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
193.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : The impact of frailty as a prognostic factor of colorectal liver metastasis, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
194.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : The value of CRP albumin ratio in patient with resectable pancreas cancer, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
195.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Basic research for aiming non-clinical PoC acquisition of insulin producing cells from ADSC with Tokushima protocol, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
196.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Optimal surgical treatment including lymph nodes dissection and adjuvant chemotherapy for intrahepatic cholangiocarcinoma, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
197.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Standardization and stepwise training for safe laparoscopic hepatectomy, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
198.	Shin-ichiro Yamada, 高露泙, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌におけるSorafenib耐性獲得機序に関する検討, 第23回日本肝がん分子標的治療研究会, Jan. 2021.
199.	Yu Saitou, Tetsu Tomonari, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Yuji Morine, Tetsuji Takayama and Mitsuo Shimada : 進行肝細胞癌に対する集学的治療-分子標的治療薬使用によるConversion Surgery-, 第23回日本肝がん分子標的治療研究会, Jan. 2021.
200.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Kazunori Tokuda and Katsuki Miyazaki : 肝胆膵領域悪性腫瘍におけるNrf2・VEGFに着目した腫瘍関連マクロファージ活性化についての検討, 第29回日本癌病態治療研究, Jan. 2021.
201.	Yu Saitou, 高露萍, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第38回日本肝移植学会学術集, Dec. 2020.
202.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, 杉本真樹 and Mitsuo Shimada : Hologramを用いた術中手術支援-術中Real-time3D胆管造影を併用した胆道手術-, 第45回日本外科系連合学会学術集会, Dec. 2020.
203.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第56回日本肝癌研究会, Dec. 2020.
204.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第56回日本肝癌研究会, Dec. 2020.
205.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第56回日本肝癌研究会, Dec. 2020.
206.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Shin-ichiro Yamada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第75回日本消化器外科学会総会, Dec. 2020.
207.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : 膵切除周術期における栄養指標からみた人工膵臓の有用性, 第75回日本消化器外科学会総会, Dec. 2020.
208.	Masato Yoshikawa, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : DWI-MRIのADC値を用いた転移性肝癌の切除後予後予測，抗癌剤効果予測に関する検討, 第75回日本消化器外科学会総会, Dec. 2020.
209.	Kazunori Tokuda, Yuji Morine, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 転移性肝癌切除症例におけるFrailの重要性についての検討, 第75回日本消化器外科学会総会, Dec. 2020.
210.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 胆嚢癌の悪性度評価におけるADCの有用性に関する検討, 第75回日本消化器外科学会総会, Dec. 2020.
211.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第75回日本消化器外科学会総会, Dec. 2020.
212.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 当院の肝胆膵手術症例におけるSSIサーベイランスによる検討, 第75回日本消化器外科学会総会, Dec. 2020.
213.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 長期予後と患者QoLに着目した膵全摘症例の検討, 第75回日本消化器外科学会総会, Dec. 2020.
214.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第75回日本消化器外科学会総会, Dec. 2020.
215.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 腹腔鏡下肝左葉切除の標準化への取り組み ∼手技定型化とstepwise training∼, 第75回日本消化器外科学会総会, Dec. 2020.
216.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのリンパ球CRP比の意義と腫瘍浸潤リンパ球との関係, 第31回日本消化器癌発生学会総会, Nov. 2020.
217.	Shin-ichiro Yamada, 高露萍, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki and Mitsuo Shimada : ソラフェニブ耐性肝癌において，Nrf2は幹細胞性・遊走能・ABCトランスポーター発現を促進する, 第31回日本消化器癌発生学会総会, Nov. 2020.
218.	Yuji Morine, Hiroki Mori, Yu Saitou, Shin-ichiro Yamada, Tetsuya Ikemoto, Satoru Imura, Hiroki Ishibashi and Mitsuo Shimada : 膵・胆管合流異常の発癌メカニズムに関する基礎研究:徳島大学の場合, 第43回日本膵・胆管合流異常研究会, Nov. 2020.
219.	Katsuki Miyazaki, Yu Saitou, 高露萍, Tetsuya Ikemoto, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から分化誘導した肝細胞様細胞の遺伝子発現解析, 第56回日本移植学会総会, Nov. 2020.
220.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導したインスリン産生細胞の凍結保存方法についての検討, 第56回日本移植学会総会, Nov. 2020.
221.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 移植医から提案する再生医療技術を用いたインスリン産生細胞自家移植による1型糖尿病根治へ向けた戦略, 第56回日本移植学会総会, Nov. 2020.
222.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 医療系学生に対するDonor Action(命の授業)の必要性, 第56回日本移植学会総会, Oct. 2020.
223.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki and Mitsuo Shimada : 膵癌切除症例における，Frailtyの意義に関する検討, 第82回日本臨床外科学会総会, Oct. 2020.
224.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 再生医療技術による1型糖尿病根治へ向けたシーズの臨床応用に関する検討, 第82回日本臨床外科学会総会, Oct. 2020.
225.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : Microbiome, HSCに着目した大建中湯の消化器癌に対する多面的効果の検討, 第82回日本臨床外科学会総会, Oct. 2020.
226.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : Hologramを用いた次世代術中手術支援 -術中Real-time 3D胆管造影を併用した胆道手術-, 第82回日本臨床外科学会総会, Oct. 2020.
227.	Katsuki Miyazaki, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 膵頭十二指腸切除術(PD)術後合併症回避に向けた腹腔動脈起始部圧迫症候群の周術期管理, 第56回日本腹部救急医学会総会, Oct. 2020.
228.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Mitsuo Shimada and 高露泙 : ソラフェニブ耐性肝細胞癌において，Nrf2は肝細胞性，遊走能，ABC transporterの発現を上昇させる, --- Nrf2 signaling promotes cancer stemness, migration and expression of ABC transporters in sorafenib-resistant HCC ---, 第79回日本癌学会学術集会, Oct. 2020.
229.	立木佐知子, 冨永誠記, Takahiro Tanaka, Shin-ichiro Yamada and Mitsuo Shimada : 徳島県における肝炎医療コーディネーターの活動―肝疾患診療連携拠点病院との連携から地域の肝炎医療コーディネーターの活動拡充へ―, 第56回日本肝臓学会総会, Aug. 2020.
230.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第120回日本外科学会定期学術集会, Aug. 2020.
231.	Masato Yoshikawa, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : DWI-MRIのADC値を用いた転移性肝癌の予後予測に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
232.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵癌術後予後予測因子としての術前fibrinogen:血小板比の有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
233.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 切除可能大腸癌限局性肝転移の治療指針, 第120回日本外科学会定期学術集会, Aug. 2020.
234.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda and Masato Yoshikawa : 外科医の視点から開発された皮下脂肪から分離した脂肪由来幹細胞のインスリン産生細胞移植に関する研究, 第120回日本外科学会定期学術集会, Aug. 2020.
235.	Kazunori Tokuda, Tetsuya Ikemoto, 高露萍, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 肪由来幹細胞(ADSC)から肝細胞様細胞(HLC)への分化誘導における3D培養の有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
236.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 膵癌切除症例におけるFrailの意義に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
237.	Yu Saitou, Mitsuo Shimada, 杉本真樹, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Holographyを用いた次世代術中手術支援とICG蛍光法による肝離断navigation, 第120回日本外科学会定期学術集会, Aug. 2020.
238.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 小型肝癌に対する肝実質温存肝区画切除は妥当である, 第120回日本外科学会定期学術集会, Aug. 2020.
239.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte/CRP ratio(LCR)の意義, 第113回日本消化器病学会四国支部例会, Jun. 2020.
240.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第113回日本消化器病学会四国支部例会, Jun. 2020.
241.	Kazunori Tokuda, Tetsuya Ikemoto, Mitsuo Shimada, Yu Saitou, Masato Yoshikawa, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura and Yuji Morine : 亜鉛イオンに着目したADSCから製造したInsulin-producing cell 成熟度に関する検討, 第19回日本再生医療学会総会, May 2020.
242.	Yu Saitou, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第19回日本再生医療学会総会, May 2020.
243.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura and Yuji Morine : T1DM患者から採取された脂肪組織から分離したADSCから製造したInsulin-producing cellに関する検討, 第19回日本再生医療学会総会, May 2020.
244.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第53回制癌剤適応研究会, Feb. 2020.
245.	Masato Yoshikawa, Shin-ichiro Yamada, Yuji Morine, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 転移性肝癌におけるDWI-MRIのADC値を用いた予後予測に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
246.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 腫瘍関連マクロファージを介した肝胆膵癌の悪性度獲得に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
247.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : NBNC肝細胞癌の発癌と進展の分子標的からみた治療戦略, 第53回制癌剤適応研究会, Feb. 2020.
248.	Masato Yoshikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第260回徳島医学学会学術集会, Feb. 2020.
249.	Yu Saitou, Tetsu Tomonari, Shin-ichiro Yamada, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Tetsuji Takayama and Mitsuo Shimada : 分子標的治療薬によりConversion Hepatectomyを施行し得た進行肝細胞癌の3例, 第21回日本肝がん分子標的治療研究会, Jan. 2020.
250.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto and Yu Saitou : MRIを利用した肝切除限界予測と，腫瘍悪性度評価に関する検討, 第43回日本肝臓学会西部会, Dec. 2019.
251.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Mitsuo Shimada : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, JDDW2019, Nov. 2019.
252.	Masato Yoshikawa, Tetsuya Ikemoto, Toshiaki Yoshimoto, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵切除周術期における人工膵臓を用いた血糖管理の有用性, 第81回日本臨床外科学会総会, Nov. 2019.
253.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Masato Yoshikawa and 杉本真樹 : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第81回日本臨床外科学会総会, Nov. 2019.
254.	Tetsuya Ikemoto, Kazunori Tokuda, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : insulin-producing cell移植の細胞移植治療への臨床応用に向けた研究, 第81回日本臨床外科学会総会, Nov. 2019.
255.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第81回日本臨床外科学会総会, Nov. 2019.
256.	Yuji Morine, Shin-ichiro Yamada, Tetsuya Ikemoto, Yu Saitou, Yusuke Arakawa, Masato Yoshikawa, Satoru Imura and Mitsuo Shimada : 腸管Microbiome解析を加えた大建中湯の消化器疾患に対する多面的効果の検討, 第81回日本臨床外科学会総会, Nov. 2019.
257.	Shin-ichiro Yamada : 肝胆膵領域悪性腫瘍におけるNrf2に着目した腫瘍関連マクロファージ活性化についての検討, 第30回日本消化器癌発生学会総会, Nov. 2019.
258.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Katsuki Miyazaki and Mitsuo Shimada : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第57回日本癌治療学会学術集会, Oct. 2019.
259.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Mitsuo Shimada : 臨床病理学的特徴と腫瘍悪性度解析からみたNBNC肝細胞癌の治療戦略, 第57回日本癌治療学会学術集会, Oct. 2019.
260.	Yusuke Arakawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞からインスリン産生細胞への分化誘導における赤色LEDの有用性に関する研究, 第55回日本移植学会総会, Oct. 2019.
261.	Tetsuya Ikemoto, Yu Saitou, Satoru Imura, Yuji Morine, Kazunori Tokuda, Shin-ichiro Yamada, Masato Yoshikawa and Mitsuo Shimada : 再生医療技術を用いたinsulin-producing cell移植の臨床応用に向けた研究, 第55回日本移植学会総会, Oct. 2019.
262.	Yukako Takehara, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Shoko Iwahashi, Koichi Tsuneyama and Mitsuo Shimada : SSTR2, Bcl2発現からみた肝内胆管癌の組織発生学的分類, 第55回日本胆道学会学術集会, Oct. 2019.
263.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第55回日本胆道学会学術集会, Oct. 2019.
264.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, JSH International Liver Conference, Oct. 2019.
265.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第78回日本癌学会学術総会, Sep. 2019.
266.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, 杉本真樹 and Mitsuo Shimada : Hologramを用いた次世代術前術中手術支援とICG蛍光法による肝離断navigation, 第14回肝癌治療ナビゲーション研究会, Sep. 2019.
267.	Masato Yoshikawa, Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Koichi Tsuneyama and Mitsuo Shimada : 卵巣様間質を伴う非粘液性嚢胞腺腫の二例, 第71回日本消化器画像診断研究会, Sep. 2019.
268.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第71回日本消化器画像診断研究会, Sep. 2019.
269.	Shoko Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : SSTR2・Bcl2発現による肝内胆管癌組織発生学的特徴に関する検討, 第74回日本消化器外科学会総会, Jul. 2019.
270.	Shuichi Iwahashi, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou and Shin-ichiro Yamada : 長期成績に着目した膵全摘症例の検討 -術後QOL評価に着目して-, 第74回日本消化器外科学会総会, Jul. 2019.
271.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝細胞癌に対する系統的肝区画切除は妥当である, 第74回日本消化器外科学会総会, Jul. 2019.
272.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : 肝細胞癌の肝切除術におけるFrailtyの意義に関する検討, 第74回日本消化器外科学会総会, Jul. 2019.
273.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : ホログラム術中胆道造影とウェアラブル近赤外蛍光法による肝切除手術支援, 第74回日本消化器外科学会総会, Jul. 2019.
274.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝内胆管癌の治療戦略:至適切除範囲と補助療法の効果, 第74回日本消化器外科学会総会, Jul. 2019.
275.	Tetsuya Ikemoto, Mitsuo Shimada, Masao Fuketa, Shinsuke Katoh, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : The utilization of `Big Data' in gastroenterological surgery, 第74回日本消化器外科学会総会, Jul. 2019.
276.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第55回日本肝癌研究会, Jul. 2019.
277.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : EOB-MRIを用いた新たな肝切除基準の有用性, 第55回日本肝癌研究会, Jul. 2019.
278.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Mitsuo Shimada : 肝内胆管癌の治療戦略:至適切除範囲と補助療法の効果, 第55回日本肝癌研究会, Jul. 2019.
279.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝癌に対する腹腔鏡肝切除の現状と今後の適応拡大, 第55回日本肝癌研究会, Jul. 2019.
280.	Masato Yoshikawa, Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Shoko Iwahashi and Mitsuo Shimada : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第26回外科侵襲とサイトカイン研究会, Jul. 2019.
281.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto and Mitsuo Shimada : DWI-MRIのADC値を用いたSorafenibの効果予測に関する検討, 第20回日本肝がん分子標的治療研究会, Jun. 2019.
282.	Tetsuya Ikemoto, Mitsuo Shimada, Masao Fuketa, Shinsuke Katoh, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Satoru Imura and Yuji Morine : 医療安全に関するAI活用と新たなアラートシステム構築, 第44回日本外科系連合学会学術集会, Jun. 2019.
283.	Katsuki Miyazaki, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : A case of preoperative nutritional and exercise intervention in HCC patient with alcoholic liver cirrhosis, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
284.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : Intraoperative support using holographic cholangiography and near-infrared fluorescence imaging, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
285.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : The effect of hepatic stellate cells on hepatocellular carcinoma progression, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
286.	Yuji Morine, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Mitsuo Shimada : Standardization of surgical technique in laparoscopic distal pancreatectomy, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
287.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
288.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : Goal for board certified HBP surgeon, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
289.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : Our scientific approaches and investigation for Japanese Kampo Medicine in hepato-biliary-pancreatic diseases; especially TU-100 and TJ-48, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
290.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Evaluation of liver function using signal intensity of EOB-MRI for safe hepatectomy, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
291.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : ホログラムとウェアラブル近赤外蛍光法による肝切除手術支援, 第73回手術手技研究会, May 2019.
292.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto, 西山光恵 and 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第105回日本消化器病学会総会, May 2019.
293.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : Usefulness of "one-stop shop" liver surgery simulation using EOB-MRI., ILLS2019, May 2019.
294.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : Standardization of surgical technique in laparoscopic left hemihepatectomy., ILLS2019, May 2019.
295.	Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 大腸癌肝転移における免疫逃避機構は原発巣と異なる可能性がある, 第119回日本外科学会定期学術集会, Apr. 2019.
296.	Katsuki Miyazaki, Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 卵巣様間質を伴う非粘液性嚢胞腺腫の2例, 第119回日本外科学会定期学術集会, Apr. 2019.
297.	Shoko Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : SSTR2発現からみた肝内胆管癌の組織発生学的分類, 第119回日本外科学会定期学術集会, Apr. 2019.
298.	Shogo Oota, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto and Shoko Iwahashi : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第119回日本外科学会定期学術集会, Apr. 2019.
299.	Toshiaki Yoshimoto, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Yuuma Wada, Shogo Oota, Shoko Iwahashi and Mitsuo Shimada : 青色LED光のOpn3を介した大腸癌抑制効果 (第2報), 第119回日本外科学会定期学術集会, Apr. 2019.
300.	Yuuma Wada, Yuji Morine, Yu Saitou, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 癌微小環境における大建中湯の肝星細胞活性化制御・癌細胞オートファジーを介した癌細胞増殖抑制効果, 第119回日本外科学会定期学術集会, Apr. 2019.
301.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : ホログラム術中胆道造影とウェアラブル近赤外蛍光法による肝切除手術支援, 第119回日本外科学会定期学術集会, Apr. 2019.
302.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Toshiaki Yoshimoto, Shoko Iwahashi, 西山光恵 and 五十嵐康 : 大建中湯(TU-100)のNASH発癌抑制効果に関する検討, 第119回日本外科学会定期学術集会, Apr. 2019.
303.	Shuichi Iwahashi, Tetsuya Ikemoto, Yuuma Wada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Toshiaki Yoshimoto, Shogo Oota and Mitsuo Shimada : 臨床応用に向けたインスリン産生細胞分化誘導に関する研究, 第119回日本外科学会定期学術集会, Apr. 2019.
304.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and Jun Higashijima : 大腸癌肝転移に対する肝切除を中心とした治療戦略 - Upfront肝切除適応基準と切除不能例に対するConversion surgery-, 第119回日本外科学会定期学術集会, Apr. 2019.
305.	Shogo Oota, Mitsuo Shimada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Yuuma Wada, Toshiaki Yoshimoto and Shoko Iwahashi : Insulin-producing cell(IPC)分化成熟と亜鉛イオン濃度相関に関する研究, 第18回日本再生医療学会総会, Mar. 2019.
306.	Yuuma Wada, Tetsuya Ikemoto, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Shogo Oota, Shoko Iwahashi and Mitsuo Shimada : 脂肪由来幹細胞からのインスリン産生細胞分化誘導に関する研究, 第18回日本再生医療学会総会, Mar. 2019.
307.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Toshiaki Yoshimoto : 肝胆膵領域癌におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第52回制癌剤適応研究会, Mar. 2019.
308.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第33回四国内視鏡外科研究会, Feb. 2019.
309.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : Lenvatinib投与中に呼吸不全を併発し急激な悪化の転機をたどった肝細胞癌多発肺転移の1例, 第2回徳島外科医会, Feb. 2019.
310.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi and Yu Saitou : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第2回徳島外科医会, Feb. 2019.
311.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Yuuma Wada : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第19回日本肝がん分子標的治療研究会, Jan. 2019.
312.	Yuuma Wada, Tetsuya Ikemoto, Shuichi Iwahashi, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masaaki Nishi, Satoru Imura and Mitsuo Shimada : 膵島保護におけるNrf2を介した Epigallocatechin-3-gallate (EGCG)の効果, 第48回創傷治癒学会, Nov. 2018.
313.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : 肝切除における術中手術支援のブレイクスル- -Virtual Reality & 肝離断Navigation –, 第80回日本臨床外科学会総会, Nov. 2018.
314.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Evaluation of liver function for safe and radical hepatectomy in elderly patients (高齢者肝切除の安全性・根治性向上のための肝機能評価), 第80回日本臨床外科学会総会, Nov. 2018.
315.	Shin-ichiro Yamada : 大建中湯は胆道閉鎖症ラットモデルにおけるbacterial translocationと肝線維化を抑制する, 第80回日本臨床外科学会総会, Nov. 2018.
316.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou and Toshiaki Yoshimoto : 当科における腹腔鏡下膵体尾部切除術の定型化と成績に関する検討, 第10回膵臓内視鏡外科研究会・第12回肝臓内視鏡外科研究会, Nov. 2018.
317.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第56回日本癌治療学会学術集会, Oct. 2018.
318.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada, Toshiaki Yoshimoto and Shogo Oota : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第56回日本癌治療学会学術集会, Oct. 2018.
319.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Shin-ichiro Yamada, Shuichi Iwahashi, Tetsuya Ikemoto and Yuji Morine : 脳死肝移植ドナー不足解消にむけての取り組み-医療系学生に対するDonor Action(命の授業)の必要性-, 第54回日本移植学会総会, Oct. 2018.
320.	Yuuma Wada, Tetsuya Ikemoto, Yuji Morine, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Satoru Imura and Mitsuo Shimada : Nrf2経路によるEGCGの膵島保護効果, 第54回日本移植学会総会, Oct. 2018.
321.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada, 杉本真樹 and Mitsuo Shimada : Virtual Realityを用いた肝切除における術中手術支援, 第13回肝癌治療シミュレーション研究会, Sep. 2018.
322.	Shin-ichiro Yamada, Yuuma Wada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Yuuma Wada and Shogo Oota : 造影効果から見た肝内胆管癌の腫瘍悪性度に関する検討, 第54回日本胆道学会学術集会, Sep. 2018.
323.	Toshiaki Yoshimoto, Mitsuo Shimada, Shuichi Iwahashi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Shin-ichiro Yamada : Nrf2に着目した肝癌細胞における腫瘍関連マクロファージ活性化の検討, 第18回日本肝がん分子標的治療研究会, Jul. 2018.
324.	Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Satoru Imura, Yuji Morine, Koichi Tsuneyama and Mitsuo Shimada : 症例, 第54回日本肝癌研究会, Jun. 2018.
325.	Toshiaki Yoshimoto, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除限界予測の可能性, 第78回日本臨床外科学会総会, Nov. 2016.
326.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Toshiaki Yoshimoto : Tr1とFoxp3陽性調節性T細胞は担癌患者の腫瘍免疫に関する検討, 第75回日本癌学会学術集会, Oct. 2016.
327.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : Boot Camp in Tokushima University., 第71回日本消化器外科学会総会, Jul. 2016.
328.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : The analysis in non-tumor liver tissue to prevent the recurrence after curative treatment of hepatocellular carcinoma., 第71回日本消化器外科学会総会, Jul. 2016.
329.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Hiroki Teraoku : A new strategy forachieving effective islet transplantation with adipose tissue derved stem cells., 第71回日本消化器外科学会総会, Jul. 2016.
330.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について., 第34回日本肝移植研究会, Jul. 2016.
331.	Yu Saitou, Sonoko Yasui, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝硬変合併肝切除症例における栄養・免疫状態の特徴, 第52回日本肝癌研究会, Jul. 2016.
332.	Toshiaki Yoshimoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa and Atsushi Takata : 症例, 第52回日本肝癌研究会, Jul. 2016.
333.	Satoru Imura, Masato Yoshikawa, Hiroki Teraoku, Daichi Ishikawa, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Intermediate stageの肝癌に対する肝切除は有効か?, 第52回日本肝癌研究会, Jul. 2016.
334.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌における発生部位別悪性度., 第52回日本肝癌研究会, Jul. 2016.
335.	Atsushi Takata, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yusuke Arakawa, Shuichi Iwahashi, Daichi Ishikawa, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : HCCに対して初回RFA治療早期にリンパ節再発をきたし外科的切除を施行した症例., 第41回日本外科系連合学会学術集会, Jun. 2016.
336.	Yu Saitou, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : PDに対するModified de-rotationを用いた``Complate artery-firstn approach''., 第41回日本外科系連合学会学術集会, Jun. 2016.
337.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : EOB-MRIを用いた機能的肝容積による新たな肝切除基準., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
338.	Tetsuya Ikemoto, Mitsuo Shimada, Daichi Ishikawa, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Masato Yoshikawa : Tr1細胞とFoxp3調節性T細胞による膵嚢胞性疾患に関する正確な免疫学的指標探索に関する研究., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
339.	Yu Saitou, Atsushi Takata, Hiroki Teraoku, Masato Yoshikawa, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 胆道癌術後肝内再発に対する肝切除導入効果の検証., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
340.	Masato Yoshikawa, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata, Toshiaki Yoshimoto and Mitsuo Shimada : 当科における胆道再建における肝管空腸吻合法の工夫., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
341.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Chie Takasu, Jun Higashijima, 川下陽一郎, Atsushi Takata, Toshiaki Yoshimoto, Satoru Imura and Mitsuo Shimada : 大腸癌肝転移肝切除症例におけるThrombospondin1(THBS)発現の意義とその分子メカニズムの検討., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
342.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku, Masato Yoshikawa and Jun Higashijima : 大腸癌多発肝転移に対する長期生存を目指した治療戦略., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
343.	Satoru Imura, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 門脈・肝静脈解剖に基づく合理的な系統的肝切除∼副右肝静脈灌流領域切除を伴う拡大前区域切除., 第28回日本肝胆膵外科学会・学術集会, Jun. 2016.
344.	Shin-ichiro Yamada, Mitsuo Shimada and Satoru Imura : EOB-MRIを用いた新たな肝切除基準の可能性., 第52回日本肝臓学会総会, May 2016.
345.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 徳島におけるABO不適合生体肝移植症例の成績., 第42回日本急性肝不全研究会, May 2016.
346.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのHIF-1の役割., 第102回日本消化器病学会総会, Apr. 2016.
347.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除基準の可能性, 第102回日本消化器病学会総会, Apr. 2016.
348.	Shogo Oota, Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Kouzou Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 胆道癌術後肝内再発に対する肝切除導入効果の検証, 第116回日本外科学会定期学術集会, Apr. 2016.
349.	Shoko Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 急速な進展を来したラブドイド様退形成性癌の一例., 第116回日本外科学会定期学術集会, Apr. 2016.
350.	関勇輔, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-., 第116回日本外科学会定期学術集会, Apr. 2016.
351.	川下陽一郎, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Hiroki Teraoku, Masato Yoshikawa, Atsushi Takata, Toshiaki Yoshimoto and Hirohisa Ogawa : 転移性肝癌におけるFbxw7低発現は再発予測因子である., 第116回日本外科学会定期学術集会, Apr. 2016.
352.	Masato Yoshikawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Atsushi Takata and Toshiaki Yoshimoto : 肝細胞癌術後再発予後不良因子としてのCEAの意義, 第116回日本外科学会定期学術集会, Apr. 2016.
353.	Hiroki Teraoku, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, 川下陽一郎, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, Masato Yoshikawa, Atsushi Takata and Toshiaki Yoshimoto : 転移性肝癌における腫瘍悪性度制御因子としてのThrombospondin-1(THBS-1)の役割- 第2報 THBS-1制御メカニズムについて -, 第116回日本外科学会定期学術集会, Apr. 2016.
354.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kouzou Yoshikawa, Hiroki Teraoku, Toshiaki Yoshimoto, Atsushi Takata and Chie Takasu : EOB-MRIを用いた新たな肝切除基準の可能性., 第116回日本外科学会定期学術集会, Apr. 2016.
355.	Yu Saitou, Toshiaki Yoshimoto, Atsushi Takata, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : HDAC阻害剤は脂肪由来幹細胞からインスリン分泌細胞への分化誘導を促進する., 第116回日本外科学会定期学術集会, Apr. 2016.
356.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Daichi Ishikawa, Hiroki Teraoku and Masato Yoshikawa : 肝内胆管癌に対する至適術式と集学的治療., 第116回日本外科学会定期学術集会, Apr. 2016.
357.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kouzou Yoshikawa, 寺奥大貴, 高田厚史 and 良元俊昭 : 肝細胞癌症例におけるNEK2発現による腫瘍悪性度評価, 第49回制癌剤適応研究会, Mar. 2016.
358.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Hiroki Teraoku and Toshiaki Yoshimoto : 脂肪由来幹細胞による膵島移植・膵島再生に関する新たな戦略, 第43回日本膵・膵島移植研究会, Mar. 2016.
359.	Yu Saitou, Masato Yoshikawa, Hiroki Teraoku, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 36.3mm細径鉗子を用いたreduced port Lap-Cに関する検討, 第30回四国内視鏡外科研究会, Feb. 2016.
360.	寺奥大貴, Mitsuo Shimada, 石川大地, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 吉川雅登, 高田厚史 and 良元俊昭 : 消化器担癌状態のバイオマーカーとしての末梢血Tr1細胞とFoxp3調節性T細胞の有用性に関する検討, 第252回徳島医学会学術集会, Feb. 2016.
361.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 吉川雅登, 寺奥大貴 and 高田厚史 : 肝細胞癌症例におけるNEK2発現による腫瘍悪性度評価, 第252回徳島医学会学術集会, Feb. 2016.
362.	良元俊昭, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada and 高田厚史 : Sorafenib+poly surgeryによるHCC長期生存例∼orafenib投与長期生存条件の検討∼, 第13回日本肝がん分子標的治療研究会, Jan. 2016.
363.	寺奥大貴, 朱呈瞻, 髙田厚史, 良元俊昭, 吉川雅登, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 加齢肝再生における肝星細胞の役割, 第22回外科侵襲とサイトカイン研究会, Dec. 2015.
364.	髙田厚史, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 吉川雅登 and 寺奥大貴 : HCCに対して初回RFA治療後早期にリンパ節再発をきたし外科的切除を施行した症例, 第41回日本肝臓学会西部会, Dec. 2015.
365.	吉川雅登, Shin-ichiro Yamada, 髙田厚史, 良元俊昭, 寺奥大貴, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝内胆管癌との鑑別が困難であった原発性放線菌症の一例, 第41回日本肝臓学会西部会, Dec. 2015.
366.	吉川雅登, Wubetu Gizachew Yismaw, 髙田厚史, 良元俊昭, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 脂肪由来幹細胞からインスリン分泌細胞への分化誘導におけるバルプロ酸の分化促進, 第45回日本創傷治癒学会, Nov. 2015.
367.	吉川雅登, Shin-ichiro Yamada, 髙田厚史, 良元俊昭, 寺奥大貴, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Hiroshi Shibata, Hidenori Miyake and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検討∼切除を含む集学的治療の重要性∼, 第77回日本臨床外科学会総会, Nov. 2015.
368.	寺奥大貴, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Jun Higashijima, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 吉川雅登, 髙田厚史 and 良元俊昭 : 若手外科医教育のための膵頭十二指腸切除における3D simulationの有用性, 第77回日本臨床外科学会総会, Nov. 2015.
369.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術における免疫指標を加味した新たな周術期栄養評価, 第77回日本臨床外科学会総会, Nov. 2015.
370.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登, Chie Takasu and Jun Higashijima : 大腸癌多発肝転移に対する治療戦略, 第77回日本臨床外科学会総会, Nov. 2015.
371.	Satoru Imura, 髙田厚史, 良元俊昭, 寺奥大貴, 吉川雅登, Shin-ichiro Yamada, Chie Takasu, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝臓外科における画像シミュレーション, 第77回日本臨床外科学会総会, Nov. 2015.
372.	Satoru Imura, 髙田厚史, 良元俊昭, 寺奥大貴, 吉川雅登, Shin-ichiro Yamada, Chie Takasu, Yu Saitou, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝切除における高齢者の特徴と戦略, 第77回日本臨床外科学会総会, Nov. 2015.
373.	Shin-ichiro Yamada, 良元俊昭, 髙田厚史, 寺奥大貴, 吉川雅登, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 腹腔鏡下肝切除術の適応拡大と標準化への工夫安全な腹腔鏡下肝切除の標準化に向けて ∼適応拡大に先立つ着実な手技の定型化∼, 第9回肝臓内視鏡外科研究会, Nov. 2015.
374.	吉川雅登, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 寺奥大貴, 髙田厚史 and 良元俊昭 : 分肝機能に着目したEOB-MRIによる肝予備能評価の有用性, 第24回日本コンピュータ外科学会大会, Nov. 2015.
375.	寺奥大貴, 髙田厚史, 良元俊昭, 吉川雅登, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝内胆管癌におけるFbxw7発現低下と臨床病理学的意義 - 細胞増殖・EMT誘導との関連に着目して -, 第26回日本消化器癌発生学会総会, Nov. 2015.
376.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 肝細胞癌におけるEpigenetic遺伝子制御の可能性, 第26回日本消化器癌発生学会総会, Nov. 2015.
377.	寺奥大貴, Shin-ichiro Yamada, 良元俊昭, 高田厚史, 吉川雅登, Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Mitsuo Shimada and Hidenori Miyake : RFA術後にリンパ節再発をきたし外科切除を施行した肝細胞癌の1例 -RFA術後再発におけるEMT誘導を介した悪性度獲得について-, 日本消化器病学会四国支部第104回例会, Nov. 2015.
378.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, 吉川雅登 and 寺奥大貴 : 肝細胞癌症例におけるNEK2発現の意義に関する検討, 第53回日本癌治療学会学術集会, Oct. 2015.
379.	髙田厚史, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 大腸癌肝転移症例における肝転移巣のKISS1発現に関する検討, 第53回日本癌治療学会学術集会, Oct. 2015.
380.	寺奥大貴, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Jun Higashijima, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 石川大地 and 吉川雅登 : 大腸癌肝転移肝切除症例におけるThrombospondin-1(THBS1)発現の意義, 第74回日本癌学会学術総会, Oct. 2015.
381.	Tetsuya Ikemoto, Mitsuo Shimada, 石川大地, 寺奥大貴, 吉川雅登, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Satoru Imura and Yuji Morine : Tr1細胞と調節性T細胞の坦癌患者における臨床的意義に関する研究, 第74回日本癌学会学術総会, Oct. 2015.
382.	Tetsuya Ikemoto, Mitsuo Shimada, 石川大地, Yuji Morine, Satoru Imura, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登 and 良元俊昭 : Tr1細胞とFoxp3調節性T細胞による消化器担癌状態の正確な診断バイオマーカー探索に関する研究, JDDW 2015, Oct. 2015.
383.	西尾進, 鳥居裕太, 平田有紀奈, 山尾雅美, Shin-ichiro Yamada, Seiji Iwamoto, Hirotsugu Yamada, Naoki Muguruma, Mitsuo Shimada and Masataka Sata : 正常肝に発症した巨大肝細胞癌の1例, 日本超音波医学会第25回四国地方会学術集会, Oct. 2015.
384.	吉川雅登, Chie Takasu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 市井啓仁 and Mitsuo Shimada : NO阻害と転写活性制御に着目した虚血再灌流傷害治療に向けた基礎的検討, 第51回日本移植学会総会, Oct. 2015.
385.	Shin-ichiro Yamada, Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Chie Takasu, 吉川雅登, 寺奥大貴, 髙田厚史 and 良元俊昭 : 脳死肝移植を推進するための学生に対するドナーアクションの必要性について, 第51回日本移植学会総会, Oct. 2015.
386.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 脂肪由来幹細胞が拓く膵島細胞移植成績向上に関する展望と課題, 第51回日本移植学会総会, Oct. 2015.
387.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第51回日本肝癌研究会, Jul. 2015.
388.	Satoru Imura, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脾機能亢進症を合併した肝癌に対する脾摘+肝切除の有用性, 第51回日本肝癌研究会, Jul. 2015.
389.	吉川雅登, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Chie Takasu and Shin-ichiro Yamada : 肝細胞癌における腫瘍マーカー発現とEpithelial-mesenchymal transitionに関する検討, 第70回日本消化器外科学会総会, Jul. 2015.
390.	寺奥大貴, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 吉川雅登 : 大腸癌肝転移における腫瘍内Ki67発現の意義, 第70回日本消化器外科学会総会, Jul. 2015.
391.	Shin-ichiro Yamada, 吉川雅登, 寺奥大貴, Satoru Imura, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 安全な腹腔鏡下切除の標準化に向けて∼適応拡大に先立つ着実な手技の定型化∼, 第70回日本消化器外科学会総会, Jul. 2015.
392.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 吉川雅登 and 寺奥大貴 : 肝予備能評価におけるEOB-MRI肝細胞相の有用性の検討, 第70回日本消化器外科学会総会, Jul. 2015.
393.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Kouzou Yoshikawa, Yusuke Arakawa, Shuichi Iwahashi, Keigo Yada, Yu Saitou and Shin-ichiro Yamada : 肝切除周術期におけるTU-100に関するトランスレーショナルリサーチ, 第70回日本消化器外科学会総会, Jul. 2015.
394.	Yusuke Arakawa, Mitsuo Shimada, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 小胞体ストレス応対に着目した加齢肝再生不全における肝星細胞の役割についての検討, 第70回日本消化器外科学会総会, Jul. 2015.
395.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第70回日本消化器外科学会総会, Jul. 2015.
396.	Yu Saitou, Sonoko Yasui, 寺奥大貴, 吉川雅登, Shin-ichiro Yamada, Chie Takasu, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究-体成分分析装置と主観的包括的アセスメントSGA -, 日本外科代謝栄養学会第52回学術集会, Jul. 2015.
397.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登 and Gizachew Yismaw : Epigallocatechin gallateはABCトランスポーターを介してstemnessを解除する, 第24 回日本癌病態治療研究会, Jun. 2015.
398.	吉川雅登, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, 石川大地, 寺奥大貴, 良元俊昭, 髙田厚史 and Hidenori Miyake : 肝細胞癌切除症例に対するRFA後肝細胞癌再発例はEMT誘導を介して予後不良となる, 第103回例会日本消化器病学会総会四国支部, Jun. 2015.
399.	Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Hiroshi Shibata, Hidenori Miyake and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検証-切除を含む集学的治療の重要性-, 第103回例会日本消化器病学会総会四国支部, Jun. 2015.
400.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術におけるNST介入による周術期栄養評価, 第40回日本外科系連合学会学術集会, Jun. 2015.
401.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究‐体成分分析装置と主観的包括的アセスメント‐, 第27回日本肝胆膵外科学会, Jun. 2015.
402.	吉川雅登, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地 and 寺奥大貴 : 肝細胞癌における腫瘍マーカー発現とEMTに関する検討, 第27回日本肝胆膵外科学会, Jun. 2015.
403.	寺奥大貴, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 石川大地 and 吉川雅登 : 大腸癌肝転移肝切除症例におけるThrombospondin-1(THBS1)発現の意義, 第27回日本肝胆膵外科学会, Jun. 2015.
404.	Shin-ichiro Yamada, 吉川雅登, 寺奥大貴, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脾機能亢進症を合併した肝癌に対する脾摘+肝切除の有用性, 第27回日本肝胆膵外科学会, Jun. 2015.
405.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 吉川雅登 and 寺奥大貴 : 3mm細径鉗子を用いたreduced port Lap-C, 第27回日本肝胆膵外科学会, Jun. 2015.
406.	Yusuke Arakawa, Mitsuo Shimada, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 下右肝静脈温存，上中右肝静脈ドレナージ領域を含む合理的拡大肝前区域切除術, 第27回日本肝胆膵外科学会, Jun. 2015.
407.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登 and 良元俊昭 : Borderline resectable膵癌に対する治療成績の検討, 第27回日本肝胆膵外科学会, Jun. 2015.
408.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴, 吉川雅登 and 良元俊昭 : 指導医の立場から見た若手外科医教育のための膵頭十二指腸切除における3Dsimulationの有用性, 第27回日本肝胆膵外科学会, Jun. 2015.
409.	Satoru Imura, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 肝予備能評価におけるEOB-MRI肝細胞相の有用性, 第27回日本肝胆膵外科学会, Jun. 2015.
410.	Shin-ichiro Yamada, 吉川雅登, 寺奥大貴, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 安全な腹腔鏡下肝切除の標準化に向けて-左葉系肝切除における着実な手技の定型化-, 第27回日本肝胆膵外科学会, Jun. 2015.
411.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 肝内胆管癌に対する至適術式と集学的治療戦略, 第27回日本肝胆膵外科学会, Jun. 2015.
412.	Satoru Imura, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 吻合部狭窄のない胆管-胆管吻合手技の工夫-, 第33回日本肝移植研究会, May 2015.
413.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shuichi Iwahashi, Yu Saitou, 吉川雅登 and 寺奥大貴 : 分肝機能に着目したEOB-MRIによる肝予備能評価の有用性, 第51回日本肝臓学会総会, May 2015.
414.	Shuichi Iwahashi, Mitsuo Shimada, Tatsuya Taniguchi, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada and 楠本彩子 : 当県肝疾患診療における円滑な地域連携推進のための活動について, 第51回日本肝臓学会総会, May 2015.
415.	Satoru Imura, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脾機能亢進症を合併した肝癌に対する非的+肝切除の有用性, 第51回日本肝臓学会総会, May 2015.
416.	Yu Saitou, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝不全におけるMEIN投与の有用性-基礎から臨床-, 第41回日本急性肝不全研究会, May 2015.
417.	Shin-ichiro Yamada, 吉川雅登, 寺奥大貴, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 若手外科医教育のための膵頭十二指腸切除における3D simulationの有用性, 第69回手術手技研究会, May 2015.
418.	Yu Saitou, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 術前3Dシミュレーションを使用した膵頭十二指腸切除におけるmodified de-rotation, 第69回手術手技研究会, May 2015.
419.	Shuichi Iwahashi, Mitsuo Shimada, 寺奥大貴, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Jun Higashijima, Chie Takasu and 吉川雅登 : Epigallocatechin gallateの消化器癌における抗腫瘍効果の検討, 第101回日本消化器病学会総会, Apr. 2015.
420.	Chie Takasu, Yuji Morine, Satoru Imura, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地 and Mitsuo Shimada : 肝虚血再灌流障害の発生・進展機序の解明と統合的治療法開発の取り組み, 第115回日本外科学会定期学術集会, Apr. 2015.
421.	Hiroki Mori, Hiroki Ishibashi, Keigo Yada, Shin-ichiro Yamada and Mitsuo Shimada : 腹腔鏡下Palomo法術後の陰嚢水瘤予防に対する少数リンパ管温存の妥当性, 第115回日本外科学会定期学術集会, Apr. 2015.
422.	太田昇吾, Yu Saitou, 吉川雅登, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : ソラフェニブ投与後切除可能となり長期生存が得られたFGF4強発現進行肝細胞癌の症例, 第115回日本外科学会定期学術集会, Apr. 2015.
423.	髙田厚史, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 吉川雅登 and 寺奥大貴 : 大腸癌肝転移症例における肝転移巣のKiss1発現は独立予後規定因子となる, 第115回日本外科学会定期学術集会, Apr. 2015.
424.	石川大地, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : 大腸癌におけるmicroRNA-449a発現の意義, 第115回日本外科学会定期学術集会, Apr. 2015.
425.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, 石川大地, 寺奥大貴 and 吉川雅登 : 肝内胆管癌における細胞周期調節因子Fbxw7の発現低下は独立予後規定因子である, 第115回日本外科学会定期学術集会, Apr. 2015.
426.	吉川雅登, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝細胞癌における腫瘍マーカー発現は無再発予後因子となる, 第115回日本外科学会定期学術集会, Apr. 2015.
427.	寺奥大貴, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Chie Takasu, Shin-ichiro Yamada, 石川大地 and 吉川雅登 : 大腸癌肝転移におけるThrombospondin-1(THBS1)発現の意義, 第115回日本外科学会定期学術集会, Apr. 2015.
428.	Yusuke Arakawa, Mitsuo Shimada, 寺奥大貴, 吉川雅登, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Jun Higashijima : 加齢肝再生不全における肝星細胞の役割についての検討, 第115回日本外科学会定期学術集会, Apr. 2015.
429.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and 吉川雅登 : Epigallocatechin gallateはABCトランスポーター関連因子を介して抗腫瘍効果を発揮する, 第115回日本外科学会定期学術集会, Apr. 2015.
430.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Jun Higashijima, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 術前3DシミュレーションおよびVSSを使用した膵頭十二指腸切除における modified de-rotation method, 第115回日本外科学会定期学術集会, Apr. 2015.
431.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地, 寺奥大貴, Chie Takasu, Jun Higashijima and Hidenori Miyake : 大腸癌多発肝転移に対する長期生存を目指した治療戦略, 第115回日本外科学会定期学術集会, Apr. 2015.
432.	Satoru Imura, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Yuji Morine, Hidenori Miyake, Mitsuo Shimada, 吉川雅登, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Yu Saitou and Chie Takasu : 手技定型化が可能にした門脈·肝静脈解剖に基づく合理的な系統的肝切除-副右肝静脈灌流領域切除を伴う拡大前区域切除術-, 第115回日本外科学会定期学術集会, Apr. 2015.
433.	Yu Saitou, Sonoko Yasui, 吉川雅登, 寺奥大貴, Shin-ichiro Yamada, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yasuhiro Hamada and Mitsuo Shimada : 肝胆膵外科手術における周術期栄養評価の有用性に関する研究-体成分分析装置と主観的包括アセスメントSGA-, 第115日本外科学会定期学術集会, Apr. 2015.
434.	吉川雅登, 良元俊昭, 寺奥大貴, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝門部胆管癌に対する拡大肝右葉切除後，門脈血栓・大量腹水により管理に難渋した1例, 第23回徳島外科術後管理研究会, Feb. 2015.
435.	吉川雅登, Mitsuo Shimada, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Yusuke Arakawa, Jun Higashijima, Tetsuya Ikemoto, Satoru Imura and Yuji Morine : 肝細胞癌における腫瘍マーカー発現は無再発予後因子となる, 第250回徳島医学会学術集会, Feb. 2015.
436.	Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : ソラフェニブ投与後長期生存例の検証 ∼切除を含む集学的治療の重要性∼, 第11回日本肝がん分子標的治療研究会, Jan. 2015.
437.	杉原康平, Hisami Okumura, 和田宵湖, 山本モモ, Yutaka Taketani, Shin-ichiro Yamada, Satoru Imura, Mitsuo Shimada and Eiji Takeda : 肝細胞癌患者における肝切除術後予後因子としての非蛋白質呼吸商, 第18回日本病態栄養学会年次学術集会平成27年1月10-11日国立京都国際会館, Jan. 2015.
438.	良元俊昭, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地, 吉川雅登 and 寺奥大貴 : ソラフェニブ投与後切除可能となり長期生存が得られたFGF4強発現進行肝細胞癌の症例, 第102回日本消化器病学会四国支部例会, Nov. 2014. (Keyword) 国内学会
439.	吉川雅登, Mitsuo Shimada, 寺奥大貴, Wubetu Gizchew Yismaw, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝細胞癌におけるSTAT4発現は腫瘍免疫を反映し予後因子となる, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
440.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Shin-ichiro Yamada, 石川大地, 吉川雅登 and 寺奥大貴 : 立体臓器モデルによる3D virtual hepatectomyと術中navigation systemを駆使した肝切除, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
441.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 膵頭十二指腸切除術に対する取り組みと在院期間短縮についての検討, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
442.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 石川大地, Jun Higashijima, Chie Takasu and Hidenori Miyake : 切除不能大腸癌肝転移に対する治療戦略, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
443.	Satoru Imura, 吉川雅登, 寺奥大貴, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 若手肝臓外科医を育成するための取り組み∼3Dプリンターによる術中ナビゲーションと評価シートによるフィードバック∼, 第76回日本臨床外科学会総会, Nov. 2014. (Keyword) 国内学会
444.	Shin-ichiro Yamada, Mitsuo Shimada, 石川大地, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi and Yu Saitou : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第25回日本消化器癌発生学会総会, Nov. 2014. (Keyword) 国内学会
445.	Yu Saitou, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Shin-ichiro Yamada, 石川大地, 吉川雅登 and 寺奥大貴 : 立体臓器モデルによる3D-virtual hepatectomyと術中navigation systemを用いた肝切除, 第23回日本コンピュータ外科学会, Nov. 2014. (Keyword) 国内学会
446.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 高齢者における肝再生不全の肝星細胞からのアプローチ, 第22回日本消化器関連学会週間(JDDW), Oct. 2014. (Keyword) 国内学会
447.	Satoru Imura, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Chie Takasu, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 根治性からみた進行肝癌初回治療法の選択, 第22回日本消化器関連学会週間(JDDW), Oct. 2014. (Keyword) 国内学会
448.	Shin-ichiro Yamada, Gizachew Yismaw, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, 石川大地, 吉川雅登, 寺奥大貴 and Mitsuo Shimada : 分枝鎖アミノ酸はオートファジーを介してインスリン存在下の癌細胞増殖を抑制する, 第73回日本癌学会学術総会, Sep. 2014. (Keyword) 国内学会
449.	石川大地, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, 寺奥大貴 and Gizachew Yismaw : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第73回日本癌学会学術総会, Sep. 2014. (Keyword) 国内学会
450.	Tetsuya Ikemoto, Mitsuo Shimada, Satoru Imura, Yuji Morine, Yusuke Arakawa, Hiroki Mori, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 紫令湯による膵島破壊抑制機序の解明に関する免疫学的検討, 第50回日本移植学会総会, Sep. 2014. (Keyword) 国内学会
451.	Yu Saitou, 寺奥大貴, 吉川雅登, 石川大地, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 肝星細胞からみた加齢肝再生不全の検討, 第50回日本移植学会総会, Sep. 2014. (Keyword) 国内学会
452.	Shuichi Iwahashi, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada and 石川大地 : RFA後肝細胞癌再発例においてEMT誘導を介し腫瘍悪性度が増強する, 第89回中国四国外科学会総会(第19回中国四国内視鏡外科研究会), Sep. 2014. (Keyword) 国内学会
453.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Yu Saitou and Shin-ichiro Yamada : MicroRNA-449a発現低下は大腸癌の腫瘍進展に関与し予後不良因子となる, 第52回日本癌治療学会学術集会, Aug. 2014. (Keyword) 国内学会
454.	Shin-ichiro Yamada, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi and Yu Saitou : RFA後肝細胞癌再発例においてEMT誘導を介し腫瘍悪性度が増強する-microRNA発現に着目して-, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
455.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : 肝細胞癌におけるSTAT4発現は腫瘍免疫を反映し予後因子となる, 第69回日本消化器外科学会, Jul. 2014. (Keyword) 国内学会
456.	吉川雅登, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 予後不良因子を有する進行胆嚢癌における術後補助GFP療法の効果, 第39回日本外科系連合学会学術集会, Jul. 2014. (Keyword) 校内学会
457.	Shuichi Iwahashi, Mitsuo Shimada, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada and 石川大地 : RFA後肝細胞癌再発例はEMT誘導を介して腫瘍悪性度が増強する-RFA後肝細胞癌における肝移植適応に関して-, 第32回日本肝移植研究会, Jul. 2014. (Keyword) 国内学会
458.	石川大地, Mitsuo Shimada, Shin-ichiro Yamada, Yu Saitou, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Satoru Imura : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
459.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 脂肪由来幹細胞(ADSCs)の膵島細胞保護作用にはIL-6ではなくVEGFシグナルが関与する, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
460.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Yusuke Arakawa, Yu Saitou, Shuichi Iwahashi, Shin-ichiro Yamada and 石川大地 : Celiac axis compression syndromeにより術後管理に難渋して膵頭十二指腸切除術, 第39回日本外科系連合学会学術集会, Jun. 2014. (Keyword) 国内学会
461.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 切除不能転移性肝癌に対する"Early Conversion"を目指したFOLFOKILI療法の可能性, 第26回日本肝胆膵外科学会学術集会, Jun. 2014. (Keyword) 国内学会
462.	Toru Utsunomiya, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 肝内胆管癌に対する系統系リンパ節郭清の意義と術後補助療法の効果, 第26回日本肝胆膵外科学会学術集会, Jun. 2014. (Keyword) 国内学会
463.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Shin-ichiro Yamada and 石川大地 : 80歳以上超高齢者における肝切除の妥当性に関する検討-術前栄養評価から見た高齢者の特徴-, 第26回日本肝胆膵外科学科学術集会, Jun. 2014. (Keyword) 国内学会
464.	Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 切除不能転移性肝癌に対する"Early Conversion"を目指したFOLFOXILI療法の可能性, 第50回日本肝癌研究会, Jun. 2014. (Keyword) 国内学会
465.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Hidenori Miyake : 肝星細胞による加齢肝再生不全機序の検討, 第50回日本肝臓学会総会, May 2014. (Keyword) 国内学会
466.	石川大地, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and Shin-ichiro Yamada : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第50回日本肝臓学会総会, May 2014. (Keyword) 国内学会
467.	Satoru Imura, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Toru Utsunomiya and Mitsuo Shimada : 局所再発させない適確な症例選択がRFA成績向上につながる∼組織学的門脈浸潤(vp)陽性肝癌を予測し，RFA適応外へ∼, 第50回日本肝臓学会総会, May 2014. (Keyword) 国内学会
468.	Yu Saitou, 寺奥大貴, 吉川雅登, 石川大地, Shin-ichiro Yamada, Shuichi Iwahashi, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Mitsuo Shimada : 高齢者の肝再生不全の機序解明と治療への応用, 第40回日本急性肝不全研究会, May 2014. (Keyword) 国内学会
469.	寺奥大貴, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Hiroki Mori, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 進行胆嚢癌の予後因子と術後補助GFP療法の効果, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
470.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 肝星細胞からみた加齢肝再生不全の検討, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
471.	Shin-ichiro Yamada, Mitsuo Shimada, Toru Utsunomiya, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou and 石川大地 : 肝細胞癌切除症例に対するRFAの影響(第2報)-RFA後肝細胞癌再発例はEMT誘導を介して予後不良となる-, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
472.	Yu Saitou, Mitsuo Shimada, Toru Utsunomiya, 石川大地, Shin-ichiro Yamada, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Hidenori Miyake : 脂肪由来幹細胞の細胞保護効果には臓器特異性がある, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
473.	Tetsuya Ikemoto, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Yuji Morine, Hiroki Mori, Yusuke Arakawa, Mami Kanamoto, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada and 石川大地 : 紫令湯による糖尿病発症マウスの膵島破壊抑制機序の免疫学的検討, 第41回日本膵・膵島移植研究会, Mar. 2014. (Keyword) 国内学会
474.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Chie Takasu, Shuichi Iwahashi, Mami Kanamoto, Hiroki Mori, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Toru Utsunomiya and Hidenori Miyake : 高齢者に対する肝切除後の肝再生不全の機序解明とその対策:ベッドサイからベンチへのアプローチ, 第248回徳島医学会学術集会(平成25年度冬期), Feb. 2014. (Keyword) 国内学会
475.	石川大地, Mitsuo Shimada, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 肝細胞癌におけるSTAT4発現は細胞性免疫の制御に関与し予後因子となり得る, 第248回徳島医学会学術集会(平成25年度冬期), Feb. 2014. (Keyword) 国内学会
476.	Yusuke Arakawa, Mitsuo Shimada, 石川大地, Shin-ichiro Yamada, Yu Saitou, Shuichi Iwahashi, Mami Kanamoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura and Toru Utsunomiya : 進行肝細胞癌に対するソラフェニブと外科治療を組み合わせた治療成績, 第9回日本肝がん分子標的治療研究会, Jan. 2014. (Keyword) 国内学会

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

腫瘍微小環境におけるexosomal micro RNA-Nrf2 addictionの機序解明と治療法の確立 (Project/Area Number: 23K08072 )
脂肪由来幹細胞ADSCから誘導した肝細胞様細胞HLCの免疫原性獲得に関する研究 (Project/Area Number: 23K08028 )
NASHにおける肝転移抑制の機序解明に関する研究 (Project/Area Number: 22K08752 )
自己脂肪由来インスリン産生細胞自家移植における抗原性発現と細胞運命の研究 (Project/Area Number: 22K08734 )
肝星細胞制御による薬剤耐性肝癌の肝内転移抑制機構の解明 (Project/Area Number: 21K08620 )
Effects of light-emitting diode irradiation on hepatic differentiation of hepatocyte-like cells (Project/Area Number: 20K08928 )
Mechanism of recurrence progression after hepatectomy in non-alcoholic steatohepatitis (Project/Area Number: 19K09095 )
Mechanism of high malignant potential with recurrence of hepatocellular carcinoma after radiofrequency ablation (Project/Area Number: 16K19895 )
The basic research for establishment of a new strategy for IBMIR control in islet transplantation by ADSC (Project/Area Number: 25462114 )
mechanism of bile duct carcinogenesis using rat model of pancreaticobiliary maljunction (Project/Area Number: 23791537 )
Search by Researcher Number (30579884)

Designated Assistant Professor : Yamada, Shin-ichiro

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)